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1. ABSTRACT 
 
Background 
The RAS genes are the most mutated genes in human cancer. More than 90 % of pancreatic tumours 
bear mutations in the Kirsten (KRAS) gene, while about 30 % of bladder tumours are characterized 
by mutations in Harvey (HRAS) gene. These oncogenes encode for highly homologues 
hyperactivated GTPases that constitutively stimulate survival and proliferation pathways in cancer 
cells. Recent data have revealed that both KRAS and HRAS are regulated by a guanine-rich sequence, 
located immediately upstream of the transcription start site. A main feature of this regulatory 
sequence is its capacity to fold into a G-quadruplex structure (or G4). Research over the last 10 years 
provided evidence that G-quadruplex in gene promoter plays an important role in the mechanism 
controlling gene expression. Although many efforts have been made, the exact function of G4 DNA 
in gene promoter is still unclear. A recent G4-ChIP-sequenceing analysis conducted on human 
chromatin found that under in vivo conditions the KRAS promoter is indeed folded into a G4. 
Combining this discovery with recent data from our laboratory support the view that, most likely, 
the main function of G4 is to recruit the transcription factors for activating transcription. However, 
it is important to consider that the formation of G4 by a G-rich sequence leaves the complementary 
pyrimidine-rich strand unpaired and exposed to cellular nucleases. The risk of DNA damage by 
nucleases is reduced if the pyrimidine-rich strand too folds into an unusual structure called the i-
motif (iM). To address this issue we have analyzed the capacity of the C-rich motif of HRAS to 
assume the i-motif structure.  We also found that the i-motif is recognized by hnRNP A1, a nuclear 
protein that interacts also with G4 structure formed by the complementary G-rich strand (Results, 
Section A). Considering that pancreatic and bladder cancer cells are addicted to HRAS and KRAS, 
respectively, both G4 and i-motif structures are viewed as attractive targets for anticancer molecules, 
as documented by several studies. Most of the strategies so far tested, directed against the RAS 
protein or downstream pathways, have not given satisfactory results, suggesting that after > 20 years 
of research, the RAS proteins are probably “undruggable”. In the light of this belief, we focused our 
efforts on the genes in order to design new strategies to suppress KRAS and HRAS in cancer cells. In 
my PhD work I pursued three strategies: (i) the use of G4-decoy oligonucleotides, opportunely 
engineered, to downregulate HRAS in bladder cancer cells (Results, Section B); (ii) the use of small 
molecules targeting the 5’-UTR sequence of KRAS mRNA which forms several RNA G-quadruplex 
(RG4) structures, in order to suppress KRAS expression in pancreatic cancer cells (Results, Section 
C); (iii) the use of a modified single-stranded miRNA, which is downregulated in pancreatic cancer 
cells, to suppress the expression of KRAS  in pancreatic cancer cells (Results, Section D). 
 
Aims 
During my research work in the laboratory of biochemistry at DAME, I have first addressed the 
question whether the C-rich sequence close to the transcription start site of HRAS folds into an i-
motif. We found that the HRAS sequence forms an i-motif which, in vitro, is stable under near 
physiological conditions. We also found that hnRNP A1 is able to bind tightly to the i-motif and 
unfold this unusual structure. The suppression of hnRNP A1 by shRNA, resulting in the 
 
4 
 
downregulation of HRAS, revealed a key role played by this nuclear protein in the activation of 
HRAS.  
Second, we applied a decoy strategy to inhibit HRAS in bladder cancer cells by using modified 
oligonucleotides mimicking either the i-motif or the critical G4 structure formed by the 
complementary G-rich strand.  
Third, to suppress oncogenic KRAS in pancreatic cancer cells, we followed two different approaches 
aiming at blocking translation: one was based on the use of small molecules that accumulate in the 
cytoplasm and bind to the G-quadruplexes formed in the 5’-UTR of KRAS mRNA, which is very rich 
in guanines; the other is instead based on the use of chemically modified single-stranded miRNAs, 
which are downregulated in pancreatic cancer, and recognize a target sequence in the 3’-UTR of 
KRAS mRNA.  
 
Results 
The results obtained in the three-years of research has produced four scientific papers, of which 
three have been published in Scientific Reports, ACS Medicinal Chemistry Letters and Journal of 
Medicinal Chemistry and the last one is in preparation. A detailed description of the results obtained 
are reported in the papers enclosed in the Results section. In breaf, the main aspects of each paper 
are here summarized: (i) “GC-elements controlling HRAS  transcription form i-motif structures 
unfolded by heterogeneous ribonucleoprotein particle A1” (Scientific Reports, 2015). This paper 
demonstrates that the two contiguous C-rich strands of HRAS fold into i-motif conformations 
characterized under crowding conditions (PEG-300, 40% w/v) by semi-transitions at pH 6.3 and 6.7, 
respectively. Chromatin immunoprecipitation shows that hnRNP A1 is associated under in 
vivo conditions to the GC-elements, while EMSA demonstrated that hnRNP A1 binds tightly to the i-
motifs. FRET and CD experiments showed that hnRNP A1 unfolds the iM structures. Furthermore, 
when hnRNP A1 is knocked out in T24 bladder cancer cells by a specific shRNA, the HRAS transcript 
level drops to 44 ± 5% of the control, suggesting that hnRNP A1 is necessary for gene activation. The 
sequestration by decoy oligonucleotides of the proteins (hnRNP A1 and others) binding to the HRAS 
iMs causes a significant inhibition of HRAS transcription. All these outcomes suggest that HRAS is 
regulated by a G-quadruplex/i-motif switch interacting with proteins that recognize non B-DNA 
conformations; (ii) “Nucleic Acid Targeted Therapy: G4 Oligonucleotides Downregulate HRAS in 
Bladder Cancer Cells through a Decoy Mechanism.” (ACS Medicinal Chemistry Letters, 2015). 
Starting from the observation that two neighboring G-quadruplexes, located immediately upstream 
of the major transcription start site of HRAS, bind MAZ, a nuclear factor that activates transcription, 
we designed G4 oligonucleotides with anthraquinone insertions and locked nucleic acids (LNA) 
modifications mimicking one of the G-quadruplex. Luciferase, qRT-PCR, and Western blot data 
demonstrate that these constructs efficiently down regulate HRAS in T24 bladder cancer cells. The 
inhibitory efficiency of the G4 oligonucleotides correlates with their nuclease resistance in the cell 
environment. By chromatin immunoprecipitation we show that the association of MAZ to the HRAS 
promoter is strongly attenuated by the designed G4 oligonucleotides, thus suggesting that these 
constructs behave with a decoy mechanism; (iii)  “RNA G-quadruplexes in Kirsten ras (KRAS) 
oncogene as targets for small molecules inhibiting translation” (Journal of Medicinal Chemistry, 
2017).  We found that the human KRAS transcript contains a G-rich 5’-UTR sequence (77 % GC) 
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harbouring several G4 motifs capable to form stable RNA G-quadruplex (RG4) structures that can 
serve as targets for small molecules. A biotin-streptavidin pull-down assay showed that 4,11-bis(2-
aminoethylamino)anthra[2,3-b]furan-5,10-dione (2a) binds to RG4s in the KRAS transcript under 
low-abundance cellular conditions. Dual-luciferase assays demonstrated that 2a and its analogue 
4,11-bis(2-aminoethylamino)anthra[2,3-b]thiophene-5,10-dione (2b) repress translation in a dose-
dependent manner. The effect of the G4-ligands on Panc-1 cancer cells was also examined. Both 2a 
and 2b efficiently penetrate the cells suppressing protein p21KRAS to < 10 % of the control. The KRAS 
down-regulation induced apoptosis together with a dramatic reduction of cell growth and colony 
formation. In summary, we reported a strategy to suppress the KRAS oncogene in pancreatic cancer 
cells by means of small molecules binding to RG4s in the 5’-UTR of mRNA; (iv) “Potent anti Kirsten 
ras (KRAS) single-stranded miRNA oligonucleotide mimics as therapeutic agents” (in preparation). 
Datasets reporting microRNA expression profiles in normal and cancer cells show that miRNA 216b 
is aberrantly downregulated in pancreatic ductal adenocarcinoma (PDAC). Oncogenic KRAS, which 
drives the pathogenesis of PDAC, is a target of miRNA 216b. We designed single-stranded miRNA 
216b mimics, engineered with unlocked nucleic acid (UNA) modifications, and found that they 
strongly suppress KRAS in PDAC cells. We also report a new delivery strategy for miRNA 216b, based 
on the use of palmitoyl-oleyl-phosphatidylcholine (POPC) liposomes, functionalized with a lipid-
modified cell penetrating peptide (TAT) and miR-216b conjugated to a palmitoyl chain. 
Impact of the research on Cancer 
Despite the enormous advances registered in oncology, pancreatic cancer is still a highly lethal 
disease that poorly responds to conventional chemotherapies. New anticancer therapies are urgently 
needed. In this PhD thesis, we have analyzed some new possible strategies designed to inhibit HRAS 
and KRAS in cancer cells.  
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2. INTRODUCTION 
2.1 RAS GENES AND CANCER 
 
RAS discovery  
 
The discovery of the ras gene has provided the basis for achieving important scientific progresses in 
cancer biology. It has opened new horizons and given important answers in the challenging 
struggle against cancer, the disease of modern society. 
The potent oncogenic transformation induced by the Harvey and Kirsten murine sarcoma viruses 
has been detected for the first time in 1964 and 1967, respectively [1, 2]. These innovative studies 
provided a first glimpse of oncogenic genetic elements, which have been successively called and 
identified as HRAS and KRAS. From late 1970, Scolnick and collaborators described the cellular 
origin of the viral HRAS and KRAS genes [3, 4]. They demonstrated that the ras genes encode for 21 
kDa proteins [5], binding to GDP and GTP [6], which are associated to the plasma membrane [7]. 
The finding that certain human cancers are not caused by infection of oncogenic virus [8] directed 
the research in the identification of the processes involved on cancer development. In 1979, 
Weinberg and his group showed that the DNA isolated from chemically transformed rodent 
fibroblasts was responsible of the morphological transformation of NIH/3T3 mouse fibroblasts [9]: 
a finding supported by several other studies [10-14]. Scientists have been spending energies for 
years trying to identify and isolate genes responsible of transformation in NIH/3T3 cells. In 1982, 
two independent studies showed that the transforming genes were exactly those identified years 
before as Kirsten and Harvey viruses [15, 16]. Strikingly, at the end of the same year, it has been 
illustrated how a single missense mutation in codon 12 drives HRAS oncogenic activation in EJ/T24 
bladder carcinoma cell line. Identical point mutations were found in the viral HRAS and KRAS 
genes [17, 18]. At the same time, another gene family member was discovered in neuroblastoma 
derived DNA and called NRAS [19, 20]. The remarkable role of ras genes in cancer has been lately 
validated through the identification of mutations in these genes in patient tumors. The discovery 
that one single mutation is able to drive the process of tumorigenesis in several cancers, have 
stimulated a continuous research overt last 30 years on the ras genes. 
RAS family and RAS isoforms  
 
The RAS proteins are low molecular weight guanosine triphosphatases (GTPases). There are more 
than 150 small GTPases, classified according to their primary structure into 5 distinct subfamilies: 
RAS, RHO/RAC, RAB, ARF and RAN. The GTPases of the RAS subfamily share a conserved G–box-
GTP/GDP-binding motif and the common ability to hydrolyze GTP into GDP. The proteins 
function as a molecular switch and oscillate between an activated GTP-bound state and an 
inactivated GDP-bound state. The conformational states depend on structural changes occurring in 
the two motile regions: switch I and switch II [21]. These regions are involved in the interaction 
with a variety of regulatory proteins. RAS proteins regulate a broad range of signalling pathways 
that transport into the cells extracellular stimuli. The RAS family is composed by three different 
isoforms: Harvey ras (HRAS), Kirsten ras (KRAS) and Neuroblastoma ras (NRAS). They encode 
proteins with a high homology in terms of amino acid (80%): the major difference is in the C-
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terminal region, defined as hypervariable region (HVR) [22] (Figure 1). In the past, their high 
homology, ability of the isoforms to transform the cells and the fact that they activate the same 
downstream cellular effectors, led to the wrong assumption that the RAS isoforms have an 
interchangeable role in vivo. Several studies revealed that the expression of the RAS isoforms is 
almost ubiquitous, but the extent of expression  is tissue specific [23-25]. Moreover, they are 
differently expressed during developmental stages [26, 27]. Mammalian RAS genes have different 
expression patterns during prenatal and postnatal development. HRAS is highly expressed in skin 
and skeletal muscles, KRAS in colon and thymus and NRAS in male germinal tissue [28]. To carry 
their biological functions RAS proteins are associated to the cell membrane. [29, 30]. The pathway 
activating RAS is mediated by tyrosine kinases receptors (RTKs) bound to the plasma membrane 
[31]. RAS cytosolic and inactive precursors need a series of post-translational modifications in order 
to acquire biological activity. Lipid modifications to the CAAX motif in the HVR (Figure 1) by the 
farnesyltransferase (FTase) are responsible for RAS localization [32, 33]. The therminal X of the 
CAAX motif represent methionine, serine, leucine or glutamine and it has a role in determing 
lipidic modification (farnesylation or geranylation) [34]. Post-translational modifications in the 
HVR explain RAS isoforms distinct localization and indeed different pattern of engagement [33]. 
For example, it has been found that FTase inhibition results with prenylation of KRAS and NRAS 
while not for HRAS [35]. Knockout studies in mice have been useful for understanding the different 
roles of the RAS genes. The abrogation of KRAS is lethal during mice embryogenesis, underling its 
pivotal role in development [36, 37]. Differently, when in the KRAS locus, KRAS was replaced with 
HRAS,  the mice developed cardiac abnormalities in adult age [38]. These observations suggested 
different roles of the RAS isoforms: for instance, HRAS is not able to replace completely the KRAS 
function. NRAS activity is essential during mouse development, growth and fertility [39]. 
Nevertheless, both NRAS and KRAS are required for SV40T Ag-induced transformation in mouse 
embryonic fibroblasts showing different functions related to a different signalling pathways 
engagement. Wild type NRAS is involved in cell adhesion, through RAF and RhoA activation. On 
the other side, KRAS plays a role in coordinating cell motility, engaging AKT and Cdc42 [40].  
These outfindings disclosed the important role of RAS localization in defining RAS effectors 
engagement and specific signalling pathway activation. 
RAS proteins control several pathways involved in cellular processes such as proliferation, 
differentiation and cell death. They are the crossroads of an enormous number of cellular signaling 
 
Figure 1. RAS protein primary sequences. 
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network and despite different tissue-specific expression and cellular localization RAS protein share 
a multitude of upstream activators and downstream effectors.  
RAS upstream regulators 
 
The RAS signalling pathway is an elaborated network activated by a wide range of inputs. It is 
responsible of the transduction of extracellular signals through the activation of membrane 
receptors (tyrosine kinases, integrins, heterotrimeric G-proteins and cytokine receptors) [41]. 
Growth factors like insulin, epidermal growth factor (EGF) [42] and nerve growth factor (NGF) [43] 
promote the binding of GTP to the RAS protein. These factors promote conformational changes on 
the protein forming docking sites for adaptor molecules such as the guanine nucleotide-exchange 
factors (GEFs) [44]. The activation of protein RAS has profound effects on the cell. For example, 
activated protein RAS promotes via the EGF signaling proliferation in many types of cancer and 
non cancer cells. Differently, NGF-dependent activation of RAS signaling promotes cell 
differentiation [43, 45]. Upon receptor activation, the major RAS regulators are GEFs and GAPs 
(GTPases activating protein). GEFs activation promotes the dissociation of guanine nucleotides 
from protein RAS. RAS-GEFs are categorized into three main classes: SOS, RAS-GRF and RAS-GRP. 
All these proteins are characterized by the CDC-25 catalytic domain and by the N-terminal RAS 
exchange factors domain. Well studied GEF proteins are SOS1 and SOS2. SOS family’s members 
display a DB1 homologous domain (DH) fundamental in managing the guanine nucleotide 
exchange [46]. Adaptor proteins present in the cytoplasm such as GRB2 recognize and recruit SOS 
to the RAS protein bound to the cell membrane [47], thus facilitating nucleotide exchange and 
activating RAS. 
The second class of RAS regulators are the GAP proteins, which are responsible of a rapid RAS 
inactivation. These proteins strongly accelerate the rate of RAS-GTP hydrolysis [48]. Several GAPs 
have been identified: p120GAP, NF1, GAP m, GAP III and CAPRI [46-49]. P120GAP has been identified 
as the first RAS-GAP and it displays a catalytic domain binding to the RAS effector domain. The N-
terminal region is involved in modulating the catalytic activity and interacting with putative RAS 
downstream effectors. The tumor suppressor gene neurofibromatosis type I (NFl), that shows a 
sequence homology to p120GAP , encodes for a protein that inhibits RAS through GTP hydrolysis 
[50,51]. Mutation in NF1 are associated to an increased risk of cancer [52]. The fundamental role of 
this class of protein is also supported by the fact that RAS oncogenic mutations often abolish the 
interaction to GAPs causing a RAS hyperactivation responsible for tumorigenesis and cancer 
hallmarks. 
 
RAS downstream effector pathway 
 
The RAS downstream signal is propagated mainly through three different signalling cascades: 1) 
RAF/MEK/ERK (MAPK pathway) stimulating cell proliferation, 2) PI3K/AKT cascade regulating cell 
survival and 3) RAL guanine nucleotide exchange factor (RAL-GEFs)/RAL family GTPases 
signalling. RAF kinase is the first discovered RAS effector (1993) followed by PI3K and RAL-GEFs. In 
the years, RAS effector number has been grown and currently, apart from RAF, PI3K, RAL-GEFs 
and p120GAP, it includes: RIN1, TIAM, AF6, Nore1, PLCε and PKCξ. The RAS/MEK/ERK cascade is 
the best described and characterized RAS effector signaling pathway [53]. The three 
serine/threonine kinases, A-RAF, B-RAF and RAF-1, phosphorylate and activate MEK1 /MEK2 that, 
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in turn, activate ERk1/ERK2 [54]. ERK kinases can activate both cytosolic and nuclear substrates, 
including JUN and ELK1 transcription factors that are involved in FOS expression. JUN and FOS, 
through AP-1 activation, are able to control cyclin D and thus cell-cycle progression [55]. The 
second important RAS downstream effector is PI3K. The PI3K activated state is composed by 
regulatory p85 and catalytic p11o subunits. Among the RAS isoforms, HRAS displays a capacity to 
activate PI3K higher than KRAS [56]. Once activated, PI3K, through PIP2 phosphorylation, 
generates phosphatidylinositol (3, 4, 5) triphosphate (PIP3) that recruits PDK1 to plasma membrane 
and activates AKT [57, 58]. The three different AKT isoforms (AKT1, AKT2 and AKT3) are 
associated to different biological processes. AKT1 is responsible of cell proliferation and survival, 
AKT2 promotes insulin mediated metabolic responses, and AKT3 deficient mice displayed 
diminished cell size and numbers [58]. PI3K also activates RAC, a RHO family GTPase that plays an 
important role in RAS-oncogenic transformation [59]. Lastly, RAS can also interact and activate 
RAL-GEFs family necessary for RAL GTPases activity. RAL-GEFs family is composed by 4 members: 
RAL-GDS, RGL, RGL2/RLF and RGL3 [60]. This class of protein share a high homology in three 
different domains: CDC25 domain, that in vitro has been shown to be sufficient for the catalytic 
activity [60], RAS exchange motif (REM) and RAS binding domain (RBD)[61]. RAS and RAL-GEFs 
interaction permits the complex localization to the plasma membrane and it drives RAL GTPase 
activation. Two RAL GTPase genes are RAL-A and RAL-B that share 80% of homology and are 
ubiquitously expressed in humans. Evidences showed that RAL-A is required for the proliferation of 
transformed cells, while RAL-B is needed for cell survival in transformed cell, but not in normal 
ones [62]. RAL proteins are able to interacts with a large numbers of downstream effectors (as Sec5, 
Filamin, RAL-BP1 or ZONAB) and their signal is implicated in regulation of endo- or exocytosis, 
cytoskeletal organization, cell migration and gene expression [63].  
Oncogenic RAS mutations 
  
RAS somatic mutations are present in about 30 % of all human cancer [64]. RAS mutations are in 
the tumorigenesis of several deadly cancers. In advanced stages of cancer, RAS mutations are 
associated to bad prognosis and more aggressive phenotype. There is a correlation between tumor 
types and ras mutations [65]. For instance, KRAS mutations are prevalent in pancreatic and 
colorectal cancers, while NRAS and HRAS mutations are associated to melanoma and bladder 
tumors [66]. The main hotspots for RAS mutations are positions 12, 13 and 61 in exon 1. These 
mutations impaired the correct GTP hydrolysis causing an aberrant hyperactivated protein. GTP-
GDP exchange is not inhibited because RAS proteins became resistant to GAPs activity. Crystal 
structure of p120GAP catalytic domain (Gap Related Domain, GRD) and HRAS revealed that the 
highly conserved GAP-arginine-finger interacts to the RAS phosphate binding loop (P loop) [67]. It 
has been found that replacing Gln 61 with any amino acids, except Glu, results in the inhibition of  
GTP hydrolysis [67]. Yet, when Gly 12 is replaced with another amino acids (proline excluded), the 
affinity of GAPs or protein RAS decreases significantly. The phenotype of the transformed cells 
depends on the type of mutation [68]. Amino acids substitutions in positions 12 and 13 are not 
favourable for the physiological RAS GTP hydrolysis, because of a steric block that prevents GAP’s 
arginine finger to enter into the GTPase site [67, 69, 70]. The mutated and hyperactivated RAS 
proteins produce dysregulated downstream signallings involved in cell growth, survival and 
differentiation.   
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HRAS oncogene in bladder cancer 
 
Bladder cancer is the fifth most frequent malignancy in Europe and USA and the second most 
frequently diagnosed genitourinary tumor after prostate cancer [71]. It is the seventh reason of 
death among cancer in men and the eighth in women [72]. Clinically, 75% to 85% of bladder 
tumors have an early-stage diagnosis, explaining the lower level of mortality respect other tumors 
[73]. The identification of HRAS as a human oncogene has been done in T24 bladder carcinoma 
[74], anyway HRAS mutations in bladder carcinomas are not higher than 30 % [75, 76]. G12V 
mutation is the predominant substitution (60 % of total mutations) followed by G12D (8 %) and 
Q61R (7 %) [77]. Viola and collaborators demonstrated that HRAS levels are increased in 
premalignant cells (dysplastic lesions) and in high grade carcinomas [78]. Moreover, pathological 
significance of HRAS mRNA overexpression in bladder cancer have been proven [79]; HRAS 
overexpression seems to be involved in early cancer development, but not in tumor progression 
[75]. In these years several anti-HRAS therapies have been developed. For example, anti-HRAS 
ribozyme has been used in cell lines and mouse cancer model. They demonstrated antitumor 
efficacy through malignant phenotypes reversion and tumor growth inhibition both in vitro and in 
vivo [79]. Alternative strategies based on DNA non-canonical structures within HRAS promoter 
have been developed. The fact that a critical G-rich sequence in the HRAS promoter forms a G-
quadruplex with regulatory functions, led to develop of a decoy strategy: oligonucleotides 
mimicking the promoter G4 of HRAS that sequester the transcription factors  and arrest 
transcription [80, 81]. 
KRAS oncogene in pancreatic adenocarcinoma (PDAC)  
 
Pancreatic adenocarcinoma (PDAC) is one of the most predominant lethal cancer; 90 % of patients 
with a pancreatic tumor diagnosis die for the disease [82]. In USA, 48’000 new cases have been 
estimate every year and 40’000 are associated with a deadly prognosis. It is the eighth and ninth 
cause of death for cancer in men and women respectively [83]. Surgical resection is the only 
potentially curative solution for this pathology, but only 15-20 % of patients are candidates for 
surgical operations [84]. Oncogenic KRAS have been associated with pancreatic cancer 28 years ago 
[85, 86]. The malignant transformation is a stepwise process that in 90 % of cases is driven by 
hyperactivating mutations in the KRAS gene [87]. The most common mutations occur in codon 12, 
13 and 61. KRAS mutations play a central role in the initiation, progression and maintenance of 
PDAC [88-90]. KRAS mutations are frequently found in precursor lesions, as intraepithelial 
neoplasia (PanIN), supporting their pivotal role in PanIN formation [86]. Recent studies have 
demonstrated that KRAS G12D plays a critical role in the initial phase of tumor development and in 
reprogramming the metabolism in the transformed cells [91]. Tumor progression however requires 
additional tumor suppressors inactivations [92, 93]. The absence of effective KRAS inhibitors made 
difficult to investigate the dependency of tumor progression by KRAS. But, the introduction of RNA 
interference-based approaches allowed to obtain important findings on this issue [94]. In addition 
to ras, also its downstream effectors may contribute to pancreatic cancers development in mice. 
For example, AKT is involved in ductal structures expansion, but differently from KRAS, it does not 
drive PanINs or PDAC progression [95]. PI3K pathway is sufficient and crucial to initiate pancreatic 
carcinogenesis [96]. These observations strongly suggest that KRAS effectors differently contribute 
and influence malignant transformation. 
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RAS cancer “addiction” 
 
In 2000, Bernard Weinstein proposed the concept of “oncogene addiction”. He started from the
observation that cancers in which cyclin D is overexpressed are particularly sensible to the
depletion of cyclin D. He also observed that the knockout of cyclin D by siRNA reverted the 
pathological phenotype [97]. Data obtained in genetically modified mouse models, in human 
cancer cell lines and in clinical trials, support the idea that some tumors strongly depend on one or 
more genes to maintain the malignant phenotype. Although a large number of genetic aberrations 
are normally present in cancer, the transformed cells exhibit a marked dependency on a specific  
 
 
oncogenic signalling pathway [98, 99]. This cellular phenomenon can been seen as the “Achilles’ 
heel” of cancer and can be exploited for the development of new anticancer drugs. Therapeutic 
agents that are able to reduce the expression of a critical oncogene, to which the cells are addicted, 
are likely to promote cell death. Tumor cell addiction has been found for several oncogenes, such 
as c-MYC in lymphomas [100, 101] and myeloma [102], BCR-ABL in leukemia [103], HRAS in 
myeloma [103] and KRAS in pancreatic cancer [104, 105]. Research of the last five years has revealed 
why pancreatic cancer cells are addicted to oncogenic KRAS.  One of the main function of 
oncogenic KRAS is to orchestrate a profound reprogramming of cell metabolism, in order to fuel a 
high proliferation rate. Oncogenic KRAS affects both glucose and glutamine metabolism, and it 
significantly boosts the biosynthesis of ribose by directing glucose towards the pentose phosphate 
pathway [106]. As illustrated in the Figure 2, in PDAC cells KRAS increases the glycolytic flux to 
produce the substrates for the synthesis of amino acids and lipids. KRAS directs a larger amount of 
glucose towards the pentose phosphate (PP) pathway to produce ribose for the biosynthesis of the 
nucleotides. Moreover, the PP pathway produces the reducing power necessary to activate the 
anabolic pathways. PDAC cells need also a high amount of glutamine (Gln) to control the redox 
 
Figure 2. Representation of KRAS metabolism reprograming. 
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balance in cancer cells [91, 107]. In fact, Gln after deamination to glutamic acid (Glu) is not oxidized 
into CO2 in the Krebs cycle, as normally does in non-cancer cells, but it is transaminated to 
aspartate (Asp), which in turn is transaminated again to oxaloacetate (OAA). OAA is reduced to 
malate and malate decarboxylated to pyruvate with the concomitant production of reducing power, 
under the form of NADPH, which is necessary to control the redox balance of PDAC cells. 
Therefore, Gln plays an essential role to avoid a dangerous level of oxidative stress in PDAC cells 
that could compromise their high proliferation rate. The picture that is coming out is that 
oncogenic KRAS is essential for PDAC cells because it adapts the metabolism to cope with a high 
rate of proliferation (Figure 2). 
 
RAS inhibitors 
Mutated RAS proteins are the highest cause of cancer and are, at the same time, the most 
“undruggable” proteins. They have been defined “too smooth”, “too floppy” or otherwise “too 
finicky” for drugs to bind to and block” [108]. Three decades of intensive work by the scientific 
community and private pharmaceutical industries have not been able to identify successful 
pharmacological RAS inhibitors. Despite past failures, targeting RAS is still nowadays one of the 
biggest challenge in therapy. Several approaches have been used and developed to repress RAS 
activity and downstream signalling. Past and ongoing approaches can be summarized as follows: (i) 
inhibitors acting directly on RAS; (ii) inhibitors of RAS membrane association; (iii) inhibitors of 
RAS downstream effectors; (iv) inhibitors of RAS-induced metabolism/cancer hallmarks (Figure 3). 
 
To compete the binding of GTP to protein RAS seems impossible because of the high affinity of 
protein RAS for GTP. In fact, ligands blocking the interaction between GTP and protein RAS have 
not yet been discovered. Neither the interaction between protein RAS and other cellular factors can 
be inhibited by small molecules, as the latter are unable to compete with protein-protein 
interaction [108]. For example, MCP1 and derivatives have been screened as inhibitors of RAS-RAF 
interactions. Although they seemed to inhibit RAF activation, partly reverting the malignant 
phenotype [109, 110] they showed to be not enough efficacious. DCAI, a compound reported by 
Genentech (California, USA), inhibits the GDP-GTP exchange, blocking the interaction between 
 
Figure 3. RAS inhibitors. 
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RAS and SOS1 [111]. X-ray studies revealed that DCAI binds to an important pocket of protein KRAS, 
but unfortunately it did not exhibit a sufficient RAS-binding affinity. The structural information 
obtained by this and other studies were useful for further investigations [111]. In the light of these 
non promising approaches, the researched focused on the use of inhibitors of the farnesyl pathway 
binding protein RAS to the membrane. Many farnesyl transferase inhibitors (FTIs) reached clinical 
trials (as lonafarnib and tipifarnib) [112]. FTIs effectively reduced cell proliferation in mice and 
human cancer cells, but one by one, they failed when used in human clinical trials. This because 
KRAS and NRAS, the less known isoforms at that time, are able to activate a compensatory 
mechanism in the absence of farnesyl tail. They are recognized by enzymes that promote an 
alternative lipidic modification (prenylation) that associates protein RAS to the membrane so that 
it can promote its oncogenic activity. As RAS controls several downstream effectors, their targeting 
could be a winning approach. The strategy is promising, but important issues have to be addressed, 
as compensatory mechanisms can decrease the efficacy of the treatment and also cross talk 
between RAS pathways can be an obstacle to downstream targeting [113]. Finally, cancer cells are 
characterized by an altered metabolism. Undoubtedly, RAS is a key player in promoting metabolic 
rewiring, becoming crucial for tumor maintenance [91, 114]. On the contrary, normal cells are not 
addicted to KRAS, suggesting that targeting tumor metabolic pathway could be an attractive and 
maybe selective anti-cancer strategy. Glutaminase (GLS) inhibitors are an example of this kind of 
approach. They block the catalytic conversion of glutamine to glutamate altering the redox balance 
in pancreatic cancer cells, thus affecting their proliferation rate [115, 116]. 
The lack of successes in these 30 years produced a sense of frustration, but increased knowledge on 
RAS structure, protein domains, RAS mediated processes, and innovative tools as computational 
screening persuade scientific community to continue the “hunt” to pharmacological RAS inhibitors. 
 
Channing Der, an acclaimed scientist in RAS field, compared the RAS inhibitors discovery to the 
climbing of Mount Everest: “We've got to climb it, even though it's tough.” 
 
 
Innovative anti-RAS strategies 
 
Blocking and repressing RAS proteins activity by small molecules has thought to be a very 
challenging, if not an impossible task.  In this scenario, there is an imperative necessity to find 
feasible and alternative therapeutic approaches to inhibit RAS oncogene in cancer cells. Novel 
strategies focused in blocking the expression of the ras gene, impairing either transcription or 
translation. Non-canonical DNA and RNA structures involved in the mechanism controlling ras 
expression are currently being explored in order to develop alternative therapeutic strategies. Several 
studies pointed out that gene expression is controlled by the action of specific transcription factors 
that recognize unusual DNA secondary structures, G-quadruplexes (or G4), formed in a critical G-
rich region located upstream of TSS, that governs ras expression [117-119]. The structure of G-
quadruplex DNA, its function and its importance as therapeutic target is amply described and 
discussed in the next chapter. Although it is not clear the exact function of G-quadruplex DNA, its 
presence in gene promoter is likely to have the function of recruiting specific transcription factors to 
activate transcription. The HRAS and KRAS G-quadruplex structures are recognized by several 
transcription factors including MAZ, hnRNP A1 and SP1 and their action is strongly involved in gene 
expression [117, 118]. The suppression of transcription factors is expected to inhibit gene expression; 
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therefore a decoy strategy can be a powerful strategy to inhibit ras genes in cancer cells. The 
rationale of the decoy strategy is based on the use of G4 oligonucleotides, mimicking the G-
quadruplex structure formed in the ras promoter, that sequester the transcription factors normally 
binding of the HRAS/KRAS promoter with the result that transcription is blocked. The efficacy of the 
decoy strategies in repressing RAS gene expression has been demonstrated [80, 120, 121]. 
The discovery that microRNAs (miRNAs) regulate gene expression opened new therapeutic 
prospectives also for the ras genes. Micro RNAs are small, non-coding RNAs that act as post-
transcriptional regulators. MiRNAs are 19-24 nucleotide single strand RNAs transcribed from the 
genome as precursors (pre-miRNAs) and then processed as mature miRNAs through Drosha and 
Dicer action [122, 123]. More than 50 % of the known miRNAs are involved in human tumorigenesis 
and metastasis by directly targeting oncogenes or tumor suppressor mRNAs targets [124-126]. Several 
miRNAs are aberrantly downregulated in tumours where the ras gene are mutated: let-7 [126], 
miRNA 96 [127], miRNA 216b [128] and miRNA 30c [129]. As they are tumor suppressors in nature, 
they can be used in a replenish strategy as anti ras agents [130, 131]. Chemical modifications can be 
used to confer nuclease resistance and enhance the oligonucleotide therapy effect [132, 133].  
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2.2  DNA AND RNA NON-CANONICAL STRUCTURES 
 
2.2.1  DNA/RNA G-quadruplex 
 
In 1910, Bang [134] noticed that a concentrated solution of guanylic acid was able to form a gel 
suggesting for the first time the formation of a DNA high-order structure. Through the optical 
features of the gel and structure investigations, he revealed that the phenomenon was due to the 
formation of a helix by the guanylic acid.  Starting from this observation, 50 years later Gellert and 
coworkers [135] using X-ray diffraction, proposed a tetrameric structure for G-quadruplex DNA 
(G4). Research in the last 20 or more years has provided solid experimental evidence that this non-
canonical structure of DNA in specific regulatory regions of the genome plays a pivotal role in the 
regulation of gene expression. 
G-quadruplex topology 
 
G-quadruplex (G4) is a non-canonical structure that can be adopted by G-rich DNA and RNA 
strands. The building blocks of the structure, called G-tetrads, are four guanines that trough 
Hoogsten bonds between the N1, N7, O6 and N2 array in a square planar conformation. Stacking of 
two or more G-tetrads leads to G4 folding (Figure 4). 
 
 
 An important feature of the structure is that it is stabilized by the presence of free metal cations 
such as K+, Na+, Mg2+, Ca2+ with a strong preference for K+ and Na+ at typical intracellular 
concentrations. Biophysical and structural studies revealed that the metal ion is located in the 
tetrad central cavity explaining some ions preference rather than others. The cation’s ray plays an 
important role allowing the correct insertion in the G-tetrad core where it neutralizes the 
electrostatic repulsions of the guanines oxygens. In general terms, G4 is defined as a stacking of at 
least two tetrads held together by loops formed by mixed nucleotides, including guanines present 
 
 
Figure 4. G-tetrads structure formed by four guanines with cation insertion and a 
representation of a G-quadruplex structure. 
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in the sequence but not involved in tetrad formation. Anyway, the G4 structure shows a huge 
variety of topologies and different stability depending on: i) number of stacked G-tetrads ii) strand 
direction and polarity iii) loops length and location iv) sequence [136]. The G4 can be formed by 
one (intramolecular), two or four strands (intermolecular). In general, they are defined parallel 
when strands run in the same direction and all guanosines glycosidic angles are in an anti 
conformation, differently they are defined antiparallel when guanines are both in anti and syn 
configuration (Figure 5). 
 
G-quadruplex biological role 
 
The G-quadruplex folding in synthetic sequences has been fully demonstrated by numerous 
biochemical and structural studies using different approaches and specific techniques. Aaron Klug, 
the winner of the Nobel Prize in Chemistry (1982) for the development of crystallographic electron 
microscopy, over 30 year ago affirmed: “If G-quadruplexes form so readily in vitro, Nature will have 
found a way of using them in vivo.” Anyway, the existence, the detection and especially the function 
of the G-quadruplex in a biological context is nowadays one of the main topics of debate.  
Computational predictions suggest that over 360.000 sequences can potentially assume a G4 
conformation [137] and a more recent algorithm developed by Mergny and coworkers [138] 
suggested that the number of potential G4 is probably higher. Computational analysis lead to map 
G4 distribution, highlighting that G4s have not a random localization.  
They tend to cluster in specific regions of the genome as promoters, telomeres, 5’-utr, near 
transcription factors binding sites and up- or downstream transcription start site (TSS) position. 
(Figure 6).  
 
Figure 5. Structures and topologies of G-quadruplexes: (A) intermolecular with parallel 
strands; (B) bimolecular with diagonal loops; (C) bimolecular with lateral loops; (D) 
intramolecular with lateral loops. 
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Moreover, G4 localization and nucleotide sequences are conserved among species. The 
conservation is higher among mammalian species and is reduced in non-mammalian and lower 
species. Putative G-quadruplex-forming-sequences are present also in bacteria [139] and viruses 
[140]. All these observations suggest a biological function of this non-canonical conformation, 
emphasizing its possible role in cellular processes regulation. In 2001, Schaffitzel and colleagues 
provide the first evidence of G4 existence in a cellular context by using a G4-selective single chain 
variable fragment of antibody (scFV) [141]. They selected the scFV from a large synthetic library and 
through indirect immunofluorescence they showed the G4 folding within telomeres in the 
Stylonychia lemnae macronuclei. The visualization of G4s in mammalian cells through two 
different G4-specific antibodies 1H6 [142] and BG4 [143], developed by two independent 
laboratories has been an important breakthrough in the field. It is important to point out that just 
some months ago the scientists responsible for the generation of the 1H6 antibody reconsidered 
their results. They found that 1H6 cross-reacts with short single strands of thymidine (poly (T)) in 
denaturated DNA fibers. For this reason previous immunofluorescence interpretations using 1H6 
need additional studies to affirm that 1H6 binding to DNA is due to G4 structure [144]. This fact 
underlines the difficulties in mapping G4 occurrence in vivo. Nevertheless, increasing evidences for 
G4 formation in both DNA and RNA are emerging and support the role of high-order structures as 
regulatory mechanisms in controlling biological processes such as transcription, replication, 
translation and telomere maintenance. A meaningful step in G4 mapping and localization in vivo 
has been the G4-dependent DNA polymerase stalling combined with the Illumina next generation 
 
 
Figure 6. G-quadruplex possible location in cells. G-quadruplex formation can occur in 
double stranded G-rich regions when DNA becomes transiently single stranded, during (A) 
transcription and (C) replication and (B) at the single stranded telomeric G-rich overhangs. 
Outside the nucleus, G-quadruplexes can also form in mRNA and (D) are involved in 
translational control. Red T-bars indicate impediments to transcription, replication and 
translation. Reproduced from [147]. 
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sequencing (G4-seq). This approach leads to obtain an experimentally genome-wide distribution of 
G4 [145]. Moreover, G4 structure-specific antibodies, used as probes for a G4-specific ChIP-seq, 
permit to achieve new considerations on G4 distribution and most importantly on the correlation 
between G4, chromatin and transcription. The immunoprecipitation of isolated chromatin through 
a G4-specific antibody (BG4), followed by sequencing, experimentally demonstrates the existence 
of 10,000 G4s in human chromatin, mainly localized in nucleosome-depleted regulatory regions. G4 
number is appreciably lower than that computationally predicted or detected by G4-seq and the 
authors explained this discrepancy by proposing suppressive role for heterochromatin in G4 
formation in human cells [146]. The G4 mapping and distribution are crucial steps to understand 
G4 biological role, and those findings are consistent with the idea that G4 folding has a dynamic 
equilibrium, which acts as a regulatory molecular switch. Genome is packaged into chromatin and 
DNA is normally present in the classical double stranded conformation, surely more favored than 
G4 folding, but nuclear G4 structures can be stabilized by superhelical stress, molecular crowding 
and by protein/transcriptional factors binding [147]. Additionally, specific situations, in which the 
classical double strand is temporary in a single strand form, could allow G4 folding; for example 
during DNA replication, transcription and DNA repairing. The single stranded RNA and certain 
telomeric G-rich single strands are other two important conditions in which non-canonical 
DNA/RNA folding could be preferred rather than classical Watson–Crick base paring. 
 
G-quadruplex in telomeres 
 
Telomeres are nucleoprotein complexes present at the 3’-ends of the eukaryotic chromosomes. 
They are responsible for genome integrity and for chromosomes protection, especially for DNA 
recombination, degradation and end-to-end fusion. DNA polymerase is not able to replicate the 3’-
ends because a template strand is lacking and consequently at each cell cycle telomeres are reduced 
by 50-100 bases in length. After reaching a critical length, the Hayflick limit [148], replication stops 
and cells enter in a senescence state. In immortalized and cancer cells, a compensatory mechanism 
that results in telomere length and integrity stabilization occurs. Telomere maintenance is due to 
reverse transcriptase ribonucleoprotein telomerase (hTERT) overexpression; this is the unique 
polymerase able to bind DNA telomeric 3’ strand in order to synthetize further hexanucleotide 
repeats through endogenous RNA. Telomerase plays a key role in tumorigenesis because it 
contributes to cellular immortalization [149]. Telomerase overexpression is a cancer hallmark and it 
is present in 80-85% of proliferating tumor cells [150]. Human telomeric DNA consists of thousands 
of single-stranded tandem repeats d(TTAGGG) [151], normally protected by proteins collectively 
known as sheltering proteins complex. G-quadruplex folding in telomeric strands has been 
hypothesized and facilitated by the complementary strand absence. Four consecutive repeats can 
fold into stable intramolecular G4s with a huge variety of topologies and polymorphic structure 
proved by X-ray [152], NMR [153, 154] and other techniques [155]. In human telomeres for example 
two-unit repeats fold into a dimeric parallel G4 [156], whereas four-repeats form two intramolecular 
G4s, different only in loops arrangements; that shows how several topologies can coexist in the 
same sequence [157]. The first direct evidence in vivo of the telomeric G-quadruplex came 10 years 
ago studying the macronuclear telomeres of Stylonchia. Most importantly they showed that G-
quadruplexes folding in telomeres is related to cell cycle, theorizing that G4s act as protective 
capping structures at chromosome ends [141]. Intramolecular G4 formed by single stranded 
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telomeric repeats is one of the best studied G4 due to its polymorphic structure and to its role as 
tumor suppressor. Telomeric G4 has been proposed as a therapeutic target in 1997. Telomerase 
inhibition has been achieved through G4 stabilization by 2,6-diamidoanthraquinone [158]. G4 
folding, induced by ligands provides a telomerase impaired activity [159]. Telomerase inhibition 
scan reverts cancer cells immortalization. A wide-range of small molecules recognize and bind to 
telomeric G4s [160-164]. All the G4 ligands were considered as telomerase inhibitors, but for 
example BRACO-19, a G4 ligand discovered by Neidle and coworkers [165], shows an antitumor 
activity in vivo [166] that could be due to its ability to induce a DNA damage in telomeres [167, 168]. 
Tumor cells are characterized by DNA-repair deficiencies and this fact could provide ligands 
selectivity. The same mechanism of DNA damage induction has been proposed for an acridinium 
derivative [169] and for pyridostatin analogues [170].  
Nowadays, telomeric G-quadruplex is a promising and valuable target for the development of novel 
anticancer therapies. 
 
 
G-quadruplex and DNA replication 
 
In literature a growing body of evidences demonstrates that replication can be influenced by 
secondary DNA structures such as hairpin [171], triplex and G-quadruplex [172, 173]. During 
replication, the classical double helix is resolved by helicases allowing replication fork formation 
required for DNA synthesis. The synthesis of the lagging strand is discontinuous and retarded and 
a slowed down replication can be an opportunity for a G-quadruplex formation in the retarded 
strand. A pre-existing G4 structure on the template strand can behave as a key regulatory factor. It 
can act as repressor causing a replication stall until G-quadruplex is in the folded form. On the 
contrary it can be a stimulatory factor acting as a protein binding site that promotes the DNA 
helicases recruitment. DNA helicases are molecular motors with a pivotal role in preserving 
genome homeostasis; they impact nucleic acids structures. Helicases are involved in human 
diseases, such as cancer, and ageing [174]; their deficiencies are responsible for genome instability 
and many of them are efficient G4 unwinders in vitro [175, 176].  For example Pif1 is a member of a 
DNA 5’-3’ helicase family, which efficiently unfolds G-quadruplex substrates [177]. Pif1 in S. 
cerevisiae binds and recognizes G4 motif and it is fundamental in DNA replication. Indeed, G4 
motifs slow the replication rate and, in cells where Pif1 is absent, double-strand breaks (DSBs) 
occur especially at G4 motifs, which are normally recognized by Pif1. G4 structures are responsible 
of genome instability, if they are not correctly resolved by Pif1 [178]. Another important evidence 
that uncorrected G4 folding/unfolding results in genomic instability, derived from the observation 
that cell lines with mutated FANCJ helicase are characterized by an accumulation of deletions in G-
rich regions with G4 signature [179]. FANCJ function in GC-rich tracts is to resolve G-quadruplex 
structures to permit correct DNA synthesis; a stall in the replication process can be risky for 
genomic maintenance [180].  
 
 
G-quadruplex in the oncogene promoters 
 
Promoter regions function is to regulate transcription initiation and it has been demonstrated that 
they display a G4 enrichment. More than 40% of human genes exhibit putative G4 in the promoter 
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regions. The G4 motifs percentage is inversely correlated to TSS distance suggesting  a role played 
by DNA non-canonical structure in transcription regulation (Figure 7) [181].  
 
A similar enrichment of G4 structures in promoter regions has been observed also in other species 
as bacteria, yeast and plants [182-184]. Compelling evidences demonstrate that G-quadruplex 
formation is a compensatory effect induced by negative supercoiling; indeed G4 folding can be a 
regulating mechanism in transcription process. G4 conformation in or near promoter regions can 
have either a positive or a negative effect in that elaborated mechanism, one hypothesis is that it 
depends on which DNA strand encodes the G4 motif. If G4 is in the template strand, it can behave 
as a transcription repressor because the folding causes a block of transcriptional activity; on the 
other hand, if G4 is on the non-template strand, it could permit template maintenance as single 
strand promoting an effortless transcription [185]. Moreover, G4 can be useful for specific proteins 
recruitment. Protein unwinding activity can be responsible of transcription activation. A clear and 
univocal role for the G4 in transcription has not yet been proposed: several biological agents 
depending on circumstances and on environmental context probably influence G4 folding and 
functions. In literature, a large body of work shows the inhibitory effect of G4s, besides others 
provided data about enhanced transcription induced by G4 folding. It is not possible to rule out a 
general function, it is just possible to analyze each G4 in its context. It has been observed that G-
quadruplexes in promoters are associated with increased transcriptional activity and enriched in 
oncogenes [186] arising the opportunity to consider them as powerful and promising targets in 
alternative anticancer therapies. The most studied G4s, on that point of view, are those present in 
the c-MYC, KRAS and c-KIT promoters [187]. 
 
 
 
Figure 7. G-quadruplex in promoter regions: (A) Model for transcription regulation through 
G4 folding in promoter region; (B) Density of putative G4 sequence related to distance 
upstream TSS. Adapted from [181] 
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c-MYC 
Deregulation of c-MYC expression is usually due to gene amplifications and translocations, altered 
ploidy or to an aberrant transcription caused by upstream signalling abnormalities [188]. An 
overexpressed c-MYC is responsible of an oncogenic transformation both in vitro and in vivo. More 
than 80% of solid tumors including gastrointestinal, ovarian, breast cancer and many non-
Hodgkin’s lymphoma tumors are associated with c-MYC overexpression. Targeting c-MYC at the 
protein level is not simple, thus the demonstration, in 2002, of the G-quadruplex folding in the 
nuclease hypersensitive element (NHE) offered an alternative way to modulate oncogenic c-MYC 
expression. It is one of the first oncogenes whose promoter was amply and deeply investigated. G-
quadruplex structure is formed by 27-nt located between -142 and -115 bp upstream  the TSS in NHE 
III [189]. The in vitro structure has been resolved by NMR studies [190, 191]. c-MYC G-quadruplex 
behaves as a repressor element: its formation and its stabilization by specific G4 binders is 
responsible of a decreased transcription and thus of a reduced gene expression. C-MYC G4 behaves 
as a repressor element while a specific G→T mutation, which destabilize c-MYC G4 in the 
promoter, is associated with an increased c-MYC transcription [189].  
 
KRAS 
KRAS promoter contains a high G-content NHE from -327 to -296, positions relative to the exon 
j/intron 1 boundary [192]. The first evidence of G4 folding in KRAS promoter region was provided 
by a primer extension assay of a plasmid bearing the template strand. The polymerase arrest was 
dependent on K+, the cation which better stabilizes G4 conformations. Circular dichroism (CD) and 
NMR of a 32-mer sequence (32R) confirmed an intramolecular parallel G-quadruplex folding. Two 
alternative G4 structures, adopted by the 32R (Q1 and Q2), are supported by two independent 
studies [193, 194]. The 32R has been used as a bait for a pull-down assay with the nuclear pancreatic 
protein extract. The 32R G4 is recognized and bound by three different proteins: PARP-1, Ku-70 and 
hnRNP A1 identified through mass spectrometry analysis [193]. HnRNP A1 is one of the most 
abundant eukaryotic proteins and it is involved in many biological processes as gene expression, 
nuclear export, RNA splicing and biogenesis [195]. This protein recognizes and unwinds the 32R G4 
in the KRAS promoter, supporting a biological role in KRAS transcription regulation [119]. HnRNP 
A1 seems to have a general DNA resolvase activity because it is able to unwind several G4 structures 
present in the genome [196, 197]. A recent study proved a link between KRAS expression, ILK and 
hnRNPA1. The existence of a KRAS-ILK-hnRNP A1 regulatory loop in pancreatic cancer supports 
the regulating function of hnRNP A1 on KRAS expression, through G-quadruplex unfolding [198]. 
Furthermore, it has been studied also a shorter G4 motif of KRAS NHE (21R) and combining 
different techniques G4 folding has been confirmed also in the 21-mer sequence [199]. Recently, 
NMR analysis of the 22-mer G4 motif performed by Salgado’s group achieved new proofs of G4 
folding in vitro [200]. If something is known about the G4 role in KRAS transcription, even less is 
known about the complementary C-rich strand and its function. Anyway, Hurley and co-workers 
have been lately described a possible G-quadruplex/i-motif switch involved in KRAS expression 
[201].  
 
 
c-KIT 
The c-KIT oncogene encodes for tyrosine kinase receptor responsible of cell proliferation, 
differentiation, apoptosis, chemotaxis and cell adhesion [202, 203]. Aberrant mutations and 
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overexpression of kit protein results in oncogenic transformation in mast cells, myeloid cell, 
melanocytes and germ cells. It has a central role in gastrointestinal stromal tumor (GIST) initiation, 
thus it has been identified as the main target for GIST therapies [204, 205]. Imatinib (Novartis) 
[206] and sunitinib (Pfizer) [207] are two recent multitarget kinase inhibitors used in the treatment 
of KIT-positive GIST, because they are active on this receptor. Anyway, drug resistance recurrence 
[208] create the need of developing a new and different way to target c-KIT expression. Also in this 
case, the presence of three G-quadruplexes (kit1, kit2 and kit*) in the promoter can be seen as an 
encouraging and attractive way to target c-KIT aberrant expression. Kit1 occurs between position -
87 and -109 base pairs and kit2 between -140 and -160 bases upstream the TSS and their structures 
are the best studied. The high-resolution structure of both kit1 and kit2 are available [209-212]. 
Moreover, the portion comprising the kit1 and kit* motif displays validated binding sites for specific 
proteins: SP1 (kit1) [213] and AP2 (kit*) [214] indicating again a biological function of these 
structures. A potential cross talk between the three G4s has been recently suggested by R. Rigo and 
C. Sissi. They provided evidence for a high order rearrangement of kit2 and kit* into a new 
intermolecular conformation compatible with a G4-G4 interaction in physiological conditions [215]. 
Many efforts are being made to understand the complex mechanism of G4s present in the c-KIT 
promoter to put the basis for an efficacious anti-c-KIT therapy. During last years, the attention of 
many scientists has been focused in testing classes of molecules that through G4 binding are able 
to decrease c-KIT transcription. Many in vitro studies demonstrated the G4s inhibiting function on 
c-KIT transcription. The negative regulatory role is proved by ligands that bind G4 conformations, 
increasing their thermal stabilities, induce a decrease of c-KIT transcription. C-KIT inhibited 
transcription is associated to an antiproliferative effect [216-218]. 
 
RNA G-quadruplex and translation 
 
Since 1962, many efforts have been done to understand DNA G-quadruplex structure and its 
biological function; but surely, RNA G-quadruplexes (RG4) have received less attention during 
these years. The central core of both DNA and RNA structure is the same, but the assumption that 
DNA G4 are like their RNA counterparts is certainly an oversimplification. The main difference 
between DNA and RNA is the presence of the deoxyribose instead of a ribose sugar. The 2’-hydroxyl 
group in the ribose sugar have several consequences in the RG4 structure. First, it allows many 
intramolecular interactions within RG4, conferring an enhanced stability. Second, the presence of 
the hydroxyl group in the grooves leads to an increased capacity to bring water molecules resulting 
in a more stable conformation [219]. Finally, the ribose sugar influences the RG4 topology. The 
steric hindrance of the hydroxyl group impairs the syn-conformation of the bases thus promoting 
the anti-configuration. Consistently, RNA G-quadruplex is limited to a parallel conformation where 
all four strands are oriented in the same direction, differently from DNA that can adopt parallel and 
antiparallel conformations. Recently, it has been also demonstrated that RG4 are more stable than 
their DNA counterparts under the same buffer conditions [220]. Some authors explored the effect 
of metal ions on formation and stability of two well-known G4 RNAs: TERRA and NRAS. In a 
systematic study, they demonstrated that there are significant differences between RG4s and G4 
DNAs: RG4s fold into stable quadruplex structure even in buffer only. The study showed that RG4s 
are less sensitive to metal ions than G4 DNAs. Considering the higher stability of RG4 and that 
RNA is a single strand nucleic acid extremely “sticky” for its attitude to form secondary structures 
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(hairpin, loops, bulges etc.) it has been proposed the G-quadruplex folding in mRNA [221, 222], 
miRNAs [223] and long-non coding RNA (lnRNA)[223]. Computational analysis confirmed the 
putative RG4 (pG4) folding in 5’- and 3’-UTR (untranslated regions), critical regions for translation 
regulation [222]. During last years, synthetic RNA oligonucleotides, derived from putative RG4s, 
have been studied by using structural and biophysical techniques (such as CD, UV melting curves 
and NMR) and their in vitro folding has been disclosed. Moreover, enzymatic and/or chemical 
footprinting have been largely used to reveal RG4s in both single RNAs and transcriptome-wide 
studies [223-226]. Important progress in this field achieved from the development of high-
throughput RNA sequencing and chemical probing methods allowing RG4s mapping throughout 
entire transcriptome [225, 226]. Balasubramanian and coworkers developed a RG4 sequencing 
(rG4-seq) that exploit reverse transcriptase stalling (RTS), caused by the presence of secondary 
structures as RG4s, coupled with a RNA next generation sequencing. They determined that about 
3500 stalls (in approximately 2500 genes) can assume a RG4 conformation [225]. It is worth 
mentioning that for the transcriptome-wide analysis a purified cellular transcriptome has been 
used, thus in a cellular context the situation could be different. J. Guo and D. Bartel last year 
published on Science a substantially different view. They developed a method that combine next 
generation sequencing sensitivity to selected cations (as K+ vs Li+) and chemical probing 
techniques, as dimethyl sulfate modification. The core of their work is that the chemical reagents 
used can penetrate living cells membrane allowing in vivo analysis. Surprisingly, they found that 
RG4s are overwhelmingly not folded and depleted in eukaryotic cells. They additionally showed 
that RG4 sequences ectopically expressed in Escherichia Coli present in the folded form cause 
translation and growth inhibition. They explained their results proposing that eukaryotic cells are 
provided with an unidentified robust machinery responsible for G4 unfolding, differently from 
bacteria where RG4s are not present in the transcriptome [226]. Although many advances, it is 
necessary to mention technical limitations in RG4s transcriptome wide analysis. It could be that 
these methods are not sensible to low levels of folded G4s and so only highly expressed G4s have 
been measured. Another important consideration: it is possible that G4 folding is a dynamic 
equilibrium and thus a short-time event (e.g. during splicing or transport); therefore some RG4s 
are not detected but they have a biological relevance. It is certain that secondary structures in RNA 
transcripts have a pivotal role in regulating translation [227, 228] so it is intuitive that also RG4 
structures probably play a role in this process. Putative G4s enrichment in regulating regions, such 
as 5’- and 3’-UTRs, supports this notion [222]. In 2001, Moine and collaborators published a glimpse 
on 5’-UTR RG4 function in translation [229]. Successively, Balasubramanian and colleagues 
discovered a highly conserved and thermodynamically stable RG4 in the NRAS 5’UTR that behaves 
as repressors in translation regulation [230]. They demonstrated that translation modulation is 
strictly dependent on the RG4 position in the 5’-UTR. The inhibition is enhanced when the G-
quadruplex forming sequence is proximal to the 5’ cap [231]. After preliminary studies, many others 
followed this path. 5’-UTR RG4 are found in several genes (e.g. TRF2, ESR1, BCL-2) reviewed in 
[232]. The translation inhibition, via RG4 unwinding, is not simply explained by steric impairment 
of the translational machinery activity; it is also strictly related to G4 distance from cap structure 
and/or AUG initiation codon [233, 234]. Translation could be regulated by the recruitment of 
different RBPs (RNA binding proteins) through an enhanced binding site exposure and/or 
promoting secondary structure. Some studies reported that RG4s within 3’-UTR and ORFs (open 
reading frame) modulate translation [235, 236]. First evidence that 5’-UTR RG4 inhibits translation 
has been provided by Arora et al. in 2008 [237]. Furthermore, the clear role of RG4 in orchestrating 
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protein recruitment led to investigate RG4 possible role in RNA alternative splicing.  Genome wide 
analysis of alternatively spliced transcripts showed more than 3 million of pG4s mapping 
approximately 30.000 mammalian genes [238, 239]. RG4s near splicing sites can affect and 
modulate RBPs binding. For example, two RG4s are located near to FMRP-binding site (FBS) on the 
FMR1 pre-mRNA. FMR1 transcript encodes for two different protein isoforms and FBS is a potent 
splicing enhancer, which plays a central role in modulating the two spliced isoforms in response to 
intracellular FMRP levels. Selective mutations, that impaired the RG4 formation, cause a decreased 
FMRP binding, impair splicing activity of exons and modify splicing pattern of FMR1 pre-mRNA 
[240]. While in FMR1 case RG4 act as splicing enhancer, the hTERT RG4 behaves as an intronic 
splicing silencer [241]. These two in vitro studies are useful to understand RG4s function in splicing 
regulation, but surely, the knowledge on this issue has to be improved.  
 
Proteins binding to G-quadruplex  
 
G-quadruplex  is a non-canonical structure that has been deeply studied in the last years. The 
biological function of G4 is still not perfectly clear, but its biological relevance is unequivocal. Even 
if G-quadruplex can act as repressor or as activator/enhancer of a specific biological process, in 
both cases, its regulatory function is strictly related to proteins that control G-quadruplex 
folding/unfolding. In literature, it is possible to find a plethora of papers describing how G4s are 
recognized, bound and unfolded/folded by specific proteins. The proteins involvement is a key 
point in understanding the complicate mechanism involving G-quadruplex regulatory function in a 
biological context. In vitro studies clearly described how G-quadruplex is a physical hindrance for 
transcriptional or retro transcriptional enzymes. Indeed, the polymerase stop assay is used as proof 
of the G-quadruplex folding. In vitro polymerases progression is blocked or slowed exactly in G4 
proximity. The G4 induce a stop or a transcription pause resulting in a truncated form of the full-
length strand [241]. These evidences easily suggest that, in a cellular context, proteins with 
unwinding activity are required and necessary for transcriptional and/or translational machineries 
action. Balasubramanian’s group last year published a paper [146] describing G-quadruplex 
correlation with chromatin organization. Strikingly, they pointed out that G4 structures are 
enriched in promoters and 5’-UTR of highly transcribed genes. They demonstrated that G4 motifs 
are particularly frequent in cancer-related genes transcriptionally active, as c-MYC and KRAS, 
indicating a positive and dynamic relationship between the G4 folding and transcriptional activity. 
In sight of this novel view, G-quadruplexes can be seen as a sort of beat for protein recruitment. 
Undoubtedly, the fact that many protein DNA/RNA binding sites are not far from a G4 motif 
supports this hypothesis [239, 242]. The important role played by proteins is provided also in 
Bartel’s work [225]. They affirmed that eukaryotic cells have been provided by evolution of a 
protein system involved in the RNA G-quadruplexes unfolding, not present in bacteria. The large 
amount of proteins that are related with the G4 are collected in the G-quadruplex structure (G4) 
Interacting Proteins Database (G4IPDB) [243] and in Table 1 are reported the main proteins 
involved in KRAS, HRAS and c-MYC oncogenes expression. 
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protein name G-quadruplex reference 
human-nuclear poly(ADP-ribose)polymerase-1 
(h PARP-1) 
KRAS (32R) [119] 
Ku70 KRAS (32R) [119] 
heterogeneous ribonucleoprotein A1 (hnRNP A1) KRAS (32R) [119] 
Pif1 c-MYC [242] 
Nucleophosmin c-MYC  [243] 
Sp1 transcription factor HRAS [117] 
MYC-associated zinc finger protein (MAZ) HRAS [117] 
shelterin protein (TRF1,TRF2,POT1,TIN2) c-MYC  [244] 
Nucleolin c-MYC [245] 
nucleoside diphosphate kinase 2 (NME/NM23) c-MYC [246] 
DNA methyltransferase 1 (DNMT-1) c-MYC  [247] 
 
Table 1. Proteins associated to c-MYC, KRAS and HRAS G4s. 
 
G-quadruplex as therapeutic target 
 
Since their discovery, G-quadruplex structures have been considered attractive and promising 
targets in human pathologies, especially in diseases correlated with gene mutations and/or 
expansions as cancer and neurological disorders. Since aberrant proteins result undruggable like 
RAS, for years considered a “nightmare for drug developers” [108] targeting a DNA/RNA unusual 
conformation could be a successful and a promising alternative. Surely, targeting a gene rather 
than an overexpressed protein or focusing on a specific conformation displayed by an oncogene, 
means to have few copies of target and thus probably a lower dose of drug. Many oncogenes are 
fundamental in the tumorigenesis and in the tumor maintenance explaining how cancer cells 
became “addicted” to them (i.e. RAS, BRAF, c-MYC). Targeting those oncogenes means to be more 
selective to tumor cells, as oncogene inhibition will induce apoptosis especially in oncogene-
addicted cells. All these advantages explained the grafting work of researchers in designing, 
screening and validating G-quadruplex ligands. Since the Hurley ’study in 2002 [189], which shows 
that G4 binders can be used to modulate c-MYC expression, many improvements have been 
achieved in considering G-quadruplex structures as potential new drug targets. A large number of 
researches highlighted that the majority of G4 binding molecules share common structural 
features. They are characterized by i) a planar heteroaromatic chromophore necessary for the 
p-p stacking onto planar G-quartets ii) an extended side chain that is involved in the interaction 
with G4 grooves and loops and iii) a cationic charge that can promote p-Cation interaction thus 
enhancing the stacking. Quindoline and berberine derivatives (Figure 8) tested in c-MYC 
overexpressing cancer cell lines can be considered classical G4 ligands for their aromatic system 
linked with one or two amino alkyl side chains [248, 249]. Moreover, the anthraquinone derivatives 
(Figure 8) used in HRAS-addicted tumor cells showed high affinity for the G4 in HRAS promoter 
and an anti-proliferative effect in T24 bladder cancer cells [81]. Trisubstituted isoalloxazines are 
able to bind and stabilize the kit1 and kit2 G4s reducing c-KIT mRNA in cells
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[216]. The natural macrocyclic telomestatin is an exception as G4 ligand for its chemical structure, 
but its eight pentagonal rings are sufficient for the p-p stacking interaction with the G-quartets. It 
has been reported its activity in reducing c-MYC expression [250]. A large number of G4 
compounds and small molecules have been tested and they exhibited a good G4 binding affinity, 
but in a drug discovery perspective, an important issue has to be investigated: the G4 ligands 
selectivity. TMPy4 (Figure 8) is a G4 binder that is largely used in the G4-field for its pronounced 
affinity (2x10-6 M) for G-quadruplex structures [251, 252] rather than for duplex conformation. 
Firstly, selectivity between G4s and other DNA conformation (as DNA duplex) is required and 
indispensable in a therapeutic view. The duplex is obviously the prevalent conformation in the 
genome, thus a molecule, that does not discriminate between duplex and G4 structure would have 
general toxicity and marked side effects, caused by the binding to a large number of genes. Another 
crucial point for a G4 ligand’s selectivity is the ability to recognize a single G-quadruplex among the 
other present in the whole genome. There are many difficulties to address this issue. It is clear that 
all G4s share common features such as the central core formed by G-quartets. The grooves are the 
only structural features that can be exploited to discriminate among G4s. They are formed by the 
phosphodiester backbones and the loops length determines their dimension, thus G4 grooves are 
strictly dependent on the sequence and therefore can be unique. Anyway, ligand discrimination 
remains minimal because it has to overcome global G4 structures. The aimed goal of many studies 
is to design a unique-G4-specific ligand. A winning solution could be focusing the attention on a 
specific G4, to identify structural features of that unique G4 to exploit them for a rationale 
molecular design. The obstacle in this case is the insufficient G4 structural information because less 
than 1% of the total G4s available in human genome are structurally characterized. The x-ray crystal 
solution of c-KIT G4 in the promoter, for example, permitted to identify a large cleft that seem to 
be typical only for this structure and is not present in any other known G4. C-KIT G4 is a clear and 
convincing example of how the high-resolution structures and overall structural details can 
improve ligand design. Trying to find G4 ligands selective solely for a specific conformation could 
appear a non-realistic challenge, but it is worth mentioning the kinases case. The kinases selectivity 
years ago seemed to be impossible because of their marked homology and similarity in the ATP 
binding site, but in 2004, the gefitinib (Iressa; AstraZeneca) changed this idea. It is a tyrosine 
kinase inhibitor selective for the mutated epidermal growth factor receptor (EGFR) expressed in 
certain human carcinomas. Nowadays this molecule is used in breast and lung cancer therapy [253]. 
The only G4 ligand who reached the clinical trial (ClinicalTrials.gov identifier: NCT 00780663) is 
quarfloxin (also named CX-35439), but unfortunately it has not passed phase II. It is a 
fluoroquinolone derivative chemically optimized to enhance its binding capacity and G4 
interaction. Quarfloxin is accumulated in the nucleolus and selectively inhibit Pol I transcription 
[254]. It disrupts DNA G-quadruplexes-nucleolin complexes, competing with nucleolin G4 binding. 
The consequent nucleolin release in the nucleoplasm is a common response to cellular stress and 
activates apoptosis through different pathways [187]. Despite quarfloxin failure in phase II for 
bioavailability issue, the toxicity profile of this molecule was encouraging. It was well tolerated by 
patients and it does not display a genotoxic profile. Recently, another compound (CX-5461) entered 
in early phase of clinical trial for the treatment of breast cancer deficient in BRCA1 and/or BRCA2. 
Like quorfloxin, it does not cause toxicity and it showed a prominent anticancer activity in 
experimental animal model [255]. The discovery of new G4 ligands and their validation as 
therapeutic molecules is the aim of many scientists around the world and recent progress in this 
field, strongly encouraged efforts in this direction.  
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2.2.2 i-motif structure of C-rich strands 
 
In genomic DNA, wherever are present G-rich strands able to form a G-quadruplex structure, there 
are complementary strands rich in cytosine (C-rich strand). In 1993, Leroy and his coworkers 
demonstrated for the first time the ability of a DNA C-rich strand to form quadruple-helical 
structures under acidic conditions [256]. This unusual structure has been named intercalated motif 
(iM) and it consists in a conformation formed by two parallel duplexes present in an antiparallel 
mode held together through intercalated hemiprotonated cytosine-cytosine base pairs (C-C+). The 
cytosine base pair is possible only if the cytosine N3 is present in the protonated form, explaining 
the strong pH-dependency of the i-motif structure. The iM folding/unfolding is strictly influenced 
by pH and this permitted its application in different fields. In nanotechnology, the iM is useful in 
designing nanomachines [257, 258] or in providing the correct assembly of gold nanoparticles [259, 
260]. In a biological context, it could be used as a pH sensor to map pH changes in living cells [261, 
262] and furthermore it has been used as switch for logic operations [263, 264].  
 
i-motif topology 
 
The hemiprotonated cytosine base pair has been identified in 1962 [265] and the hairpin formed by 
C-C+ base pairs [266] was already known when Leroy and Guèron proposed the i-motif 
conformation. They described the i-motif conformation as two cytosinic strands that formed a 
parallel duplex through C-C+ base pairs and two of these duplexes again through C-C+ pairing 
resulted in an intercalated conformation (Figure 9).  
 
Figure 8. G-quadruplex ligands. 
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Oligonucleotides can have different intercalation topologies: terminal cytidine can be either on the 
3’ end or on the 5’ end of the strand, respectively classified as 3’E and 5’E topologies [267, 268]. 
Structures with different intercalation topologies can have similar stabilities. The third possible and 
less stable topology is the one with a mixture of two or more structures (called the T-form). PH 
range from 4 to 7 provides the N3 protonation and DNA folding into the closed i-motif structure; 
the highest stability of iM structures occurs at pH value close to cytosine pKa [269]. At higher 
values, cytosine is deprotonated and it results in the iM conversion to the single-stranded form. On 
the contrary, if the pH is too low (approximately ˂ 3) all the cytosines are protonated not 
permitting the hydrogen pattern needed for the C-C+ base pairing [270].  Sequences d(TAACCC)n 
present in the human telomeres are also stabilized by interactions between non-cytosine bases. In 
this case the TAA part can form an A-T base pair which stacks on the cytosine core [269]. Loop 
interactions are important in determing iM stability: in the human telomeric DNA, non-cytosinic 
bonds are responsible of a thermal stability increase. The systematic substitution of loop bases 
resulted in a decrease of melting temperature of ~2°C /substitution. The i-motif structure is the 
spatial arrangement of C-C+ base pairing: if cytosines involved in the structure are all present in one 
nucleic acid strand it is defined an intramolecular iM, on the other hand if it is composed by 2 or 
many strands it is defined as an intermolecular iM. In 2010 Brooks, Kendrick and Hurley 
categorized the intramolecular iMs into two “classes” depending on the iM loop length [271]. “Class 
I” i-motif are characterized by short loop whereas “class II” is formed by iM structures with longer 
loops. “Class II” i-motifs are reasonably more stable than “class I” iMs for additional interactions 
within long loop regions. Moreover, in addition to the three hydrogen bonds at each C-C+ base 
pairing, extra interactions in the loop region and C+-positive charges on the backbone favor the 
four strand association. Therefore, a balance between the sugar interactions and any potential extra 
interactions in the loops region generates a stable iM conformation [272]. 
 
i-motif in a biological context 
 
Bioinformatics tools to map i-motif structure in the genome has not yet been developed, but 
starting from the point that the iM is naturally the G-quadruplex complementary strand, an overlap 
in their prevalence in the genome is possible, at least partially. The iM structure is particularly 
 
Figure 9. Cytosine-Cytosine base pair and i-motif structure. 
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stable at pH values below the physiological one (~7.4) and that is the main reason why it has been 
considered less interesting and attractive in a biological approach, if compared to the G-
quadruplex. Anyhow, recent progress and efforts have been done in understanding how this 
structure could be possible in vivo and in pointing out its biological significance. Special attention 
has been devoted to the iM formation and stability in order to propose an i-motif biological role in 
vivo. Obviously, the canonical Watson-Crick duplex in physiological conditions of pH and 
temperature is the prevalent DNA conformation due to its high thermodynamic stability. Negative 
superhelicity induced by nuclear processes as transcription, replication and repair, results in a local 
unfolding of the double helix. In this condition unusual DNA secondary structures as G-quadruplex 
and i-motif could be favored [273]. The importance of supercoiling in modulating the c-MYC G4/iM 
folding has been described by Hurley and colleagues [274]. They employed a system to induce 
negative supercoiling upstream the TSS in a supercoiled plasmid. They inserted into a Del4 plasmid 
wild-type or mutated sequence of the c-MYC NHE III and comparing chemical/enzymatic 
footprintings they showed the negative superhelicity contribution in promoting secondary DNA 
structures at physiological conditions [274]. A cancer hallmark is certainly an altered metabolism 
and one of the main consequences is surely a dysregulated pH. In normal and differentiated cells 
the intracellular pH is generally around 7.2 and the extracellular one is ~7.4. Differently, a typical 
feature of a cancer cell is a higher intracellular pH (~7.4) and a lower extracellular pH (6.7-7.1) [275, 
276]. The acidic environment of cancer cells could be a biological condition in which the iM folding 
could be promoted and favored resulting in an altered gene expression. Moreover, some biological 
processes could cause a local and transient acidification in the cell. For example, Poly (ADP-ribose) 
polymerase (PARPs) produces 1 mol of proton nicotinamide for each mol of NAD consumed. 
Therefore, PARPs activation is responsible for protons release in a very short period resulting in a 
transient acidification [277], which could drive and regulate i-motif folding in cells. Another 
important consideration must be the formation of the iM conformation in a biological 
environment: the crowding nature of the in vivo condition. The cellular context is surely 
characterized by a crowded environment defined as the excluded volume effect and dehydration 
effect. Rajendran and colleagues demonstrated that polyethylene glycol (PEG 2000 and PEG 8000), 
used to mimic the molecular crowding in vitro, induces the iM folding at neutral pH value (pH 7.0) 
[278]. These outfindings have been showed also for the c-MYC promoter sequence: c-MYC i-motif 
forms a stable structure at pH values as high as 6.7 in 40% w/w polyethylene glycol with a 
molecular weight higher than 12000 g/mol [279].  In spite of the uncertain existence in vivo it has 
been proved that C-rich sequences, so putative i-motif conformations,  are source of error in DNA 
amplification [280]. The C-rich region of the murine KRAS promoter is one of the first oncogene i-
motif that has been characterized [281]. In the last years, several iMs present in oncogene 
promoters have been investigated and described such as c-MYC [282], BCL2 [283], VEGF [284], RET 
[285], Rb [286]. In addition, a dual i-motif/G-quadruplex system in KRAS promoter has been 
presented as a possible mechanism to modulate gene expression [201]. The increasing number of 
studies on this topic in the last years demonstrates a growing interest on the iM structure and on 
its possible involvement in gene expression regulation.  
Proteins recognizing the i-motif  
 
In order to support the biological relevance of the i-motif folding, protein interacting with C-rich 
DNA strands have been deeply investigated. The iM geometry and charge distribution could be a 
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sophisticated mode to enhance specific structural protein recruitment [287]. Hurley’s group 
presented a detailed mechanism in which transcription factor hnRNP LL activates BCL-2 
transcription. Through electrophoretic mobility shift assays (EMSA) the study shows that the i-
motif folding is needed for hnRNP LL binding. The hnRNP LL binding does not occur if the protein 
is incubated with a mutated C-rich sequence incapable of forming the iM structure [288]. Hurley’s 
in vitro study is the first example of how gene expression could be modulated targeting the i-motif 
structure. They demonstrated that BCL-2 promoter exist in a dynamic equilibrium between iM and 
hairpin conformations. Through the addiction of two compounds, one selective for the BCL-2-i-
motif (IMC-48) and the other for the hairpin conformation (IMC-76), the equilibrium is shifted to 
each structure, respectively. I-motif stabilization lead to a BCL-2 up-regulated expression and on 
the other hand the hairpin impairs the iM structure and causes a downregulated BCL-2 
transcription. Furthermore, hnRNP LL transcription factor, through RNA recognition motifs (RRM) 
1 and 2, is able to recognize and bind the i-motif loop II and loop VI promoting a conformational 
change which yield BCL-2 transcriptional activation [288]. The discovery of the i-motif binding 
protein hnRNP LL supports, in the BCL-2 case, a plausible role of this unusual DNA structure in a 
biological process. The iM hypothesized function is to provide a structural arrangement for protein 
recognition causing the unfolding and so the transcription initiation. They proposed the i-motif as 
a mode to display specific nucleotide sequences (loops region) in the most kinetically favorable 
conformation for protein binding. The protein recognition yields the structural unwinding and 
promotes single stranded form, needed for a “fluent” transcription. HnRNP K is a transcription 
factor, belonging to the same protein family able to bind the C-rich region present in the c-MYC 
promoter [289]. It has similar spaced domains that recognize the c-MYC TCCC sequences [290]. As 
in BCL-2 promoter, the recognition sequences are present in the lateral loops of the c-MYC i-motif 
and are spaced by the same number of bases, hence, hnRNP K may have the analogous regulatory 
function on c-MYC transcription. Additionally, it has been shown that hnRNP K is able to bind the 
C-rich strand of human telomeres that displays the same CCCT repeats [287]. Despite the fact that 
these sequences of the telomeric i-motif are not present in the lateral loops, Lacroix and coworkers 
showed that protein binding to the human telomeric i-motif is stable at pH values ≥ 6 [287]. 
Maurice Gueròn’s laboratory investigated the proteins binding to the yeast, tetrahymena and 
vertebrate telomeric sequences that are expected to form i-motif structures [291].  In literature a 
large variety of protein that selectively bind C-rich single strand are reported [292, 293] and it could 
be possible that their recruitment depends on a secondary DNA structure. Further studies in this 
direction are necessary to better understand the i-motif physiological role. The perception of G-
quadruplex has changed in time, from a simple unusual DNA structure to a potential therapeutic 
target involved in many oncogenes expression. Compared to the deep knowledge on G-quadruplex, 
our information on the i-motif structure and its biological implications needs to be improved. 
Anyway, the growing evidences supporting the iM folding in physiological conditions can 
encourage researches and stimulate scientists in proposing the i-motif structure as hypothetical 
new potential target for genetic diseases.   
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2. AIM OF MY PhD WORK 
As the ras genes are considered “undruggable” since a long time, the search for alternative anti-
cancer strategies to suppress their expression in ras addicted tumors is one of the most important 
goals to be pursued in cancer therapy. My PhD work started from the above consideration; I have 
investigated the role of unusual nucleic acid structures in the ras promoters and in the 5’-
untraslated region (5’-UTR) of KRAS with the aim of developing alternative anti-ras strategies. 
Specifically, my work focused on the regulatory function of DNA and RNA non-canonical 
structures (G-quadruplex and i-motif) associated to the HRAS promoter and to the KRAS 5’-UTR 
(Figure 10). In addition, I have developed a single-stranded miRNA-oligonucleotide therapy 
specific for oncogenic KRAS. 
In the first part of my research, I focused on the HRAS oncogene. It is often mutated in bladder 
tumours and since it is involved in the pathogenesis of this disease, its downregulation is expected 
to sensitize cancer cell to chemotherapy. Previous studies made in our laboratory demonstrated 
that the HRAS oncogene is regulated at transcriptional level by a molecular switch involving two G-
quadruplex structures located immediately upstream of the transcription start site [117]. 
Considering that the formation of G4 DNA by the G-rich strand leaves the complementary C-rich 
strand unpaired and subjected to nuclease, we asked if the latter is able to fold into the so called i-
motif conformation. I therefore focused on the C-rich complementary strand of the HRAS 
promoter. I have investigated the capacity of the HRAS C-rich strand to fold into the i-motif 
conformation at several conditions, including a near-physiological condition. I also discovered that 
hnRNP A1, a protein associated to the CG-elements of the ras genes, is able to bind to the i-motif 
and unfold this particular DNA structure.  On the basis of this finding we proposed the formation 
in the HRAS promoter of a G-quadruplex/i-motif switch controlling transcription in bladder cancer 
cells. Subsequently, as the HRAS G-quadruplex is recognized by specific transcription factors (Sp1, 
MAZ and hnRNP A1) essential for transcription, I employed a decoy strategy to suppress HRAS in 
bladder cancer cells. Its rationale is based on the principle that delivering to the cells 
oligonucleotides that mimic the HRAS G-quadruplexes, they will compete with the binding of the 
transcription factors to the promoter with the result that transcription will be decreased, if not 
completely suppressed. We designed decoy oligonucleotides engineered with anthraquinone 
insertions and locked nucleic acids (LNA) modifications, mimicking one of the two neighbouring 
G-quadruplexes controlling HRAS expression.  
My PhD work then focused on KRAS which is mutated in pancreatic cancer cells. The aim was to 
suppress this oncogene through strategies based on the use of small molecules. To address this 
issues I focused on the transcript of KRAS, especially on the 5’-UTR and 3’-UTR untranslated 
regions. The 5’-UTR is very rich in guanines (77 % CG) and contains three non overlapping G-
quadruplex motifs in the first 80 nt. Using a combination of techniques, we demonstrated that the 
5’-UTR exists in equilibrium between a stem-loop structure and a G-quadruplex structure. I used a 
new class of small molecules (anthrathiophenediones and anthrafuranediones) to target the G-
quadruplexes of the KRAS 5’-UTR. With my work I found that these small molecules are able to 
inhibit the process of translation. The suppression of KRAS induced apoptosis in pancreatic cancer 
cells. I also focused on the 3’-UTR, where there is the target region of miR-216b: a microRNA that is 
aberrantly down-regulated in pancreatic cancer. MiRNAs are small non-coding RNA endogenous 
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molecules (containing about 22 nucleotides) that function as post-transcriptional regulators of 
gene expression. We designed single-stranded miR-216b mimics, modified with unlocked nucleic 
acid (UNA) insertions to increase their nuclease resistance. We evaluated the efficacy of a new 
delivery strategy for miR-216b mimics based on the use of palmitoyl-oleyl-phosphatidylcholine 
(POPC) liposomes functionalized with lipid-modified miR-216b and lipid-modified cell penetrating 
TAT peptide. 
The results obtained by our work have been published and/or submitted in peer-reviewed journals 
and are reported in the “Results” section of this dissertation. 
 
 
 
  
 
Figure 10. Cartoon to recap the aim of the study. 
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 e HRAS oncogene encodes for a 21-kD GTP-ase conveying signals to the nucleus that stimulate cell prolifer-
ation1. In many tumours HRAS is mutated, normally in exon 1, codon 12, 13 or 61, and encodes for an altered 
protein which constitutively activates downstream pathways causing normal cells to become cancerous cells2. In 
previous works, we have demonstrated that HRAS is regulated by two neighbouring GC-rich elements that we 
called hras-1 (nt 432-464, A.N. J00277) and hras-2 (nt 509-530, A.N. J00277), located immediately upstream of 
the major transcription start sites (TSS’s), each capable of folding into a G-quadruplex structure3,4. By site-directed 
mutagenesis of the GC-elements, we found that the G-quadruplexes behave as transcription repressors3. Under 
normal conditions, hras-1 and hras-2 are folded into G-quadruplexes, thus locking the promoter into an inactive 
state characterized by a low transcription level3. Transcription is activated when the G-quadruplexes are unfolded, 
and the G-elements transformed into canonical B-DNA forms. We found that MAZ, a zinc-#nger transcription 
factor recognizing blocks of guanines, interacts with the promoter GC-elements under cellular conditions3. MAZ 
is an essential protein for gene expression, as it unfolds the HRAS G-quadruplexes and activates transcription3,4. 
Our data support a transcription model according to which the two neighbouring G-quadruplexes behave as a 
molecular switch that controls gene expression.
In the present work we interrogated if the complementary C-rich strands of hras-1 and hras-2 (namely hras-
1Y and hras-2Y) fold into the well known iM conformation5–15. We found that hras-1Y and hras-2Y assume the iM 
conformation under slightly acidic conditions, which are close to neutrality in the presence of a crowding agent, for 
example PEG-30016. We also discovered that the HRAS iMs are recognized by nuclear proteins, including nuclear 
factor hnRNP A1. is protein, which shows a binding preference for cytosines, unfolds the iM conformation of 
ͷ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the HRAS sequences. When hnRNP A1 was knocked out in T24 bladder cancer cells by a speci#c shRNA, the level 
of HRAS transcript also dropped to 44 ± 5% of the control. Together, our data provide evidence that hnRNP A1, 
with its unfolding activity against the iM, is an essential factor for the activation of HRAS. Indeed, when hnRNP 
A1 was sequestered by decoy oligonucleotides mimicking the iM, HRAS transcription was signi#cantly down-
regulated. e outcome of this work support the notion that HRAS expression is regulated by a G-quadruplex/iM 
switch that is controlled by proteins.
Results and Discussion
 e sequence of the HRAS promoter immediately upstream of the major transcription start sites is reported in 
Fig. 1A. It contains two GC-rich elements, hras-1 and hras-2, composed of blocks of guanines and capable of folding 
into G-quadruplex structures. In previous works we have demonstrated that these sequences behave as a regulatory 
switch controlling gene expression3,4. Such a mechanism has been proposed for other relevant oncogenes including 
KRAS17,18, CKIT19,20, and CMYC21,22. A couple of comprehensive reviews on this subject have been reported23,24. 
In this work we have focused on the complementary C-rich strands hras-1Y and hras-2Y and have investigated if 
they fold into stable iMs.
iM formation by the HRAS C-rich sequences. To #nd out if hras-1Y and hras-2Y can assume the iM 
conformation, we performed circular dichroism (CD) experiments as a function of pH, in 50 mM KCl, 50 mM 
Tris-acetate, 25 °C. To mimic the crowding conditions of the cell, we analysed the sequences both in the presence 
and absence of 40% (w/v) PEG-30016. Typical CD titrations are shown in Fig. 1B,C. It can be seen that the spectra 
of hras-1Y and hras-2Y change dramatically as the pH is gradually decreased from 8 to 4.5. Under acidic condi-
tions (pH 5) both sequences exhibit the characteristic enhanced ellipticity at ~287 nm of a classical iM10,12,25–27, 
while at pH 8 the sequences exhibit a much lower ellipticity, shi*ed at ~285 nm. By plotting the 287-nm ellipticity 
as a function of pH, we obtained for each sequence, in the presence or absence of PEG-300, sigmoidal curves 
re+ecting iM formation (Fig. 1D). e crowding agent drives the folding at higher pH values: the semi-transition 
of hras-1Y increases from pH 5.9 to 6.3, whereas that of hras-2Y increases from pH 6.2 to 6.7. ese plots suggest 
that the iMs are stable in a slightly acidic medium. However, under cellular conditions the iM can be stabilized by: 
Figure 1. (A) Sequences of the GC-rich elements located in the HRAS promoter upstream of major TSS’s; (B,C) 
Circular dichroism titrations of hras-1Y and hras-2Y (3 µ M, 1 cm pathlength cell) in 50 mM Tris-acetate, 50 mM 
KCl, 40% PEG-300 and pH from 4.5 to 8; (D) Ellipticity (287 nm) versus pH curves for hras-1Y and hras-2Y in 
the presence and absence of PEG-300; (E) Determination of number of protons picked up by hras-1Y and hras-
2Y upon folding into the iM.
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(i) transcriptionally induced DNA superhelicity28,29; (ii) more e<ective cellular crowding conditions30,31; (iii) an 
increased intracellular acidity generated by an increase of the glucose-lactate +ux32,33.
As the ellipticity-versus-pH curves are reversible, we evaluated the number of protons involved in the folding 
of hras-1Y and hras-2Y, by considering the following equilibria:
+ ⋅ ( )+ +R ⁎mH U U mH 1
⋅ + ⋅ ( + ) ( )+ + +R⁎U mH nH F m n H 2
where equilibrium 1 takes into consideration the fact that the unfolded C-rich sequence, U, may bind m protons 
before folding into the i-motif (as the pKa of cytosine is ∼ 4.434, at pH 5 about 3 cytosines out of 12 are expected 
to be protonated); U*·mH+ is the unfolded sequence with m bound protons. e bases in U*·mH+ are assumed 
to be unstacked, so the formation of this species is accompanied by a negligible change in the CD spectrum35. In 
contrast, upon folding into i-motif F, U*·mH+ assumes in a cooperative manner other n protons to form (n+ m) 
CH+:C base pairs that are stacked in the structure. A signi#cant CD spectral change is expected for the formation 
of the iM8,10 (equilibrium 2), whose equilibrium constant is KD = ([F·(m+ n)H+]/([U*·mH+][H+]n) (3). From 
the CD plots of Fig. 1B,C, we determined for each sequence the fraction of folded and unfolded species and ratio 
[F(n+m)H+]/[ U*·mH+]. By plotting log [F(n+m)H+]/[ U*·mH+] versus pH, we obtained a straight line whose 
slope is n (Fig. 1E). We obtained values of n ∼ 4 and n ∼ 2 for hras-1Y and hras-2Y, respectively. is suggests that 
when hras-1Y and hras-2Y fold into the iM, they assume 4 and 2 protons, respectively, which agrees with the fact 
that the sequences are partially protonated before folding. A similar behaviour has been previously observed for 
the formation of the i-motif by (C3TA2)414.

Ǥ  e intramolecular iM, being a folded structure, migrates in a 
polyacrylamide gel faster than an unfolded oligonucleotide of the same length. We analysed hras-1Y and hras-2Y by 
PAGE under di<erent pH conditions. e mobility of the two C-rich sequences was compared with that of hras-1Y 
variants: ODN-1 (unable to form any structure); ODN-2 (forming an iM with 4 CH+:C) and ODN-3 (forming a 
stable W.C. hairpin) (Fig. 2A,B) (Methods). Under denaturing conditions (7 M urea), the 27-mer oligonucleotides 
(hras-1Y and variants) exhibited the same mobility, with the exception of ODN-3 that forms a hairpin even in the 
presence of 7 M urea. Sequence hras-2Y, being embedded in a 36-mer oligonucleotide, migrates slowly (Methods). 
In contrast, under native conditions at pH 5, hras-1Y, that assumes the iM according to CD, migrates with a sharp 
band faster than that of ODN-1. Interestingly, when the hras-1Y sequence is modi#ed to fold into a hairpin stabilized 
by a stem of 8 W.C. bps (ODN-3) (S1), it migrates even quicker than the iM. is is because the 6 positive charges 
of iM reduce its negative charge density. e folding of hras-1Y into the iM is quite fast, as the mobility does not 
change when the sample is heated before loading. Variant ODN-2, forming an iM with 4 positive charges (S1), 
migrates slightly faster than hras-1Y, as expected. At pH 5, the 36-mer oligonucleotide containing sequence hras-2Y 
migrates quicker than unstructured 27-mer ODN-1, as it folds into the iM (see CD). At pH 7, both hras-1Y and 
hras-2Y still migrate faster than ODN-1, indicating that even at neutral pH the sequences are folded. However, they 
Figure 2. (A) PAGE of hras-1Y and hras-2Y and variants ODN-1, ODN-2 and ODN-3 in denaturing conditions 
(7 M urea); native conditions at pH 5 and 7. e oligonucleotide sequences are reported in Methods. e 
electrophoresis was run at 20 °C, the bands stained with stains-all. ∆ = heated 10 min 90 °C; (B) CH+:C base 
pair; (C) Putative equilibrium between iMs involving di<erent protonation levels and a +exible hairpin formed 
by hras-1Y at pH ≥ 7.
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migrate either with a smeared band (hras-1Y) or with two bands (hras-2Y), suggesting that more than one folded 
structure is formed: most likely iM-like structures stabilized by C:C and CH+:C bps. It is also possible that at pH 
7, the iM-like structure is in equilibrium with a +exible hairpin (Fig. 2C, S1).
We have also examined the thermal stability of the iMs by CD- and FRET-melting experiments. Typical 
CD-melting pro#les for hras-1Y and hras-2Y are reported in Fig. 3A,B. By heating (20 → 85 °C) and then cooling 
(85 → 20 °C) the DNA solutions in 50 mM sodium cacodylate, pH 5, 50 mM KCl, the folded/unfolded transitions 
showed to be cooperative and reversible, as previously found for C-rich oligonucleotides under similar experi-
mental conditions10,12–14. e melting in the pH range between 5 and 7 was examined by FRET experiments, using 
oligonucleotides end-labelled with ATTO-488 (5′ -end) and TAMRA (3′ -end) (Fig. 3C,D). e TM of both hras-1Y 
and hras-2Y decreased with increasing pH: hras-1Y, 55.9, 52.1, 47.6, 44.8, 41.3 °C at pH 5, 5.5, 6, 6.5, 7, respec-
tively; hras-2Y, 65.5, 58.7, 55.1, 53.8, 53.1 °C at pH 5, 5.5, 6, 6.5, 7. At pH values > 5, the TM of the iMs decreases 
as the structure is probably stabilized by a number of CH+:C < 6. It is indeed reasonable to assume that when the 
medium is not su=ciently acidic, the iM is stabilized by both C:C and CH+:C base pairs36,37. iM structures of dif-
ferent protonation levels may coexist in solution. Mechanical stability experiments with the ILPR C-rich sequence 
showed that partially folded iM-like species are in equilibrium with fully folded iM at neutral pH36. e higher TM 
of hras-2Y is likely due to the additional CH+:C bp that stabilizes the iM. e two structures have similar rupture 
forces and su=cient stability to stall RNA polymerase36. Yang and Rodgers have reported that the energy of C:C 
is about 1/3 of that of CH+:C38. Sequence hras-2Y shows a behaviour similar to hras-1Y, with the di<erence that at 
pH 5 it shows a higher TM, 65.5 °C (Fig. 3D).
We evaluated the thermodynamics of the folding transitions according to a two-state model. is was 
done at pH 5, where the two sequences fold into only one structure, as shown by PAGE. From the CD- and 
FRET-melting curves at pH 5, we obtained the following average thermodynamic data (± 10%): ∆ H = 252 kJ/mol 
and ∆ S = − 770 J/mol K and ∆ G = − 17 kJ/mol for hras-1Y; ∆ H = 323 kJ/mol and ∆ S = − 950 J/mol K and 
∆ G = − 27 kJ/mol for hras-2Y. Assuming that the breaking of a CH+:C bp needs approximately 46 ± 4 kJ/mol12, 
the number of CH+:C broken by the thermal disruption of hras-1Y is ~6, of hras-2Y is ~7, in accord with the number 
of expected protons that should bind to the sequences at pH near pKa10,12. At pH 5, nearly half of the cytosines is 
protonated and the sequences are completely folded into iM, showing the highest stability.
The HRAS iͷǤ As the iM-forming sequences overlap critical GC-elements 
immediately upstream of TSS, we interrogated if these unusual structures are recognized by nuclear proteins. 
Previous studies have reported that DNA sequences composed by runs of cytosines such as the C-repeats in the 
telomeres and in the CMYC promoter are recognized by proteins of the heterogeneous nuclear riboproteins fam-
ily (hnRNP)39,40 Moreover, Hurley and co-workers recently reported that the iM formed in the BCL2 promoter 
interacts with hnRNP LL6. Speci#c binding of heterogeneous ribonuclear proteins to C-rich DNA sequences is 
Figure 3. (A,B) CD melting curves of 3 µ M hras-1Y and hras-2Y in 50 mM sodium cacodylate, pH 5, 50 mM 
KCl. Denaturing curve (20 → 85 °C), renaturing curve (85 → 20 °C); (C,D) Fraction of iM versus T curves 
obtained from FRET-melting experiment (0.3 °C/min), in 50 mM sodium cacodylate, pH 5 to 7, 50 mM KCl. 
 e curves of hras-1Y and hras-2Y at pH 5 are fully reversible. FRET-melting gives TM values ∼ 3 °C higher than 
CD-melting values, due to the presence of the +uorophores in the oligonucleotides analysed by FRET.
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also supported by previous work, according to which hnRNP A1 binds to the GC-element of KRAS17, which shows 
a high sequence/functional homology with the HRAS GC-elements. HnRNP A1 is one of the most abundant 
nuclear proteins of eukaryotic cells that regulates several aspects of mRNA biogenesis41. As it is over-expressed 
in a variety of cancers41,42, we wondered if this protein plays a role in the promoter of the HRAS oncogene, in the 
region where the iM can potentially be formed. To address this question, we #rst investigated by chromatin immu-
noprecipitation (ChIP) if in HRAS-mutant T24 bladder cancer cells, hnRNP A1 is associated to the GC-elements 
under in vivo conditions. e occupancy of hras-1 and hras-2 (located 6 bp upstream of #rst TSS) by hnRNP A1 
was compared with the occupancy of a reference GC-rich sequence unable to fold into a non-B DNA structure 
(located 870 bp downstream from #rst TSS). A typical ChIP is shown in Fig. 4A. We found that the occupancy of 
hras-1 and hras-2 by hnRNP A1 was, respectively, ~6- and ~5-fold higher than the occupancy by IgG (negative 
control). As hras-1 and hras-2 are located in the region of the major transcription start sites, they show a signif-
icant occupancy by RNA Pol II: ~4-fold higher than the IgG signal. In contrast, the reference sequence showed 
almost no occupancy by any of the proteins considered. e ChIP data provided strong evidence that hnRNP A1, 
under in vivo conditions, is indeed associated to the critical GC-elements of the HRAS promoter. However, ChIP 
data do not provide information about the conformation of the GC-elements interacting with hnRNP A1. To 
know if the nuclear factor recognizes the iM, we performed EMSA at pH 5.5 and 20 °C of mixtures composed by 
hras-1Y or hras-2Y and recombinant hnRNP A1, which was produced with a high degree of purity (Fig. 4B,C). It 
Figure 4. (A) ChIP experiment to determine the occupancy of hras-1, hras-2 and control sequence (870 bp 
downstream from TSS) by hnRNP A1. Histograms shows the relative occupancy of hras-1 and hras-2 by hnRNP 
A1, RNA Pol II (positive control) and IgG (negative control). Data have been normalized by IgG signal; (B) 
EMSA of 32P-labelled hras-1Y and hras-2Y in 50 mM Tris-acetate pH 5.5, 50 mM KCl, incubated 40 min at room 
temperature with increasing amounts of recombinant hnRNP A1 (0–12 µ g). Lane (∆ ,A1) indicates the iM 
incubated 40 min at room temperature, with denatured hnRNPA1 in binding bu<er (see Methods); (C) EMSA 
at pH 5.5 of hras-1Y with BSA or denatured hnRNP A1 and EMSA of hras-1Y (m) with hnRNP A1; ss = single-
stranded oligonucleotide; 1:1 and 1:2 DNA-protein complexes.
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can be seen that at pH 5.5 hras-1Y and hras-2Y (which are in the folded iM conformation) form with hnRNP A1 a 
retarded band due to a 1:1 DNA-protein complex. In the presence of 4 µ g hnRNP A1, the iM is completely bound 
to the protein (Fig. 4B). With higher protein amounts, a second retarded band of much weaker intensity, probably 
a 1:2 complex, can be seen in the gel. When hnRNP A1 was thermally denatured before being added to the iM, 
the DNA-protein complex was abrogated and the iM migrated as a free molecule. As a further control, we used 
an unspeci#c protein like BSA and we found that it did not bind to the iM, as expected (Fig. 4C). When the iMs 
was destabilized by replacing 4 C with 4 T (hras-1Y(m)) (see Methods), the binding was signi#cantly attenuated, 
suggesting that the iM conformation is essential for optimal hnRNP A1 binding.
ͷi-motif. In a previous work we have found that the HRAS promoter is highly 
active when the GC-elements are unfolded in the double-stranded conformation3,4. We now asked if the binding 
of hnRNP A1 to the iM involves the unfolding of this non B-DNA structure. To this purpose, we performed FRET 
experiments with hras-1Y tagged with ATTO-488 (donor) and TAMRA (acceptor) in 50 mM sodium cacodylate, pH 
5.5, 50 mM KCl. By exciting the donor at 480 nm, both donor (520 nm) and acceptor (580 nm) emit +uorescence, 
as a result of FRET between the +uorophores (Fig. 5A). When hras-1Y is folded into the iM, the energy transfer, 
ET, between the two +uorophores is 0.77, and their end-to-end distance is ∼ 40 Å (S2). e e<ect of hnRNP A1 on 
the iM was investigated by incubating protein and DNA for 1.5 h and measuring the +uorescence between 500 and 
650 nm, upon donor excitation at 480 nm. It can be seen that hnRNP A1 causes a dramatic increase of the donor 
emission, accompanied by a decrease of ET as a function of r (r = [protein]/[iM]), in a dose-dependent manner, 
from 0.77 (r = 0) to 0.18 (r = 7) (inset). is means that the end-to-end distance in the iM increases from ~40 to 
~64 Å, suggesting that upon binding to the protein, hras-1Y goes through a conformational change. When hras-
1Y is in the duplex conformation, the +uorophores are separated by ~86 Å (26 × 0.33 = 86 Å, where 0.33 Å is the 
vertical rise per bp), as a 27-mer duplex behaves as an extended rigid rod. It follows that the iM bound to hnRNP 
A1 is not fully extended as in the duplex. As a control we used an unspeci#c protein as BSA and heated hnRNP 
A1 before incubation with the iM (20 min, 95 °C). In both cases the +uorescence of the donor did not increase, as 
expected (Fig. 5A).
To further support the #nding that hnRNP A1 disrupts the iM, we carried out FRET-melting experiments, rea-
soning that the iM would not give its typical melting pro#le when bound to hnRNP A1. Fig. 5B shows that hras-1Y 
iM in 50 mM sodium cacodylate, pH 5.5, 50 mM KCl has a TM ~ 50 °C. In the presence of 4 equivalents (r = 4) of 
Figure 5. (A) FRET spectra of 200 nM hras-1Y treated with increasing amounts of puri#ed hnRNP A1 at pH 
5.5, 50 mM sodium cacodylate, 50 mM KCl. As a control BSA and denatured hnRNP A1 (A1 ∆ ) have been used. 
Note that hnRNP A1 causes a dramatic increase of the 520 nm donor emission. e emission spectra of hras-1Y 
hybridized to its complementary strand to yield the duplex is reported. Insight shows the energy transfer (ET) 
between donor-acceptor as a function of hnRNP A1 concentrations; (B) FRET-melting of hras-1Y incubated 
with increasing amounts of hnRNP A1 (r = 1–7). e protein abrogates the melting pro#les; (C) Cartoon 
showing the melting of hras-1Y bound to its complementary strand or to hnRNP A1 (r = 1–7); (D) –dRFU/
dT versus T curves of hras-1Y alone, hras-1Y+ protein, hras-1Y in duplex, i.e. hybridized to its complementary 
strand.
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BSA or denatured hnRNP A1, the melting pro#le of hras-1Y did not change, as expected. In contrast, when the hras-
1Y iM was incubated with increasing amounts of native hnRNP A1 (r = 1–7), its melting pro#le strongly changed, 
in keeping with the fact that hras-1Y bound to the protein is not in the iM conformation. It is worth noting that free 
hras-1Y melts with an increasing sigmoidal curve, whereas hras-1Y bound to hnRNP A1 melts with a decreasing 
sigmoidal curve (Fig. 5B). A melting pro#le similar to that of the hras-1Y:hnRNP A1 complex is obtained with 
hras-1Y in the duplex conformation with its complementary strand, where the two +uorophores are separated by 
~86 Å. Upon melting, the duplex releases the hras-1Y strand which, thanks to its +exibility, will have an end-to-end 
distance < 86 Å (Fig. 5C). is results in a decreasing sigmoidal melting curve, and thus in a –dRFU/dT versus T 
curve marked by a positive peak. In the same way, hras-1Y bound to hnRNP A1 is more extended than when it is 
free. erefore, also the complex gives a decreasing melting curve and a #rst derivative curve with a positive peak 
at ∼ 50 °C. e melting of free hras-1Y folded in the iM gives an increasing melting curve and a –dRFU/dT versus 
T curve with a negative peak (Fig. 5D). Summing up, both FRET titrations and melting provide strong evidence 
that hnRNP A1 unfolds the HRAS iM.
We have also analysed the e<ect of hnRNP A1 on the hras-2Y iM. We found that the protein unfolds the iM 
of hras-2Y at higher r values, as the iM formed by hras-2Y has a higher stability than the hras-1Y iM (58.7 versus 
52.1 °C, at pH 5.5) (S3).
 e e<ect of hnRNP A1 on the HRAS iMs was also investigated by CD (Fig. 6). At pH 5.5, hras-1Y and hras-2Y 
show the typical strong ellipticity at 287 nm of the iM conformation. When the iMs are thermally denatured, the 
positive 287 nm ellipticity drops dramatically. is is a hallmark of the transformation of iM into ssDNA. A similar 
spectral change was obtained when we added increasing amounts of hnRNP A1 (r = 1, 2, 3, 4) to the iMs. HnRNP 
A1 causes a progressive reduction of the 287 nm ellipticity, indicating that the iM structures are unfolded by the 
protein. As already observed with the FRET experiments, the unfolding e<ect is stronger with hras-1Y than with 
hras-2Y, owing to the di<erent stability of the two iMs.
ͷhrasǦͷY iM. Clues to the binding mode of hnRNP A1 to 
the iM can be obtained from the co-crystal structure of UP1 (the N-terminus of hnRNP A1 with DNA binding 
activity) and the human telomeric sequence d(TTAGGG)243. e co-crystal shows that a protein dimer binds to 
two single-stranded strands, in the antiparallel orientation. As the two binding domains (RRM1 and RRM2) within 
each protein molecule are also antiparallel, the 5′ → 3′ polarity of ssDNA with respect to the RRM orientation is the 
same for each RRM. e two lateral loops of the iM may (a*er a minor adjustment) provide suitable binding sites 
for hnRNP A1, as they are antiparallel and separated by ~15–20 Å. So, the iM’s main function should be to provide 
a rigid chemical frame displaying two lateral loops with the precise nucleic acid directionality with respect to the 
RRM orientation. In other words, the iM structure should o<er a kinetic advantage to the binding of hnRNP A1 
(indeed, when the iM is disrupted, the binding is strongly attenuated, Fig. 4C). If we assume that the protein binds 
to the lateral loops, it can form either a 1:1 or a 1:2 complex, depending whether one or two protein molecules bind 
to the iM. e equilibria occurring in solution are: P + iM =1tJ.	
1+1tiM = (P)2tiM (5), where P is hnRNP 
A1. In the presence of a large excess of P compared to iM (1:100), both equilibria shi* to the right forming complex 
1:2. In contrast, with less P (ratio 1:50) equilibrium (5) does not shi* to the right and only complex 1:1 is formed 
(Fig. 7A, lanes 1–3). In addition, as hnRNP A1 unfolds the iM, its binding depends on temperature: at 0 °C only 
complex 1:1 is formed probably because it requires a partial unfolding of iM, at 37 °C complex 1:2 is favoured as it 
requires a complete opening of the iM (S4). To support the binding of the protein to the lateral loops we performed 
the following competition experiment. As the two lateral loops of the hras-1Y iM are separated by 10 nt, complex 
1:2 should be competed by an oligonucleotide containing the two lateral-loop binding sites separated by a spacer of 
10 nt (with a 10 nt spacer the competitor assumes a U-shape so that two antiparallel binding sites can interact with 
the protein RRMs). Moreover, if the spacer of the competitor is reduced to 8, 6, 4, and 2 nt, its capacity to compete 
with the formation of the 1:2 complex should gradually become weaker. To test this hypothesis we designed the 
competitors shown in Fig. 7C. When the competitors (150-fold in excess over iM) were incubated with the iM and 
hnRNP A1 (100-fold over iM), we found that the best competitor was the oligomer containing a spacer of 10 nt, 
Figure 6. Circular dichroism analysis of 3 μM (0.5 cm pathlength cell) hras-1Y and hras-2Y at pH 5.5, 50 mM 
Tris-acetate, 50 mM KCl, a*er incubation with increasing amounts of hnRNP A1 (r = 0–4) . Spectra of DNA-
protein complex have been subtracted of protein spectrum.
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which corresponds exactly to the distance of the lateral-loop binding sites in the wild-type hras-1Y iM. ese data 
support the binding of hnRNP A1 to the lateral loops of the iM, as observed for hnRNP LL and BCL2 iM6. As 
stated above, the iM facilitates the initial binding to hnRNP A1. en, a*er the iM is unfolded, the protein should 
bind more stably to the iM sequence.
ͷHRAS transcription in human bladder cancer 
cells. As hnRNP A1 binds to the critical GC-elements of the HRAS promoter, we asked if the protein plays a 
role in transcription. We therefore evaluated the e<ect on transcription of knocking out hnRNP A1 by shRNA. 
First, we determined by quantitative real-time PCR the e=ciency of shRNA to knock out hnRNP A1, #nding that 
hnRNP A1 mRNA (normalized by the transcripts of β 2-microglobulin and hypoxanthine guanine phosphor-
ibosyltransferase, HPRT) was reduced to 29 ± 8% of the control (cells untreated or treated with a non-speci#c 
shRNAC), 48 h a*er treatment (Fig. 8A). In the same cells we also measured the level of HRAS mRNA #nding 
that when hnRNP A1 is knocked out, the HRAS transcription is also down-regulated to 44 ± 5% of control. is 
suggests that hnRNP A1 is an essential factor for transcription, as previously reported41. Further evidence that the 
proteins recognizing the iMs of HRAS are essential for transcription was obtained with decoy oligonucleotides 
mimicking hras-1Y iM. ese molecules, once introduced in the cells, should sequester the proteins (hnRNP 
A1 included) recognizing the C-rich strand of the HRAS GC-elements. To increase their nuclease resistance, 
the decoy oligonucleotides, namely 5291–5294 (see Methods), have been designed with unlocked nucleic acid 
(UNA) modi#cations (Fig. 8B) (S5)44,45. e capacity of the UNA-modi#ed oligonucleotides to inhibit HRAS 
transcription was investigated by quantitative real-time PCR. T24 bladder cancer cells were transfected with the 
decoy oligonucleotides as well as with wild-type hras-1Y, using as transfecting agent jet-PEI46. A*er an incuba-
tion of 24 h, the total cellular RNA was extracted and the amount of HRAS mRNA relative to the housekeeping 
HPRT mRNA was evaluated by qRT-PCR (Fig. 8C). e results showed that oligonucleotides 5292 and 5293 
reduced HRAS mRNA to ~50% of the control (untreated cells). We also examined by electrophoresis the nuclease 
resistance of the decoy oligonucleotides (Fig. 8D). e oligonucleotides were incubated in cell cultured medium 
containing 10% fetal bovine serum at 37 °C, pH 5.5 for 0, 18, 24 and 48 h. While hras-1Y was quickly degraded, 
the UNA-modi#ed oligonucleotides, in particular 5292 and 5293, showed a remarkable stability, as the fraction 
of unbroken oligonucleotide was > 0.5, a*er 48 h of incubation. Interestingly, the enhanced activity shown by 
these compounds correlates nicely with their higher stability in serum.
Conclusion
We have demonstrated that two neighbouring GC-rich elements controlling HRAS expression can form non 
B-DNA iM structures, which are stable under near-physiological conditions. ese unusual DNA structures are 
recognized by hnRNP A1, one of the most abundant nuclear proteins involved in the biogenesis of RNA. We have 
discovered that hnRNP A1 has a clear unfolding activity against the iM. As the knockout of hnRNP A1 by shRNA 
in T24 bladder cancer cells results in the inhibition of HRAS, hnRNP A1 behaves as an activating transcription 
factor. Our data, together with those of Hurley and co-workers, who showed that hnRNP LL binds to the iM of 
Figure 7. (A) 5% PAGE, lanes 4–8 show how the binding of hnRNP A1 to hras-1Y–dy781 (Methods) (ratio 
1:100) at pH 5.5 is competed by oligonucleotides 2-nt - 10-nt (150-fold over iM). Lanes 1–3 shows the binding 
of iM to hnRNP A1 at ratios 1:50, 1:75, 1:100. Experimental conditions: DNA and protein incubated for 40 min 
at 37 °C, pH 5.5 before 5% PAGE analysis; (B) structure of the iM with the two lateral loops to which the protein 
is expected to bind; (C) sequences of the oligonucleotide competitors 2-nt, 4-nt, 6-nt, 8-nt, 10-nt.
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the BCL2 promoter and activates transcription6, provide the #rst evidence that non B-DNA iM structures are 
recognized by nuclear proteins.
 e proteins of the hnRNP family have been associated with the promoter of several genes where they are 
supposed to participate in the transcription regulation mechanisms, although their exact role is not yet fully under-
stood. Some of them recognize C-rich sequences in the promoters of CMYC (hnRNP K)39,40, BCL2 (hnRNP LL)6 
and HRAS (hnRNP A1) (present study). ese proteins seem to have a complex binding capacity, as hnRNP A1 is 
also able to bind to G-quadruplex DNA structures in KRAS17 and telomeres47. Remarkably, this type of binding is 
also associated with the disruption of G-quadruplex structures17.
Recent mechanical folding/unfolding experiments showed that G-quadruplex and iM are mutually exclusive 
within the same double-stranded tract48. However, whether this also holds under in vivo conditions, where double 
stranded DNA is exposed to negative superhelicity and located in a molecular crowding environment, has not 
yet been demonstrated. It is possible that both G-quadruplex and iM are extruded from each double-stranded 
GC-element, in the same way as two opposing hairpins (a cruciform) are extruded from a palindromic sequence. 
HRAS could therefore be regulated by a G-quadruplex/iM switch that represses transcription when the structural 
elements are in the folded conformation. Transcription will be activated when hnRNP A1 and MAZ, which rec-
ognize the HRAS G-quadruplexes3, bind to the iM and G-quadruplex, respectively, and then to other proteins of 
the transcriptional activator complex. ese non B-DNA structures provide a mechanism for the control of gene 
expression at a di<erent level than duplex, involving proteins recognizing these unusual structures that play a 
central role in gene regulation.
Methods
ͷǤ  e oligonucleotides used in this study have been obtained from 
Microsynth AG (Switzerland) and Euro#ns Genomics (Germany):
5′ -CGCCCGTGCCCTGCGCCCGCAACCCGA (hras-1Y)
5′ -ACCGCGCGCCCCCGCCCCCGCCCCGCCCCGGCCTCG (hras-2Y)
5′ -ATTO-CGCCGCCCGTGCCCTGCGCCCGCAACCCGAGC-TAMRA (A-hras-1Y-T)
5′ -ATTO-CGC GCC CCC GCC CCC GCC CCG CCC C -TAMRA (A-hras-2Y-T)
Figure 8. (A) Real-time determination of hnRNP A1 and HRAS mRNAs a*er knocking down hnRNP A1 
in T24 bladder cancer cells with a speci#c shRNA. When hnRNP A1 is knocked down, HRAS mRNA is 
downregulated. P < 0.05 (*); (B) UNA modi#cation introduced in the decoy oligonucleotides; (C) Level of 
HRAS mRNA in T24 cells treated with 200 nM hras-1Y or UNA-modi#ed analogues. Total RNA was extracted 
24 h a*er oligonucleotide transfection, retro-transcribed and subjected to real time ampli#cation. HRAS mRNA 
expression is normalized with housekeeping gene HPRT. e percentage of residual HRAS mRNA compared 
to HPRT mRNA in each sample is reported. P < 0.05 (*); (D) Resistance in fetal serum of hras-1Y and UNA-
modi#ed analogues. Oligonucleotides have been incubated in serum for 0, 18, 24, 48 and 72 h at 37 °C. A*er 
incubation the samples have been run in denaturing PAGE, 7 M urea, 55 °C. e gels were stained with “stains all”.
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5′ -TCG GGT TGC GGG CGC AGG GCA CGG GCG (hras-1R)
5′ -CGG GGC GGG GCG GGG GCG GGG GCG (hras-2R)
5′ - CGC TCG TGC TCT GCG CTC GCA ACT CGA (hras-1Ym)
5′ - TTTTTGTGTTTTTTTTTGCAATTTTT (ODN-1)
5′ -CGTCCGTGTCCTGCGTCCGCAATCCGA (ODN-2)
5′ -CGCCCGTGCCCTGCGCCCGCAGGGCGA (ODN-3)
5′-Dy 781-TTTTTTTCGCCCGTGCCCGTCGCCCGCAACCCGATTTTTTT-3′ (hras-1Y-dy 781). 
The oligonucleotides with UNA modifications have been synthesized in solid phase as previously 
described44,45: 5′-CGCCCGTGCCCTGuCGCCCGCuAACCCGuA (5291); 5′- CGCCCGTGCCCuUG 
CGCCCuGCAACCCGuA (5292); CGCCCGuUGCCCTGuCGCC-CGCuAACCCGuA (5293) and 
5′-CGCCCGuUGCCCuUGCGCCCuGCAACCCGuA (5294) where uC, uU, uG, uA are unlocked nucleic acid 
nucleotides.
Recombinant hnRNP A1 tagged to GST was obtained with a high degree of purity as previously described49 (S6).
Chromatin immunoprecipitation. T24 urinary bladder cancer cells (1.2 × 106) were cultured overnight 
in 6-cm diameter plates up to about 80% con+uency and #xed in 1% formaldehyde in PBS for 5 minutes at room 
temperature to crosslink proteins to DNA. Chromatin immunoprecipitation assays were performed using the 
ChIP-ITTM Express kit (Active Motif, Rixensart, Belgium). Details are reported in S7.
ǡǦǤ T24 cells were plated in 96-well plate (104 
cells/well). A*er 1 day we transfected the cells with hnRNP A1-speci#c (sc-35576-SH) and control shRNA (sc-
108066) (Santa Cruz, Dallas, USA) using as transfectant agent jetPEITM (Polyplus, NY, USA). A*er 48 h, RNA was 
extracted by using iScript TM RT-qPCR sample preparation reagent (BioRad, USA).
For cDNA synthesis, 1.25 µ l of RNA was heated at 70 °C and placed in ice. e solution was added with 7.5 µ l 
of a mix containing (#nal concentrations) 1 × bu<er; 0.01 M DTT (Invitrogen); 1.6 µ M primer dT [MWG Biotech, 
Ebersberg, Germany; d(T)16]; 1.6 µ M random primers; 0.4 mM dNTPs solution containing equimolar amounts 
of dATP, dCTP, dGTP and dTTP (Euroclone, Pavia, Italy); 0.8 U/µ l RNAse OUT; 8 U/µ l of M-MLV reverse tran-
scriptase (Life Technologies, Monza, Italy). e reactions were incubated for 1 h at 37 °C and stopped with heating 
at 95 °C for 5 min. As a negative control the reverse transcription reaction was performed with a sample containing 
DEPC water.
Real-time PCR multiplex reactions were performed with 1xKapa Probe fast qPCR kit for HRAS and house-
keeping genes hypoxanthine-guanine phosphoribosyltransferase (HPRT) and β 2-microglobulin, 2.2 µ l of cDNA 
and primers/probes at the concentrations speci#ed in S1. e PCR cycle was: 3 min at 95 °C, 50 cycles 10 s at 95 °C, 
60 s at 58 °C. Real-time PCR ampli#cation of hnRNP A1 was performed with 1 × Kapa Sybr Fast BioRad iCycle 
qPCR kit (KAPA Biosystems, Wilmington, MA, USA), 300 nM of each primer, 3.5 µ l of cDNA (cycle: 3 min at 
95 °C, 40 cycles 10 s at 95 °C, 30 s at 58 °C). PCR reactions were carried out with a CFX-96 real-time PCR apparatus 
controlled by an Optical System so*ware (version 3.1) (Bio-Rad Laboratories, CA, USA). All expressions were 
normalized with housekeeping genes. e sequences of the primers and probes used for the ampli#cations are 
given as supplementary data (S8).
CD and FRET experiments. CD spectra have been obtained with a JASCO J-600 spectropolarimeter 
equipped with a thermostatted cell holder. CD experiments were carried out with oligonucleotides hras-1Y and 
hras-2Y (3 µ M) in 50 mM Tris-acetate, pH from 4.5 to 8, 50 mM KCl. Spectra were recorded in 1 or 0.5 cm quartz 
cuvette. A thermometer inserted in the cuvette holder allowed a precise measurement of the sample temperature. 
 e spectra have been calculated with J-700 Standard Analysis so*ware (Japan Spectroscopic Co, Ltd) and reported 
as ellipticity (mdeg) versus wavelength (nm). Each spectrum was recorded three times, smoothed and the baseline 
subtracted. CD spectra of 3 µ M hras-1Y and hras-2Y have been obtained also at various temperatures (20-85 °C), 
by both heating and cooling the sample solutions (in 50 mM sodium cacodylate pH 5, 50 mM KCl). By plotting 
the 287 nm ellipticity versus temperature, sigmoidal denaturing and renaturing curves were obtained, which were 
practically overlapping.
FRET with oligonucleotides hras-1Y and hras-2Y, tagged at the 5′ and 3′ ends with ATTO-488 and TAMRA (as 
donor we used ATTO-488 because its pH dependence is weaker than that of FAM), were carried out on a Microplate 
Spectro+uorometer System (Perkin Elmer 2300 Enspire, USA). Each sample contained 50 µ l dual-labelled oligo-
nucleotide (200 nM) in 50 mM Tris-acetate bu<er, pH from 4.5 to 8, 50 mM KCl and an amount of hnRNP A1 as 
speci#ed in the #gure captions. e samples were incubated at 37 °C as speci#ed in the text. Emission spectra were 
obtained setting the excitation wavelength at 480 nm and recording the emission from 500 to 650 nm. FRET-melting 
experiments of hras-1Y and hras-2Y have been performed on a real-time PCR apparatus (CFX96, BioRad, Hercules, 
CA) in 50 mM sodium cacodylate at pH 5, 5.5, 6, 6.5 and 7, 50 mM KCl. FRET-melting experiments were obtained 
by increasing the temperature from 20 °C to 95 °C (0.3 °C/min). From the melting data we obtained curves reporting 
the fraction of folded iM against temperature. ese curves were reversible (denaturing and renaturing curves 
overlapping). e energy transfer (ET) was calculated from the +uorescence intensity of the donor D in the presence 
(IDA) and absence (ID) of the acceptor as:
= −
( )
E
I
I
1
6T
DA
D
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IDA and ID were measured in same bu<er under identical concentrations (ID was obtained by transforming the 
dual-labeled oligonucleotide into the corresponding duplex in which the +uorophores are at a distance for which 
FRET = 0). e FRET e=ciency values were converted to distances between donor and acceptor by using:
= −
( )
R R
E
1
1
7T
0 6
where R is the distance (Å) and R0 is the Föster distance [de#ned as the distance at which energy transfer is 50% 
of the maximum value, assumed to be 50 Å50].
iǤ  e thermodynamic parameters for the 
folding of C-rich sequence into the iM conformation were obtained from the melting curves. From ∆ G° = − RT 
ln K = ∆ H°–T∆ S° (8) it is obtained lnK = (∆ H°/R)(1/T) + ∆ S°/R (9). e equilibrium constant K as a function 
of T is given by K = f/(1–f), where f, the fraction of sequence folded in the iM conformation, is obtained form the 
melting curves. e plot of ln K versus 1/T gives a straight line whose slope (–∆ H/R) and y-intercept (–∆ S/R) 
provide the thermodynamic parameters (S9).
PAGE assays. Oligonucleotides hras-1Y and hras-2Y were end-labelled with [γ -32P]ATP and T4 polynucleotide 
kinase. For competition experiments we used a DNA chemically labelled to dy-781. Before EMSA, the iM-forming 
oligonucleotides were allowed to form their structure in 50 mM Tris–acetate, pH 5.5, 50 mM KCl, (overnight 
incubation at room temperature). Radiolabelled oligonucleotides (10 nM) were incubated for 30 min at 20 °C with 
increasing amounts of hnRNP A1 (0–12 µ g) as speci#ed in Fig. 4B, in 50 mM Tris–acetate, pH 5.5, 50 mM KCl, 
1 mM DTT, 8% glycerol, 1% Phosphatase Inhibitor Cocktail I (Sigma, Milan, Italy), 5 mM NaF, 1 mM Na3VO4, 
2.5 ng/µ l salmon sperm DNA (binding bu<er). A*er incubation, the reaction mixtures were loaded in 5% PAGE 
in 50 mM Tris-acetate pH 5.5, thermostatted at 20 °C. A*er running the gel was dried and exposed to autoradi-
ography (G E Healthcare, Milan) for 16 h at –80 °C. Mobility-shi* experiments of cold hras-1Y and hras-2Y have 
been performed on 15% PAGE, 25 mM KCl, at pH 5 (50 mM sodium acetate) or pH 7 (50 mM Tris-acetate), 20 °C. 
20% PAGE in denaturing 7 M urea conditions, was carried out in TBE. e gels were stained with “stains-all” dye. 
Competition assay with 28 nM hras-1Y-dy781 were performed at 37 °C with 3 µ M of hnRNP A1 (100-fold over iM 
hras-1Y-dy781) and competitor oligonucleotides (150-fold over iM) in 50 mM Tris-acetate, pH 5.5, 50 mM KCl, 
1 mM EDTA, 2.5ng/µ l Salmon sperm. A*er incubation, the reaction mixtures were loaded in 5% PAGE 1xTBE, 
thermostated at 20 °C. A*er running the gel was analysed by Odyssey CLx scanner /ImageStudio So*ware (Li-Cor 
Biosciences).
Cell culture and transfections. T24 human urinary bladder cancer cells were maintained in exponential 
growth in Dulbecco’s Modi#ed Eagle’s Medium (DMEM) containing 100 U/ml penicillin, 100 mg/ml streptomycin, 
20 mM L-glutamine and 10% fetal bovine serum (Euroclone, Milan, Italy).
For transfection we plated 10000 cells for each well in a 96 well plate and transfected using Jet PEI (Polyplus 
Illkirch FRANCE) following manufacturers in vitro protocol for DNA oligonucleotides transfection with 400 nM 
oligonucleotide (48 pmol) and N/P = 3.
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GC-rich elements controlling HRAS transcription form i-motif structures unfolded by 
heterogeneous ribonucleoprotein particle A1 
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Supporting data S1: Sequence of wild type hras-1Y that form an iM in the pH range between 5 and 
7. At pH ≥ 7 the sequence may form a hairpin stabilized by a stem with 5 W.C. base pairs. 
Sequence of mutant ODN-3 forming a hairpin stabilized by a stem of 7 base pairs. Sequence and 
possible structure of mutant ODN-2 forming an iM stabilized by 4 CH+:C base pairs.  
 
 
 
 
Supporting data S2: The inter-phosphate distance across the wide and narrow groove are 
respectively 1.5 and 0.7 nm (1-3). The high of the iM was estimated by assuming CH+:C stacking 
interval of 0.32 nm (4). The distance between two consecutive nt is assumed to be 0.43 nm (5). The 
end-to-end distance should be 7+4x4.3=24 Å, without taking into account the dyes. Considering 
that each dyes is conjugated at the 5’ and 3’ ends through a spacer, the end-to-end distance given by 
FRET, 40 Å, is consistent with the size of the iM.   
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Supporting data S3: (Left) FRET spectra of 200 nM hras-2Y treated with increasing amounts of 
purified hnRNP A1 at pH 6.5, 50 mM sodium cacodylate, 50 mM KCl. As a control BSA and 
denatured hnRNP A1 (A1 D) have been used. HnRNP A1 causes a dramatic increase of the 520 nm 
donor emission. Insight shows the energy transfer (ET) between donor-acceptor as a function of 
hnRNP A1 concentrations; (B) FRET-melting of hras-2Y incubated with increasing amounts of 
hnRNP A1. The protein abrogates the melting profiles. 
 
 
 
 
 
 
 
 
 
Supporting data S4. Binding of hnRNP A1 (100-fold) to the iM (28 nM) in binding buffer at pH 
5.5 and T= 0, 20 and 37 °C. The iM sequence is 5’-Dy 781-TTT TTT TCG CCC GTG CCC GTC 
GCC CGC AAC CCG ATT TTT TT-3’ (hras-1Y-dy781). Before incubation with hnRNP A1 it was 
allowed to form its structure in 50 mM Tris-acetate pH 5.5 and 50 mM KCl. Then hras-1Y-
dy781was incubated for 40 min at 0, 20  or 37 °C with 3 mM of hnRNP A1 (100-fold) in 50 mM 
Tris-acetate, pH 5.5, 50 mM KCl, 1 mM EDTA, 2.5ng/ml Salmon sperm. After incubation, the 
reaction mixtures were loaded in 5% PAGE 1 x TBE thermostated at 20°C. After running the gel 
was analysed by Odyssey CLx scanner and the shapes quantified by ImageStudio Software (Li-Cor 
Biosciences). 
 
 
 
 
 
 
Supporting data S5: UNA decoy oligonucleotides. 
The decoy oligonucleotides used are: 
5’-CGCCCGTGCCCTGuCGCCCGCuAACCCGuA (5291);  
5’- CGCCCGTGCCCuUGCGCCCuGCAACCCGuA (5292);  
5’-CGCCCGuUGCCCTGuCGCCCGCuAACCCGuA (5293)  
5’-CGCCCGuUGCCCuUGCGCCCuGCAACCCGuA (5294)  
where uC, uU, uG, uA are unlocked nucleic acid nucleotides. 
 
A 
 
B 
 
(A) Spectra of UNA-modified and wild-type hras-1Y oligonucleotides (3 mM) at 20 and 90 °C in 50 
mM cacodylate pH 5.5, 50 mM KCl. Note that the UNA modifications do not alter the structure of 
the iM. For each sequence we report the melting temperature obtained by CD spectra measured as a 
function of temperature. In panel B we show a typical CD-melting experiment obtained with 
oligonucleotide 5292. 
Supporting data S6: Recombinant hnRNP A1 
In brief, hnRNP A1 tagged to GST was expressed in Escherichia coli BL21 using pGEX-hnRNP  
A1. After transformation, the bacteria were grown at 37°C in the presence of 50 μg/ml ampicillin 
up to an absorbance at 600 nm of 0.8 before the IPTG treatment (100 μM final concentration). The 
cells were allowed to grow for 5 h, harvested and centrifuged at 5000 r.p.m., 4°C. The supernatant 
was removed carefully and the pellet was re-suspended in a solution of PBS with 20 mM PMSF and 
5 mM DTT. The bacteria were lysed by sonication (3 times 30 s, 20 kHz, Bioruptor, Diagenode, 
NY), added with Triton X-100 (1% final concentration) and incubated for 1.5 h on a shaker at room 
temperature. The lysate was then centrifuged for 10 min at 4°C at 10 000 r.p.m. Glutathione 
Sepharose 4B (GE Healthcare) (50% slurry in PBS) was added to the supernatant and incubated for 
1.5 h at 4°C on a shaker. The mix was centrifuged for 5 min at 500 g and the pellet was washes 3 
times in PBS and eluted with elution buffer containing 20 mM NaCl, 20 mM reduced glutathione,  
200 mM Tris–HCl, pH 9.5. Finally, purification of hnRNP A1 was checked by SDS–PAGE. 
 
 
 
Supporting data S7: Chromatin Immunoprecipitaion 
T24 urinary bladder cancer cells (1.2 x 106) were cultured overnight in 6-cm diameter plates up 
to about 80% confluency and fixed in 1% formaldehyde in PBS for 5 minutes at room temperature 
to crosslink proteins to DNA. Chromatin immunoprecipitation assays were performed using the 
ChIP-ITTM Express kit (Active Motif, Rixensart, Belgium). The cells were lysed in 100 mM NaCl, 
20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.5 % NP-40, 0.5 % Na-deoxycholate, 0.1 SDS and 
sonicated to fragment chromosomal DNA into ~ 500 bp (8 min, 20 kHz, Bioruptor, Diagenode, 
NY). Sheared chromatin (6 mg in each sample) was diluted and incubated overnight, at 4 °C, with 
0.5 mg of each specific antibody (Ab) and recovered with Protein G magnetic beads. The Abs used 
are hnRNP A1, (Sigma Aldrich), negative control mouse IgG (Active Motif), positive control RNA 
Pol II mouse monoclonal Ab (Active Motif). After incubation, the mixtures were spinned and the 
beads washed 3-times with kit washing buffers. The chromatin was treated with kit elution buffer 
for 15 min at RT on a shaker. We then used proteinase K (37 °C) to reverse the crosslinking and 
after 1 h we stopped the reaction with a proteinase K stop solution. The DNA recovered was 
amplified by PCR, using the following primers (accession number J00277): (i) 5’-
GGCTCCTGACAGACGGG (304-320; hras-1for) and 5’-GCATGGGCTCCGTCC (477-491; 
hras-1rev) giving a 188 bp product; (ii) 5’-GGACGGAGCCCATGC (477-491; hras-2for) and 5’-
CGTATTGCTGCCGCCT (624-639; hras-2rev) giving a 163 bp product. Amplification of control 
G-sequence (133 bp) downstream of the GC-elements was performed with: 5’-
TCATTAAGAGCAAGTGGGGGC (1407-1428; control-for), 5’-
CATCTGAAGGGCAAACCCACA (1518-1539, control-rev). Amplification products were 
separated by 8 % acrylamide gel in TBE and quantified with a Gel–DOC apparatus (Bio-Rad 
Laboratories, CA, USA). The data have been normalized by IgG. 
 
 
 
 
 
 
Supporting data S8: Sequences of primers and probes used in this study 
 
 
 
 
 
 
 
 
 
 
Accession 
Number 
SENSE ANTI-SENSE PROBE 
NM_001130442 
(HRAS) 
GCTGATCCAGAACCATTT 
(from 254 to 271) 
GTATCCAGGATGTCC
AAC 
(from 344 to 361) 
HEX-CAATGACCACCTGCTTCCG-
BHQ2 
(from 309 to 327) 
NM_004048 
(b2-
microglobulin) 
CCCCACTGAAAAAGATGA 
(from 333 to 350) 
CCATGATGCTGCTTAC
AT 
(from 415 to 432) 
ROX-TATGCCTGCCGTGTGAACC-
BHQ2 
(from 352 to 370) 
NM_000194 
(HPRT) 
CTTGATTGTGGAAGATATAA
TTG 
(from 557 to 575) 
TATATCCAACACTTCG
TGG 
(from 672 to 690) 
Cy5-CTTGCGACCTTGACCATCTT-
BHQ2 
(from 633 to 652) 
NM_002136 
(hnRNP A1) 
CATCGTTAAAGTCTCTCT 
TCAC 
(from 74 to 95) 
CAGGCTCTCATCAGTT
GT 
(from 177 to 194) 
 
 Supporting data S9: (Top panel) Denaturation profile of hras-2Y in 50 mM sodium cacodylate pH 
5, 50 mM KCl, obtained from FRET-melting experiments. The profile is reversible; (B) Typical 
thermodynamic analysis of the denaturation profile according to a two-state model. The parameters 
obtained are: DH= -338.2 kJ/mol, DS= -0.9 kJ/mol K, DG= -29.6 kJ/mol.  
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Nucleic Acid Targeted Therapy: G4 Oligonucleotides Downregulate
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ABSTRACT: In a previous study we have demonstrated that two neighboring G-
quadruplexes, hras-1 and hras-2, located immediately upstream of the major transcription
start site of HRAS, bind MAZ, a nuclear factor that activates transcription (Cogoi, S.; et al.
Nucl. Acid Res. 2014, 42, 8379). For the present study we have designed G4 oligonucleotides
with anthraquinone insertions and locked nucleic acids (LNA) modifications mimicking
quadruplex hras-1. Luciferase, qRT-PCR, and Western blot data demonstrate that these
constructs efficiently down regulate HRAS in T24 bladder cancer cells. The inhibitory
efficiency of the G4 oligonucleotides correlates with their nuclease resistance in the cell
environment. By chromatin immunoprecipitation we show that the association of MAZ to the
HRAS promoter is strongly attenuated by the designed G4 oligonucleotides, thus suggesting
that these constructs behave with a decoy mechanism.
KEYWORDS: HRAS, G4-oligonucleotides, anthraquinone insertions, T24 bladder cancer cells, decoy mechanism
M utations in the ras genes have been associated withabout one-third of all human cancers.1 In particular,
mutations in codon 12 of HRAS are found in more than 35% of
bladder cancers.2,3 The ras genes encode for a GTP-binding
protein activating downstream signal pathways that control
several cell functions including proliferation.3 The involvement
of mutant HRAS in the pathogenesis of bladder cancer is well
established.4−6 Bladder cancer is commonly treated with
cisplatin-based combination therapies, which, however, develop
drug resistance. As this limits the efficacy of the therapy,7
innovative therapeutic strategies are desirable. Given the central
role of mutant HRAS in the pathogenesis of bladder cancer, the
downregulation of this oncogene should inhibit cell growth
and/or sensitize cancer cells to chemotherapy.8 To address this
issue, we focused on the HRAS region immediately upstream of
the major transcription start site (TSS), including two
neighboring G-rich quadruplex-forming sequences, namely,
hras-1 and hras-2, which play a critical role in transcription
regulation (Figure 1).9,10 These two sequences overlap binding
sites for MAZ and Sp1, two zinc-finger transcription factors that
are essential for HRAS expression. By FRET experiments we
demonstrated that MAZ upon binding to the promoter unfolds
the G-quadruplexes.10 We proposed a regulatory mechanism
according to which the two quadruplex-forming sequences
behave as a molecular switch for the control of gene expression.
Under normal conditions, HRAS transcription is blocked by the
two G-quadruplexes. Transcription is then activated when MAZ
binds to and unfolds the G-quadruplexes, thus favoring the
formation of the activated transcription complex (Figure
1).10,11 In the light of this regulatory model we have
hypothesized a decoy strategy to inhibit oncogenic HRAS in
human bladder cancer cells. According to this approach, when
Received: August 4, 2015
Accepted: October 18, 2015
Published: October 18, 2015
Figure 1. (A) Sequence of the HRAS promoter upstream of TSS. Two
neighboring G4 sequences, hras-1 and hras-2, form a molecular switch
that control transcription. (B) Decoy strategy.
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short DNA fragments mimicking one of the HRAS G-
quadruplexes are delivered to the cells, they should compete
with the binding of the transcription factors MAZ and Sp1 to
the promoter, with the result that transcription will be
inhibited.
This nucleic-acid target strategy was first applied to block the
binding of NF-kB and STAT3 to the corresponding cis-
elements.12−17 Recently, we employed decoy oligonucleotides
against KRAS in Panc-1 cells obtaining very promising results
both in vitro and in vivo.18 To suppress HRAS in cancer cells by
a decoy strategy, we designed quadruplex-forming (G4)
oligonucleotides with locked nucleic acids (LNA) modifications
and anthraquinone insertions.
The primary structure of these compounds is reported in
Table 1. The LNA modifications should increase the resistance
to nucleases,19 whereas the anthraquinone insertions, by
promoting pi-stacking interactions, should increase the stability
of the folded decoy oligonucleotides. The anthraquinone
chromophore is a well-known intercalator that has been used
in the development of G4 conjugates.20 To insert the
anthraquinone moiety into specific positions of the decoy
oligonucleotides, we used a 1,4-substituted anthraquinone
phosphoramidite21 and synthesized the decoy oligonucleotides
in solid phase (Supporting Information, S1). The anthraqui-
none-modified G4 oligonucleotides have been purified by
HPLC and their molecular weights verified by matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF) mass
spectrometry analysis (Table 1). The calculated and measured
molecular weights were in excellent agreement, with a
difference of <0.03%. The G4 decoys have been designed
with the sequence of the promoter HRAS segment called hras-1
(Figure 1), which is known to assume an antiparallel G-
quadruplex in the presence of KCl (S2).9,10 All the compounds
were engineered with two or three LNA modifications and two
anthraquinone insertions, each replacing one nucleotide, in
positions H2/H4 (7213), H1/H5 (7214), H1/H3 (7215), and
H3/H5 (7216) (Figure 2A,B). Compound 7217 was instead
designed with only LNA modifications. By CD we examined if
the insertions modified the conformation of the G-quadruplex
formed by hras-1. Figure 2C shows the CD spectra of the
designed compounds in 100 mM KCl, 20 mM phosphate
buffer, pH 7.4. It can be seen that 7213, 7215, and 7217
maintain the antiparallel conformation with positive and
negative ellipticities at 290 and 260 nm,17 whereas compounds
7214 and 7216 adopt a mixed parallel/antiparallel (P/A) form
characterized by two positive ellipticities at 290 and 260 nm.22
Thus, the positions of the anthraquinone insertions influence
the folding of the resulting G4 oligonucleotides. The change in
G4 topology modified the electrophoretic mobility of the
compounds. Figure 3A shows that the two oligonucleotides
with a mixed P/A conformation migrate a little more slowly
than the sequences in the antiparallel form. Moreover, by UV-
melting we found that the compounds with a mixed P/A
conformation, 7214 and 7216, have a thermal stability, 56.8
and 55.0 °C, respectively, similar to that of 7217 (56.2 °C),
which lacks the anthraquinone insertions (Table 1). This
suggests that in the oligonucleotide with a mixed P/A
conformation, the two anthraquinone insertions, which are
placed at opposite ends of the quadruplex, should not promote
stabilizing pi-interactions neither with the external G-quartets
Table 1. Sequences of the Designed Anthraquinone G4 Decoys
aH = 1,4-anthaquinone insertion; underlined bases are LNA modified. bMolecular weight measured by matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF). cTMs from UV-melting profiles of compounds in 100 mM KCl and 20 mM phosphate buffer, pH 7.4.
dTopology of
the G4 decoys determined by circular dichroism.
Figure 2. (A) Putative structure of the designed decoy oligonucleo-
tides reported in Table 1 with LNA modifications and anthraquinone
insertions H2/H4 (7213), H1/H5 (7214), H1/H3 (7214), H3/H5
/(7216). (B) Structure of the anthraquinone insertion.21 (C) CD
spectra of the designed decoy oligonucleotides in 20 mM phosphate
buffer, pH 7.4, 100 mM KCl. (D) putative structure of the decoy
oligonucleotides, H1−H5 = anthraquinone insertions.
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nor with the neighboring bases. In contrast, compound 7213
with insertions H2 and H4 in the two lateral loops lying at the
same side of the quadruplex (Figure 2A,D), shows a TM 8 °C
higher than that of 7217. In this oligonucleotide the two
anthraquinones are in close proximity and probably stacked on
each other. To support this interpretation we performed
fluorescence experiments, as the polycyclic anthraquinone
chromophore may change its fluorescence quantum yield
when it is involved in pi-interactions.23 When it is excited at 444
nm, it emits at 560 nm (Figure 3B). By fixing the emission of
7214 to 1, all the other compounds showed a higher emission:
7213, 3.75-fold more intense, 7215, 1.75-fold, and 7215, 1.3-
fold. Since the TM of 7214 (56.8 °C), with two anthraquinone
at the 5′ and 3′ ends, is similar to the TM of 7217 (56.2 °C), we
jumped to the conclusion that in 7214 the two chromophores
are oriented outside the structure and do not promote pi-
interactions with the adjacent G-quartets. In contrast,
compound 7213 shows a dramatic increase of fluorescence,
as the two anthraquinones, inserted in neighboring lateral
loops, promote reciprocal pi-interactions. In this case the
quadruplex is stabilized by 8 °C compared to 7217.
In keeping with this interpretation, compound 7215 shows
an increase of both TM (4 °C) and fluorescence (1.75 fold), as
the two anthraquinones lying at the same side of the
quadruplex can promote pi-interactions, to some extent. Instead,
7216 shows TM similar to that of 7217, as the anthraquinones
are at opposing ends of the quadruplex (Figure 2D). In a
parallel work, we inserted two anthraquinones in the
neighboring loops of the thrombin aptamer, which is known
to adopt an antiparallel structure.24 This modified aptamer
showed a CD similar to that of 7213 (S3). Molecular modeling
studies showed that the two anthraquinones are indeed stacked
in a face-to-face manner, as we have hypothesized for the
parental 7213 compound (S4).
Next, we interrogated if the designed oligonucleotides
behave as decoys and are able to downregulate HRAS in
human T24 bladder cancer cells. To address this issue, we first
carried out a dual luciferase assay with pHRAS-luc (an
expressing vector where the whole HRAS promoter drives the
synthesis of firefly luciferase10) and pRL-CMV (a vector in
which Renilla luciferase is driven by the CMV promoter). T24
cancer cells were treated with increasing amounts (50−400
nM) of G4 oligonucleotides, control oligonucleotides unable to
form a G-quadruplex [CTRL-1, 5′-GAGGGAGC-GGCTGC-
AGCGCTGGGAG; CTRL-2, 5′-GAAGGAGTG-AGTGAGG-
GAGCGGCTGCAG; CRTL-3, 5′-TGCAGCC-GCTCCC-
TCACTCACTCCTTCCCT], pHRAS-luc, and pRL-CMV.
Figure 3C shows that all the designed G4 oligonucleotides
cause the inhibition of firefly luciferase compared to Renilla
luciferase in a dose−response manner, whereas the three
control sequences that did not assume any folded structure,
were not effective, even at their highest concentration (400
nM). The result of this reporter assay showed that both types
of G4 oligonucleotides, antiparallel and mixed P/A, disrupt the
mechanism leading to gene expression, seemingly by
sequestering the proteins interacting with hras-1. To provide
further support for the activity of the designed G4
oligonucleotides, we focused on genomic HRAS. We treated
T24 cancer cells with 800 nM G4 or control oligonucleotides.
Twelve hours after treatment, HRAS mRNA in both untreated
and oligonucleotide-treated cells was determined by qRT-PCR.
The qRT-PCR data showed that all G4 decoys, but not the
control oligonucleotides, reduced HRAS mRNA compared to
those of β2-microglobulin and HPRT to ∼50% of the control
(untreated cells) (S5). We also examined the effect of the G4
decoys on HRAS expression by Western blots (Figure 4). In
accord with the luciferase and qRT-PCR data, all the
compounds decreased the level of protein HRAS, in particular
7215, 7216, and 7217 (to <30% of control), while the control
oligonucleotides CTRL 1−3 did not.
Next, we examined the stability of the designed decoy
oligonucleotides in a T24 cellular extract, up to 93 h of
incubation (Figure 5A). The results showed that wild-type hras-
1 oligonucleotide undergoes a nearly complete degradation in
93 h. In contrast, all the other compounds appeared more
stable, and this provides a key to rationalize their activity. So,
there is a correlation between the stability of the G4
oligonucleotides in the cell environment and their capacity to
lower luciferase and HRAS expression.
Figure 3. (A) Native PAGE of the G4 decoys and of 15-, 20-, 24-, 30-,
and 36-mer reference oligonucleotides, m = mixed P/A, A =
antiparallel. (B) Fluorescence spectra of the decoy oligonucleotides
in 50 mM Tris-HCl pH 7.4, 100 mM KCl; Ex = 444 nm, Em = 470−
750 nm. (C) Dual luciferase assay with pHRAS-luc, pRL-CMV, and
decoy oligonucleotides. The ordinate reports % luciferase, i.e., T/C ×
100, where T = firely/Renilla in oligonucleotide-treated cells and C =
firely/Renilla in oligonucleotide-untreated cells. *P < 0.05.
Figure 4. Western blot showing that the G4 decoys (A) but not the
control oligonucleotides (B) (800 nM) reduce protein p21HRAS in T24
cancer cells. The % inhibition of p21HRAS is shown in the histogram as
T/C × 100, where T and C are the p21HRAS/β-actin ratios in treated
and untreated cells, respectively.
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As the designed G4 oligonucleotides suppress HRAS, we
wondered if they really act through a decoy mechanism. To
provide evidence for this, we examined by chromatin
immunoprecipitation (ChIP) if the G4 decoys attenuate the
occupancy of the HRAS promoter by proteins essential for
transcription. We previously demonstrated that MAZ is a key
transcription factor for HRAS;9,10 therefore, we focused our
ChIP analysis on this protein, by using an antibody specific for
MAZ. A typical ChIP analysis for 7214, 7217, and CTRL-2 is
reported in Figure 5B. The histogram summarizes the results
obtained with all the G4 decoys. The occupancy of the HRAS
promoter by MAZ in the decoy-treated cells is about 1/3 of the
occupancy observed with the untreated or control-treated cells.
Note that hras-1, being located near to TSS, is significantly
occupied by RNA Pol II too (positive control) but not by IgG
(negative control).
Furthermore, by an EMSA competition assay we found that
all the designed G4 decoys are able to compete with the
binding of MAZ to the hras-1 quadruplex (S6). So, both ChIP-
PCR and EMSA proved that MAZ, under in vivo conditions, is
associated with the critical G-rich elements of the HRAS
promoter and that the binding of MAZ to the HRAS promoter
is attenuated by the G4 decoy oligonucleotides.
As a final point we tested the efficacy of the G4 decoys to
inhibit the proliferation of the HRAS mutant T24 bladder
cancer cells. The cells were transfected with increasing amounts
of decoy or control oligonucleotides and incubated for 72 h,
before a resazurin assay was carried out. To various extents, all
compounds lowered the percentage of viable cells in a dose−
response manner. The estimated IC50 values (nM) are ∼600 for
7213, ∼300 for 7214, >800 for 7215, ∼800 for 7216, and >800
for 7217. In contrast, in noncancer 293 cells the compounds
had a weaker effect on cell viability, with IC50 ≫ 800 nM (S7).
We have designed a decoy strategy to inhibit the expression
of oncogene HRAS in bladder cancer cells. To strengthen the
nuclease resistance and the folded conformation, the G4 decoys
have been synthesized with LNA modifications and anthraqui-
none insertions. Luciferase, qRT-PCR, and Western blot assays
showed that the decoy oligonucleotide repressed HRAS
expression, while ChIP and EMSA provided evidence that the
molecules actually behave through the postulated decoy
mechanism. It might be argued that the decoy strategy lacks
specificity because the sequestration of a transcription factor (as
MAZ) could have impact on other genes as well. However,
bladder cancer cells are addicted to oncogenic HRAS, just as
pancreatic cancer cells are addicted to mutant KRAS.25 This
means that the metabolism of these transformed cells strongly
depends on the expression of these oncogenes. Indeed, it has
been reported that the ras oncogenes remodulate the metabolic
pathways of cancer cells to fuel their higher proliferation rate.25
So, cancer cells are more responsive to ras gene expression than
normal cells. In other words, the inhibition of HRAS in HRAS
mutant bladder cancer cells is less tolerated than in noncancer
293 cells bearing wild-type HRAS. The concept of oncogene
addiction for targeted anticancer therapy has been recently
illustrated.26
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ABSTRACT: The human KRAS transcript contains a G-rich 5′-UTR
sequence (77% GC) harboring several G4 motifs capable to form stable
RNA G-quadruplex (RG4) structures that can serve as targets for small
molecules. A biotin−streptavidin pull-down assay showed that 4,11-bis(2-
aminoethylamino)anthra[2,3-b]furan-5,10-dione (2a) binds to RG4s in the
KRAS transcript under low-abundance cellular conditions. Dual-luciferase
assays demonstrated that 2a and its analogue 4,11-bis(2-
aminoethylamino)anthra[2,3-b]thiophene-5,10-dione (2b) repress trans-
lation in a dose-dependent manner. The effect of the G4-ligands on Panc-1
cancer cells has also been examined. Both 2a and 2b efficiently penetrate
the cells, suppressing protein p21KRAS to <10% of the control. The KRAS
down-regulation induces apoptosis together with a dramatic reduction of
cell growth and colony formation. In summary, we report a strategy to
suppress the KRAS oncogene in pancreatic cancer cells by means of small molecules binding to RG4s in the 5′-UTR of mRNA.
■ INTRODUCTION
The three ras genes (HRAS, KRAS, and NRAS) encode for
highly homologous (83−90% sequence identity) GTPases of
21 kDa that cycle between an active GTP-bound and an
inactive GDP-bound state.1,2 This cycling is mediated by
guanine nucleotides exchange factors (GEFs) and by GTPase
activating proteins (GAPs).1,3 In the GTP-bound state, the
p21RAS protein interacts with downstream effectors, activating
specific cellular processes including proliferation, survival, and
differentiation.3,4 Mutations in the ras genes are estimated to be
present in ∼30% of all human cancers.5 However, in pancreatic
ductal adenocarcinoma (PDAC), KRAS is mutated in ∼95% of
patients.6,7 The mutant alleles carry a single missense point
mutation in exon 1, codon 12, 13, or 61, which impairs GAP-
mediated GTP-to-GDP hydrolysis. This results in an aberrant
protein that is locked into the activated state, transmitting
constitutively signals for proliferation to the nucleus.8
According to recent studies, mutations in the KRAS gene can
be seen as primary genetic lesions that initiate the malignant
transformation of pancreatic cells.9,10 Progression to invasive
PDAC occurs through a stepwise accumulation of other genetic
lesions, in particular those causing the inactivation of tumor
suppressor genes.11
Recent studies have demonstrated that KRAS is essential for
the maintenance of PDAC as it reprograms the metabolism of
glucose and glutamine to fuel a high proliferation rate.9,12,13
The dependence of metabolic pathways on specific oncogenes
has led to the concept of “oncogene addiction”, which means
that, although cancer cells may depend on a number of genetic
aberrations, they often develop a dependency on a particular
oncogene.14,15 Considering the central role played by KRAS on
the pathogenesis of PDAC, KRAS is considered a crucial target
for anticancer drugs. However, despite more than two decades
of research, up to now no antiras drugs have reached the clinic,
creating the impression that ras genes may be “undrug-
gable”.16,17 Recently, the design of new inhibitors binding
directly to protein p21RAS has fueled research in this
direction.18 Other strategies that are being pursued use drugs
that inhibit either the association of p21RAS to the membrane
or the activity of downstream pathways.19−22 In our laboratory,
we developed an alternative anti KRAS strategy by focusing on
two targets for small molecules: (i) a G4-motif located
upstream of the transcription start site (TSS) (−320/−306),
which is recognized by essential transcription factors (MAZ,
Ku70, PARP-1, and hnRNP A1);23 (ii) G4-motifs located in the
5′-untranslated region (5′-UTR) of the KRAS transcript.24,25
Previous studies have shown that the presence of G4 motifs in
5′-UTR of mRNA inhibits translation, on the basis of luciferase
assays.26,27 In this study, we demonstrate by a streptavidin−
biotin pull-down assay that small molecules bind to RNA G-
quadruplexes (RG4s) formed in the 5′-UTR of low-abundant
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cellular KRAS transcripts. These small molecules, anthrafur-
andiones (ATFD) and anthrathiophenediones (ATPD),
suppress luciferase from specific vectors as well as p21RAS in
pancreatic Panc-1 cancer cells. ATFD and ATPD strongly
induce apoptosis and reduce the metabolic activity and colony
formation of Panc-1 cells carrying mutant KRAS G12D. Our
results demonstrate that ATPD and ATFD are promising
therapeutic drugs to suppress oncogenic KRAS in pancreatic
cancer cells, through their binding to RG4s located in the 5′-
UTR of mRNA.
■ RESULTS AND DISCUSSION
Since Hurley and co-workers published their seminal study on
the transcription of CMYC controlled by a regulatory
mechanism involving a G4 DNA,28 a great number of papers
on this unusual structure has been reported in the
literature.29−35 The biological function of G4 DNA is rather
complex: some studies indicate that it behaves as a transcrip-
tional repressor,28,32,35 others that G4 DNA is associated with
transcriptionally active chromatin.36 Whatever its function is,
G4 DNA is an attractive target for therapeutic small
molecules.32 However, bioinformatics analyses showed that
the transcript of certain oncogenes contains a 5′-UTR rich in
guanines that can form G4 RNA structures (RG4s).26,27,37−40
The 5′-UTR region of mRNA plays an essential role in the
initiation of translation. This occurs through three steps: (i)
association of the 7-methylguanosine cap with the 43 S
initiation complex; (ii) scanning of complex 43 S along 5′-UTR
up to codon AUG; (iii) assembly of a larger 80 S ribosome that
proceeds with protein synthesis. The process is normally
regulated by eukaryotic translation initiation factors (eIFs). In
addition, certain transcripts use a cap-independent translation
initiation that depends on internal ribosomal entry sites.26,39,40
It has been hypothesized that excess secondary structure
including RG4s in 5′-UTR may have a regulatory function on
translation.26,27,37−40 Indeed, as observed with RNA hairpins,
RG4s can either inhibit the assembly of the translation
initiation machinery at the 5′-cap or interfere with the scanning
of the ribosome toward the AUG codon (Supporting
Information S1).26,41−47 Luciferase data obtained with ex-
pression plasmids designed with G4 in specific positions
upstream of AUG have been reported as a proof-of-
principle.26,43,44 In our work we demonstrate that furan- and
thiophene-fused anthraquinone derivatives bind to RG4s in the
5′-UTR of KRAS mRNA under low-abundance cellular
conditions. These G4-specific molecules are found to suppress
the KRAS oncogene in pancreatic cancer cells through a
mechanism involving the inhibition of translation.
Human KRAS 5′-UTR Forms RNA G-Quadruplex
Structures. The human KRAS transcript contains a 5′-UTR
of 192 nucleotides, characterized by a high GC content (77%)
(Figure 1). Its putative secondary structure can be predicted by
Mfold,48 a bioinformatic tool that generates a secondary
structure by taking into consideration the orthologues of the
RNA sequence. However, Mfold does not take into account G4
motifs; thus, one wonders if the secondary structure predicted
for the KRAS 5′-UTR is actually formed, considering that it
Figure 1. (A) Primary structure of the 5′-UTR of the human KRAS transcript. The sequence is very rich in guanines (77% GC) and contains 33 GG-
runs. (B) Predicted secondary structure of the first 80 nt of 5′-UTR (s-80) given by Mfold.48 In s-80 there are three putative nonoverlapping G4
motifs utr-1, utr-z, and utr-c, indicated with colored arrows on the stem-loop structure. According to QGRS, the G4 motifs have a G-score = 21. (C)
Cartoon showing the three nonoverlapping G4 RNAs and the structure of a G-tetrad.
Table 1. G4 Motifs in s-80, the First 80 nt in the KRAS 5′-UTR mRNA
position sequence (5′→3′) G/Ca G-score TM
b G4 RNA ΔGc (kcal/mol)
utr-1 16−30 GCGGCGGCGGAGGCA 4 21 53 −4.9
utr-z 36−55 GGCGGCGGCAGUGGCGGCGG 2.6 21 64 −3.7
utr-c 59−71 AGGUGGCGGCGGC 4 21 52 −5.6
aG/C ratio of the G4 motifs (>1.5 favors G4 over loop-hairpin).37 bTM obtained in 50 mM Na-cacodylate, pH 7.4, 100 mM KCl.
c
ΔGs (298 K)
obtained from UV-melting curves, using a two-state model.
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contains 33 GG runs which give rise to a multitude of G4
motifs. To identify the G4 motifs with the highest G-score (i.e.,
highest propensity to fold into a G4), we interrogated QGRS
Mapper.49 We considered a consensus G4 motif composed by 2
G-tetrads and loop length up to 12 nt. The analysis gave three
nonoverlapping G4 motifs with a G-score = 21 (Table 1). If the
overlapping G4 motifs were included in the analysis, their
number was >300, suggesting that the human KRAS 5′-UTR
sequence has a high propensity to form RG4s. The three
nonoverlapping G4 motifs are located within the first 80 nt of
Figure 2. (A) Circular dichroism spectra at 25 °C and 90 °C of 5 μM NRAS, utr-1, utr-c, and utr-z RG4s in 50 mM Tris-HCl, pH 7.4, 100 mM KCl
(or 100 mM LiCl); for NRAS, the KCl or LiCl concentration was 20 mM. The spectra were obtained in 0.5 cm cuvettes. (B) UV-melting curves of 5
μM utr-1, utr-z, and utr-c in 50 mM Na-cacodylate, pH 7.4, 100 mM KCl or LiCl. The curves were obtained by measuring the absorbance at 296 nm.
The absorbance was normalized with the value at 20 °C. (C) EMSA in 50 mM Tris-HCl, pH 7.4, 100 mM KCl of mixtures containing NRAS RG4
and BG4 (lanes 2 and 3 from left) or utr-z RG4 and BG4 (lanes 5 and 6 from left). BG4 was used at 1 and 2 μg, and the gel was 5% polyacrylamide
in TBE.
Figure 3. (A) Stem-loop structure of the first 80 nt of KRAS 5′-UTR (s-80) given by Mfold. Sequence s-80 is in equilibrium with an alternative
structure characterized by three nonoverlapping G4 RNAs. (B) EMSA in 5% polyacrylamide, TB 1X, of mixtures between BG4 and s-80 or RNA
hairpin (hair) 5′-GGCCGCCGCAGUGGCGGCGG or ssRNA 5′-UGUAAACAUCCUACACUCAGCU in 50 mM Tris-HCl, pH 7.4, 100 mM KCl
(K+-buffer) or 100 mM LiCl (Li+-buffer). Except mixture 4, all have been prepared in K+-buffer. Loading: s-80 (lane 1); s-80 + 1 μg BG4 (lane 2); s-
80 + 2 μg BG4 (lane 3); s-80 + 1 μg BG4 in Li+-buffer (lane 4); hair (lane 5), hair +1 μg BG4 (lane 6); ssRNA (lane 7); ssRNA + 1 μg BG4 (lane 8).
(C) RNase T1 footprinting of s-80. Loading from left to right: alkaline RNA fragmentation (Seq); RNase T1 reaction in urea (urea), in K+-buffer
(K100), in Li+-buffer (Li100), in K+-buffer + 2a (r = 4) to see if the hairpin = G4 equilibrium is shifted by the ligand (2a), in K+-buffer with 150 mM
KCl (K150) in Li+-buffer with 150 mM (Li150). The bottom band (band 7) matches the mobility of a 7-mer fragment.
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5′-UTR, and each displays a circular dichroism spectrum
characterized by a strong ellipticity at 265 nm and a negative
ellipticity at 240 nm, typical of parallel G-quadruplexes, as does
the well-known G4-motif located in the 5′-UTR of NRAS
(Figure 2 A).26,50 The G4 motifs show UV-thermal difference
spectra characterized by a negative peak at 295 nm in K+, but
not in Li+, buffer, a distinctive feature of G4 structures
(Supporting Information S2).51 They show cooperative UV-
melting curves at 296 nm (as well as at 260 nm), with TM
varying from 53 °C to 64 °C in K+ buffer (Figure 2 B and Table
1). The melting curves analyzed with a two-state model gave
ΔG of quadruplex formation between ∼−3.7 and −5.6 kcal/
mol (Table 1).
To confirm that the selected G4 motifs adopt a RG4
structure, we analyze by EMSA if they are recognized by BG4,
an antibody specific for G-quadruplexes.52,53 This analysis was
performed with only the 20-mer utr-z G4 motif, as utr-1 and
utr-c are too short for binding to BG4. We found that BG4
formed a stable RNA−protein complex with utr-z as well as
with the NRAS RG4, which was used as a positive control
(Figure 2 C).26 Next, we analyzed by EMSA the first 80-nt of
5′-UTR (s-80), which contains the three nonoverlapping G4
motifs. We wanted to find out if the G4 structures are also
present in this longer RNA s-80 sequence, although it could
form a mismatched stem-loop structure, according to Mfold
(Figure 3 A). We found that in K+-buffer, BG4 clearly bound to
s-80, while it did not essentially bind to single-stranded RNA or
hairpin RNA sequences, thus suggesting that KRAS 5′-UTR
forms indeed local G4 structures (Figure 3 B). We found that
BG4 bound to s-80, although with a weaker intensity, also in
Li+-buffer. This is probably due to the fact that s-80 exists as a
hairpin = G4 equilibrium, which is more shifted to the right in
K+- than Li+-buffer. BG4, upon binding to the existing
quadruplex, is likely to push the equilibrium to the right. The
capacity of RNA sequences to fold into G4s in the absence and
presence of various metal ions, including K+, Na+, and Li+, has
been examined by Miserachs et al.54 Further evidence that G4
is present in s-80 was obtained by measuring the reactivity of
the guanines with RNase T1,55 taking into account that the
guanines involved in the formation of Watson−Crick or
Hoogsteen hydrogen bonds do not react with RNase T1. If s-80
assumes the stem-loop structure of Figure 3 A, the loop
guanines G23-G24 and G26-G27 should be reactive. On the
other hand, if s-80 forms the three nonoverlapping G4
structures, the loop guanines should not be reactive, as they
should be involved in the formation of the G-tetrads. In
contrast, guanines G30 and G33, falling between the utr-1 and
utr-z RG4 structures, should be reactive to RNase T1. The
footprinting of s-80 over the loop region shows that there is a
prevalence of stem-loop structure in Li+-buffer, as G30 and G33
are not or very slightly reactive (Figure 3 C, from left lanes 4
and 7). By contrast, in K+-buffer both G4 and stem-loop
structures are present in solution, as G30 and G33 as well as
G23-G24 and G26-G27 are clearly reactive with RNase T1
(lanes 3 and 6 from left). This behavior suggests that s-80 exists
in solution in equilibrium between G4 and the stem-loop
structure. To further support this conclusion, we tested the
presence of RG4s in s-80 with thioflavin T (ThT), a
fluorescence sensor specific for G4.56 As illustrated in Figure
4 A, ThT exhibited a strong increase of fluorescence emission
upon binding to s-80 but not upon binding to a RNA hairpin
(5′-GGCCGCCGCAGUGGCGGCGG). In Figure 4 B we
compared the fluorescence enhancement of ThT induced by s-
80 or hairpin RNA, in K+- or Li+-buffer.
K+-buffer s-80 caused an increase of fluorescence (F/F0) up
to 25 while in Li+-buffer only up to 10, in agreement with the
fact that the hairpin = G4 equilibrium is more shifted to the
right in the K+-buffer. By comparison, a designed hairpin RNA
increases F/F0 up to 5. These data strongly suggest that under
physiological conditions, RG4 structures are certainly present in
the first portion of KRAS 5′-UTR. Recently, Weldon et al.57
performed RNA footprintings on wild-type Bcl-x-681 transcript
and its 7-deaza-G analogue, which cannot form RG4. They
found that RG4 is present in the transcript, despite a possible
formation of competing stem-loop structures. The Bcl-x G4
Figure 4. (A) Fluorescence emission spectra in 50 mM Tris-HCl pH 7.4, 100 mM KCl (K+-buffer), of 0.2 μM ThT in the presence of increasing
amounts of 80-mer RNA fragment s-80 (top panel) or RNA hairpin 5′-GGCCGCCGCAGUGGCGGCGG (bottom panel). (B) Structure of
thioflavin T (ThT) and increase of fluorescence quantum yield at 485 nm of ThT following addition of increasing amounts of s-80 or hairpin in K+-
buffer and Li+-buffer (50 mM Tris-HCl pH 7.4, 100 mM LiCl).
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motifs have G-scores similar or lower (15 ≤ G-score ≤ 21) than
those found in the 5′-UTR of KRAS (G-score = 21).
ATPD and ATFD: Uptake and Capacity To Stabilize
RG4. As the 5′-UTR of KRAS is conserved in mammals
(Supporting Information S3) and forms RG4s, we hypothesized
that these unusual structures could be involved in the
mechanism regulating translation of KRAS. Previous studies
have showed that translation can be modulated by small
molecules targeting to RG4s.41,58,59 We therefore searched for
molecules that obey the following criteria: (i) high capacity to
penetrate cell membranes; (ii) binding to KRAS mRNA despite
its typical cellular low-abundance; (iii) high affinity for RG4s. In
previous studies we reported that anthrathiophenediones
(ATPD) with alkyl side chains carrying either guanidine or
chloroacetamidine terminal groups penetrate bladder cancer
cells and bind to DNA and RNA G4s.60,61 Because the side
chains strongly impact the uptake of these molecules,60 we
tested in human pancreatic Panc-1 cancer cells several ATPD
analogues and focused on 4,11-bis[2-guanidinoethylamino)-
anthra[2,3-b]thiophene-5,10-dione (1b) and 4,11-bis(2-
aminoethylamino)anthra[2,3-b]thiophene-5,10-dione (2b)62 as
well as on their furan analogues, anthrafurandiones (ATFD) 1a
and 2a63 (Figure 5 A). Both types of ligands have alkyl side
chains ending either with guanidine or amine groups. As the
chromophore of these molecules emits fluorescence upon
excitation at 488 nm, we investigated their cellular uptake by
FACS (Figure 5 B). The results showed that compounds 2a
and 2b with aminoethyl side chains are taken up 20- and 4-fold
more efficiently than the corresponding guanidine analogues 1a
and 1b, respectively. An explanation can be that compounds
carrying a localized charge generally display lower membrane
permeability than neutral compounds. Compound 2a differs
from 2b only for an atom in the five-member ring: oxygen
against sulfur. Nonetheless, the former is 5-fold more
permeable to Panc-1 cells than the latter. The higher
polarizability of sulfur compared to oxygen provides a rationale
for this behavior.64 Due to their high uptake in Panc-1 cells, we
used 2a and 2b to design a strategy aiming at inhibiting
translation of KRAS in Panc-1 cells. The guanidine analogues
1a and 1b were used as reference compounds: because their
uptake is lower, they are expected to produce a weaker cellular
effect. We first asked if the molecules bind to and stabilize the
RG4 structures. UV-melting experiments showed that 2a and,
to a lesser extent, 2b strongly stabilize the three nonoverlapping
RG4s located in the KRAS 5′-UTR. The increase of TM (ΔTM)
of the three RG4s in the presence of the G4 ligands at r = 1, 2,
and 4 (r = [ligand]/[G4]) are reported in the histograms of
Figure 5 C. 2a caused a TM increase up to 32 °C, while 2b up to
20 °C. The lower ΔTM brought about by 2b is probably due to
the polarizability of sulfur that may reduce the stacking of the
chromophore upon the G-tetrads. Our data show that when
thiophene is replaced with furan, the ligand increases not only
its capacity to stabilize RG4 but also the uptake in Panc-1 cells.
We also investigated the quadruplex-to-duplex specificity of the
G4 ligands by competition experiments. For instance, the TM of
utr-1 RG4 in the presence of 2a at r = 4 did not change when a
5- or 10-fold excess of 21-mer RNA duplex was added to the
mixtures (not shown). This is in keeping with our previous data
on analogue ligands.60,61
Finally, the affinity of ligands 2a and 2b for various G4 RNAs
located in 5′-UTR was determined by fluorescence titrations. A
typical titration obtained with utr-1 and 2a is shown in
Supporting Information S4. The various KDs are reported in
Table 2. The average KD value for 2a is ∼140 nM and for 2b is
Figure 5. (A) Structures of ATFD 2a, 1a and ATPD 2b, 1b. Two amine- or guanidine-alkyl side chains have been attached to the ring system of the
molecules. (B) Flow cytometry data showing the uptake of 3 μM compounds by Panc-1 cells after an incubation of 4 h. The two alkylamine
compounds 2a and 2b are taken up more than the guanidine analogues. (C) ΔTM is the TM increase of utr-z, utr-1, and utr-c G4 RNAs caused by 2a
and 2b at r = 1, 2, and 4, in 50 mM Tris-HCl, pH 7.4, 100 mM KCl.
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∼156 nM. The KD for the binding of the ligands to competing
mismatched hairpin RNAs could not be measured, as we were
unable to find experimental conditions in which these putative
structures, predicted by Mfold, are stable. We also designed a
non-natural RNA stem-loop structure and found that 2a and 2b
have affinities for this hairpin from 2 to 6 times lower than that
for the RG4s. Interestingly, the KDs for the binding of the
ligands to the critical G4 DNA formed in the KRAS promoter
are 626 ± 71 nM for 2a and 278 ± 21 nM for 2b. Although the
ligands can bind also to G4 DNA, the fact that they accumulate
more in the cytoplasm than in the nucleus (Supporting
Information S5) and that there are many copies of mRNA
RG4s, suggest that the main target, i.e., those producing a
stronger cellular effect, is likely to be in mRNA.
ATFDs Target the KRAS Transcript under Cellular
Low-Abundance Conditions. Studies so far reported on the
use of small molecules to inhibit translation are based on
luciferase assays and on the assumption that the G4 ligands
bind to mRNA.26,43−45 The first issue that we addressed in our
study was to demonstrate that 2a (the compound showing the
highest uptake) does indeed bind to KRAS mRNA, under its
low-abundance cellular condition. To do this, we synthesized
biotinylated 2a (b-2a) and set up a biotin−streptavidin pull-
down assay.
Synthesis of Biotinylated 2a (b-2a). The synthesis of
compounds 1a, 1b, 2a, and 2b, based on the nucleophilic
substitution of alkoxy groups in the peri-positions of
heteroarene-fused anthracenediones, has been described
previously.62−65 To link biotin to 2a we used as spacer 1,6-
diaminohexane.66−68 First, biotin (1) was coupled with mono-
Boc-protected 1,6-diaminohexane using HATU as coupling
reagent. The subsequent cleavage of the protecting group led to
building block HDA−biotin (3) (Scheme 1 A).66 As starting
compound for the biotinylation of 2a, we used 4,11-dimethoxy-
5,10-dioxoanthra[2,3-b]furan-2-carboxylic acid (4).69 The
condensation of the amine group of 3 with the carboxylic
group of 4 in the presence of PyBOP yielded the biotinylated
4,11-dimethoxy intermediate 5 (Scheme 1 B). Finally, by
treating 4,11-dimethoxyanthra[2,3-b]furan-2-carboxamide (5)
with ethylenediamine in THF at 50 °C we obtained to
biotinylated 4,11-bis(aminoalkylamino)anthra[2,3-b]furan-
5,10-dione 6 (b-2a).
Streptavidin−Biotin Pull-Down Assays with b-2a. To
demonstrate that the ligands bind to RG4s in KRAS mRNA,
we first ask if, by means of a biotin−streptavidin assay, b-2a is
Table 2. KD Values Relative to the Interaction between KRAS G4 RNAs and Ligands 2a and 2b
sequence (5′→3′) 2a KD (nM)
a 2b KD (nM)
a
utr-1 GCGGCGGCGGAGGCA 75 ± 6 91 ± 15
utr-z GGCGGCGGCAGUGGCGGCGG 251 ± 151 294 ± 138
utr-4b CAGCAGCGGCGGCGGCAGUGG 96 ± 45 83 ± 27
WC hairpinc CCGCCGCAGUGGCGGCGG 514 ± 103 482 ± 109
aObtained from fluorescence titrations in 50 mM Tris-HCl, pH 7.4, 100 mM KCl. bG4 motif present in the KRAS 5′UTR that overlaps other G4
motifs; cWC RNA hairpin with 7-C:G stem and 4-nt loop (AGUG) .
Scheme 1. Synthesis of Biotinylated Anthrafurandiones b-2aa
aReagents and conditions: (a) BocNH(CH2)6NH2, HATU, NMM, DMF, rt; overnight; yield 89%; (b) DCM, TFA, rt; 3 h; yield 87%; (c) 3,
PyBOP, DIPEA, DMSO, rt, 1 h, yield 80%; (d) ethylendiamine, THF, 50 °C, 1.5−2 h, yield 68%.
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Figure 6. (A) Structure of b-2a conjugated with biotin. (B) Total cellular mRNAs contain KRAS mRNA with G4 RNA in the 5′-UTR. G4-RNA is
bound by b-2a. HPRT is not bound or little bound by b-2a. (C) The streptavidin−biotin pull-down assay: b-2a pulls down preferentially G4-motif
mRNAs. The recovered mRNA was used to determine by RT-qPCR the amounts of KRAS and HPRT mRNAs. (D) The histograms show the ratio
of KRAS/HPRT mRNAs in the input, i.e., total cellular extract (fixed to 1), and in the recovered RNA from a total cellular extract treated with
increasing amounts of b-2a. An enrichment of KRAS over HPRT of nearly 3 times was obtained, suggesting that the biotinylated ligands bind to
KRAS mRNA within the total cellular extract.
Figure 7. (A, B) Dual luciferase assay showing the effect of compounds 2a, 2b, 1a, and 1b (0−1.6 μM) on Renilla luciferase driven by the KRAS
promoter comprising the 5′-UTR (pRL-KRAS). As reference, we used a plasmid in which Firef ly luciferase was driven by the HRAS promoter
mutated to abolish its capacity to form quadruplex structures.61 The assay shows that 2a strongly inhibits luciferase expression. Also 2b shows a
strong inhibitory activity. (C) When Panc-1 cells are treated with 2a at lower concentrations (0−0.33 μM), a dose−response reduction of luciferase
is observed. T = Renilla/Firef ly in treated cells, C = Renilla/Firef ly in untreated cells. *P < 0.05.
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capable to pull down a DNA containing a G4 structure (Figure
6 A). We designed two DNA strands of 115 and 89 nt of which
the former contained in the middle a G4 motif (telomeric
htel70). Both DNA strands had the same 5′- and 3′-ends and
could be amplified with the same couple of primers. A 1:1
mixture of the two strands was incubated with an excess b-2a,
and the DNA bound to the biotinylated ligand was pulled down
by streptavidin−magnetic beads and the recovered DNA
amplified. On a calibration curve, the DNA recovered was
dramatically enriched with the 115-nt sequence containing G4,
suggesting that b-2a efficiently pulled down the DNA strand
carrying G4: a prerequisite essential for the next step of the
experiment (Supporting Information S6).
The pull-down experiment was repeated by replacing the 1:1
mixture with total cellular RNA extracted from Panc-1 cells.
Cellular RNA is composed by ribosomal, transfer, and, in
minimal part, mRNA. As illustrated in Figure 6 B, the
transcriptome contains mRNAs without G4 structures (such
as HPRT) and with G4 structures in 5′-UTR as KRAS. We
reasoned that while all transcripts will have weak binding sites
for b-2a (RNA stem-loop secondary structures), only a fraction
of transcripts will exhibit both weak (stem-loop) and strong
(G4) binding sites for b-2a. On the basis of this assumption,
total cellular RNA from Panc-1 cells was incubated with b-2a
and the RNA bound to the ligand was pulled down with
streptavidin-coated magnetic beads. The amounts of KRAS and
HPRT transcripts in the recovered RNA were determined by
quantitative RT-PCR and compared to the amounts of the
same genes detected in the input (untreated cellular RNA).
The results showed that KRAS/HPRT in the pulled-down RNA
increased nearly 3-fold compared to the input, suggesting that
b-2a binds indeed to RG4s in KRAS transcripts (Figure 6 C,D).
The pull-down experiment was repeated with increasing
concentrations of b-2a (from 400 to 800 nΜ). The highest
enrichment in KRAS transcript was obtained at a concentration
of 2a of 600 nM. With higher concentrations of b-2a, the
enrichment decreased as the ligand bound to both strong (G4)
and weak (stem-loop) sites (Figure 6 B). Together, the data
demonstrate that a small molecule such as 2a, designed to
inhibit gene expression, targets G4 RNA in the 5′-UTR of the
KRAS transcript under cellular conditions in which the
transcript is typically in low abundance.
Capacity of Compounds 2a and 2b To Repress
Translation in Pancreatic Cancer Cells. After having
demonstrated that ATPD and ATFD bind to RG4s in the
KRAS transcript, we asked if they inhibit the translation of the
oncogene in pancreatic cancer cells. First, we performed a dual-
luciferase assay as a proof-of-principle. We used a plasmid
where Renilla luciferase was driven by the KRAS promoter
including 5′-UTR (pRL-KRAS). To determine the transfection
efficiency, we used pHRAS-mutA-luc, in which Firef ly luciferase
is driven by a mutated HRAS promoter, which does not bear
G4 motifs (Figure 7 A).71 Panc-1 cells were first treated for 6 h
with increasing amounts of 2a and 2b, with the guanidine
analogues 1a and 1b (from 0.3 to 1.6 μM), and then with the
luciferase vectors. The ratio between Renilla and Firef ly
luciferases was measured 48 h after transfection. 2a and 2b at
concentrations between 0.3 and 1.6 μM dramatically lower
luciferase, much more than that of the reference guanidine
analogues (Figure 7 B). When 2a was used at lower
concentrations, between 0.07 and 0.33 μM, a clear dose−
response inhibitory effect was observed (Figure 7 C). If one
considers that the four ligands have similar affinity for utr-z
(and also for the other RG4s) but different uptake in Panc-1
cells, there is a clear correlation between luciferase inhibition
and uptake. The higher the uptake (2a and 2b), the higher the
luciferase inhibition.
It might be argued that the luciferase repression mediated by
2a and 2b is due to the binding of the ligands not only to the
RG4s in 5′-UTR but also to G4 in the KRAS promoter.23,72,73
To address this point, we prepared a vector where Renilla
luciferase is driven by the cytomegalovirus (CMV) promoter.
At the 3′-end of CMV promoter, we inserted the KRAS 5′-UTR
(pRL-CMV-UTR). As the CMV promoter does not form G4
structures, the strong binding sites for 2a are only located in the
5′-UTR sequence. As a reference vector, we used pHRAS-
Figure 8. Dual luciferase assay with Renilla luciferase plasmid pRL-CMV-UTR or pRL-CMV and Firef ly luciferase plasmid pHRAS-mutA-luc. Left
histograms show a strong dose−response luciferase reduction caused by increasing amounts of 2a (0−1.6 μM), while the right panel shows that
when the KRAS 5′-UTR is removed, the luciferase reduction is not observed, suggesting that the inhibitory effect is mediated by 5′-UTR. T =
Renilla/Firef ly in treated cells, C = Renilla/Firef ly in untreated cells. *P < 0.05.
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mutA-luc. The dual luciferase assay showed that 2a represses
Renilla luciferase expression in a dose−response manner,
suggesting that the presence of KRAS 5′-UTR alone is
sufficient to promote the repression of luciferase (Figure 8,
left panel). The inhibition is observed with higher ligand
concentrations than those used with plasmid pRL-KRAS,
because the CMV promoter is stronger than the KRAS
promoter. We then measured the effect of 2a on pRL-CMV,
which lacks the KRAS 5′-UTR downstream of the CMV
promoter. In this case 2a did not repress Renilla luciferase, in
agreement with the fact that G4 is not present in this construct
(Figure 8, right panel). This experiment supports the
conclusion that 2a upon binding to RG4 in the 5′-UTR of
KRAS inhibits translation. We cannot rule out that the
compounds also bind to the KRAS promoter. However,
considering that (i) the G4 ligands accumulate more in the
cytoplasm than in the nucleus (Supporting Information S5)
and that (ii) there are many copies of RNA targets in the cells,
even under mRNA low-abundance cellular conditions, 2a and
2b are expected to bind more favorably to G4 in mRNA than in
promoter DNA.
Effect of 2a and 2b on KRAS Expression in Pancreatic
Cancer Cells. As the designed compounds, in particular 2a,
decrease the luciferase from vectors containing the KRAS 5′-
UTR, we asked if these G4 ligands are also able to inhibit the
expression of genomic KRAS in pancreatic cancer cells. We
measured by quantitative RT-PCR the level of KRAS transcript
in Panc-1 cells after 6 and 24 h of treatment. The results
showed that while 2b, 1a, and 1b did not lower the level of
mRNA, 2a reduced it to about 50% of the control, at both time
points. By contrast, all the compounds displayed a strong
capacity to suppress the KRAS protein. In particular 2a and 2b,
which are efficiently taken up by Panc-1 cells, brought the
protein down to <10% of the control (Figure 9 A,B). In light of
these results, we concluded that 2a and 2b inhibit KRAS mainly
at the translational level. Moreover, both luciferase and Western
blot data show that compound 2a is slightly more active than
2b, possibly because 2a has a higher capacity to penetrate the
cell membrane than 2b, and a fraction of it may also target G4
in the KRAS promoter.
Pancreatic cancer cells, being addicted to KRAS, respond to
the repression of the oncogene by activating apoptosis.74 We
found indeed that 2a and to a lesser extent 2b caused a strong
activation of caspases 3/7 (Figure 10 A). In contrast, the
reference compounds 1a and 1b showed a much weaker
caspase activation. To confirm the activation of apoptosis, we
also performed an annexin/propidium iodide assay (Figure 10
B). This is based on the observation that an early event
occurring in apoptosis is the translocation of phosphatidylserine
from the inner to the outer leaflet of the plasma membrane,
thus exposing the phospholipid to the external cell environ-
ment. Annexin V, a phosphatidylserine recognizing protein
labeled with FITC, can be used to detect this event by FACS.
Early and late apoptosis can be distinguished by using both
annexin V and propidium iodide (PI).75 The experiment
showed that 1.6 μM 2a and 2b increased the population of
apoptotic cells 72 h after treatment: untreated Panc-1 cells
(apoptotic cells ∼1.2%); Panc-1 cells treated with 2a (apoptotic
cells ∼32.5%); Panc-1 cells treated with 2b (apoptotic cells
∼20.6%).
Finally, the metabolic activity of Panc-1 cells treated with the
designed compounds was evaluated by a resazurin assay.
Compound 2a causes an inhibition of the metabolic activity
(IC50 = 0.26 μM) stronger than 2b (IC50 = 0.9 μM) (Figure 10
C). Moreover, 2a caused a strong inhibition (∼80%) of colony
formation in two pancreatic cancer cells: Panc-1 and BxPC-3
(Supporting Information S7).
■ CONCLUSION
By setting up a streptavidin−biotin pull-down assay, we have
demonstrated that 2a, an anthrafurandione with amino-
ethylamino side chains, which efficiently internalizes and
accumulates in the cytoplasm of Panc-1 cancer cells, targets
KRAS mRNA under low-abundance cellular conditions.
Luciferase assays with specific vectors showed that 2a and its
anthrathiophenedione analogue 2b repress translation in a
dose−response manner, suggesting that they have a great
potential in cancer therapy. Indeed, Western blots showed that
these molecules strongly decrease the KRAS protein in Panc-1
cancer cells. Moreover, the compounds activate apoptosis, as
indicated by the caspase 3/7 and annexin/propidium iodide
assays, and reduce the metabolic activity as well as the colony
formation of the cells.
The mechanism of action of the designed compounds 2a and
2b is based on their capacity to bind to G4 structures located in
the 5′-UTR of KRAS mRNA. The presence of these folded
structures in mRNA has been demonstrated by immunostain-
ing in fixed cells.76 A recent study by Guo and Bartel casts
doubts on the existence of RG4s under in vivo conditions, as
the authors found that RG4s are globally unfolded by single-
stranded binding proteins.77 If this is also true for the KRAS
transcripts in pancreatic cancer cells, compounds 2a and 2b
could inhibit translation by competing with the binding of
single stranded-binding proteins to the RNA G4-motifs.
Finally, having established in cancer cells that 2a and 2b have
a potential as anticancer agents, the next step will be in vivo
testing. As pancreatic cancer cells are addicted to KRAS,
therapeutics targeting this oncogene should be much more
injurious for the malignant cells than for normal cells.
Figure 9. (A) Quantitative RT-PCR of KRAS mRNA in Panc-1 cells
treated for 6 and 24 h with 1.6 μM 2a, 2b, 1a, and 1b. Ordinate
reports the level of KRAS mRNA normalized to β2-microglobulin and
HPRT. (B) Western blot determination of KRAS protein and β-actin
in Panc-1 cells treated with 1.6 μM 2a, 2b, 1a, and 1b for 48 h. *P <
0.05.
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■ EXPERIMENTAL SECTION
Oligonucleotides. The oligonucleotides used in this study have
been purchased from Microsynth (Switzerland). Oligonucleotide
solutions in DEPC-treated Milli-Q water have been conserved at
−80 °C. The sequences are reported in Table 1 and Supporting
Information S8.
Synthesis of 2a, 2b, 1a, 1b, and Biotinylated Ligand b-2a.
General information. NMR spectra were recorded on a Varian VXR-
400 instrument operated at 400 MHz (1H NMR) and 100 MHz (13C
NMR). Chemical shifts were measured in DMSO-d6 using
tetramethylsilane as an internal standard. Analytical TLC was
performed using silica gel F254 plates (Merck) and column
chromatography with SilicaGel Merck 60. Melting points were
determined using a Buchi SMP-20 apparatus and are uncorrected.
High-resolution mass spectra were recorded with electron-spray
ionization using a Bruker Daltonics microOTOF-QII instrument.
UV spectra were recorded on a Hitachi-U2000 spectrophotometer.
HPLC was performed using a Shimadzu Class-VP V6.12SP1 system.
All solutions were dried over Na2SO4 and evaporated at reduced
pressure using a Buchi-R200 rotary evaporator at a temperature below
45 °C. All products were vacuum-dried at room temperature. All
solvents, chemicals, and reagents were obtained commercially and
used without purification. The ligands 2a, 2b, 1a, and 1b have been
synthesized as previously described.60,61 The purity of final conjugates
b-2a was >95% as determined by HPLC analysis (Supporting
Information S9).
Synthetic Procedures. tert-Butyl (6-(5-((3aS,4S,6aR)-2-Oxohexa-
hydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)hexyl) carba-
mate (2, N-Boc-HDA−Biotin). N-Boc-1,6-Diaminohexane (0.50 g,
2.05 mmol) was added to a stirred solution of biotin (1, 0.50 g, 2.05
mmol), N-methylmorpholine (NMM, 0.23 mL, 2.05 mmol) and 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxide hexafluorophosphate (HATU, 0.77 g, 2.05 mmol) in dry DMF
(20 mL). The reaction mixture was stirred overnight at room
temperature and diluted with water, and the product was extracted
with ethyl acetate (2 × 25 mL). The extract was washed twice with
water, dried, and evaporated. The residue was purified by using
column chromatography with chloroform−methanol (1:0 → 3:1) as
the eluting solvent. The solid precipitate was recrystallized from n-
propanol to give 0.84 g (89%) of the white powder of N-Boc-HDA−
biotin (2);63 mp 173−176 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.73
(t, 1H, J = 5.4 Hz, NH); 6.77 (t, 1H, J = 5.0 Hz, NH); 6.43 (br s, 1H,
NH-biotin); 6.36 (br s, 1H, NH-biotin); 4.31−4.28 (m, 1H, CH);
4.13−4.11 (m, 1H, CH); 3.11−3.06 (m, 1H, SCHCH2); 3.01 (dd, 2H,
1J = 6.2, 2J = 7.8 Hz, NCH2); 2.89 (dd, 1H,
1J = 6.0, 2J = 7.2 Hz,
NCH2); 2.81 (dd, 1H,
1J = 5.2, 2J = 7.5 Hz, SCHH); 2.57 (d, 1H, J =
12.4 Hz, SCHH); 2.03 (t, 2H, J = 7.5 Hz, COCH2CH2); 1.60−1.20
(m, 23H, C(CH3)3, 7CH2); HRMS (ESI) calculated for
C21H39N4O4S
+ [M + H]+ 443.2687, found 443.2673.
N-(6-Aminohexyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno-
[3,4-d]imidazol-4-yl)pentanamide Trifluoroacetate (HDA−Biotin,
3). A solution of N-Boc-HDA−biotin (2, 0.80 g, 1.81 mmol) in a
mixture of DCM (10.0 mL) and TFA (2.0 mL) was stirred for 3 h at
the room temperature. The solvent was evaporated and residue
reprecipitated from warm water with acetone. The precipitated crystals
were filtered, washed with acetone, and dried to yield 0.72 g (87%) of
HDA−biotin (3); mp 92−95 °C; 1H NMR (400 MHz, DMSO-d6) δ
7.76 (t, 1H, J = 5.4 Hz, NH); 7.70 (br s, 3H, NH3); 6.42 (br s, 1H,
NH-biotin); 6.37 (br s, 1H, NH-biotin); 4.32−4.29 (m, 1H, CH);
4.14−4.11 (m, 1H, CH); 3.11−3.06 (m, 1H, SCHCH2); 3.01 (dd, 2H,
1J = 6.0, 2J = 6.8 Hz, NCH2); 2.82 (dd, 1H,
1J = 5.0, 2J = 7.5 Hz,
SCHH); 2.76 (dd, 1H, 1J = 6.0, 2J = 7.2 Hz, NCH2); 2.58 (d, 1H, J =
12.6 Hz, SCHH); 2.04 (t, 2H, J = 7.5 Hz, COCH2CH2); 1.64−1.24
(m, 14H, 7CH2); HRMS (ESI) calculated for C16H31N4O2S
+ [M +
H]+ 343.2162, found 343.2156.
Biotinyl-N-(6-aminohexyl)-4,11-dimethoxy-5,10-dioxo-5,10-
dihydroanthra[2,3-b]furan-2-carboxamide (5). A mixture of 4,11-
dimethoxyanthra[2,3-b]furan-5,10-dione-2-carboxylic acid (4;66 0.30 g,
0.85 mmol), ethyldiisopropylamine (DIPEA, 0.5 mL, 3.00 mmol),
biotinyl-N-(6-aminohexyl)amine trifluoroacetate (3, 0.39 g, 0.85
mmol), and benzotriazol-1-yloxytripyrrolidinophosphonium hexafluor-
ophosphate (PyBOP, 0.52 g, 1.00 mmol) in DMSO (15 mL) was
stirred at room temperature for 1 h. The reaction mixture was diluted
with water, and the product was extracted with ethyl acetate (2 × 20
mL). The extract was washed twice with water, dried, and evaporated.
The residue was purified by using column chromatography with
chloroform−methanol (1:0→ 3:1) as the eluting solvent. The yield of
the orange solid of 5 was 0.46 g (80%); mp 132−134 °C; 1H NMR
(400 MHz, DMSO-d6) δ 8.87 (t, 1H, J = 5.9 Hz, NH); 8.05−8.03 (m,
2H, 6,9-H); 7.88 (s, 1H, 3-H); 7.82−7.80 (m, 2H, 7,8-H); 7.76 (t, 1H,
J = 5.3 Hz, NH); 6.44 (br s, 1H, NH-biotin); 6.37 (br s, 1H, NH-
biotin); 4.31−4.27 (m, 1H, CH); 4.12 (s, 3H, OMe); 4.07 (s, 3H,
OMe); 4.13−4.12−4.10 (m, 1H, CH); 3.28 (dd, 2H, 1J = 6.2, 2J = 6.8
Hz, NCH2); 3.10−3.06 (m, 1H, SCHCH2); 3.02 (dd, 2H,
1J = 6.0, 2J =
7.0 Hz, NCH2); 2.81 (dd, 1H,
1J = 4.9, 2J = 7.5 Hz, SCHH); 2.56 (d,
1H, J = 12.3 Hz, SCHH); 2.04 (t, 2H, J = 7.1 Hz, COCH2CH2); 1.59−
1.25 (m, 14H, 7CH2);
13C NMR (100 MHz, DMSO-d6) δ 182.05
(CO); 181.65 (CO); 171.87 (N−CO); 162.75 (N−CO−N);
Figure 10. (A) Activation of caspase 3/7 in Panc-1 cells treated with 2a, 2b, 1a, and 1b (0.8 and 1.6 μM). Compounds 2a and 2b show activity
higher than that of analogues 1a and 1b. (B) Annexin−propidium assay of Panc-1 cells treated for 72 h with 2a (1.6 μM) and 2b (1.6 μM). (C)
Metabolic activity in Panc-1 cells treated with increasing concentrations of 2a, 2b, 1a. and 1b. Compound 2a shows the highest activity. *P < 0.05.
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156.92 (N−CO); 151.61 (C); 150.47 (2C); 142.60 (C); 133.99
(C); 133.80 (C); 133.64 (C); 127.30 (C); 123.33 (C); 120.43 (C);
133.98 (CH); 126.10 (CH); 126.00 (CH); 108.44 (CH); 61.81 (CH);
61.71 (CH); 61.07 (OCH3); 59.22 (OCH3); 55.47 (CH); 39.86
(CH2); 38.95 (CH2); 38.31 (CH2); 35.25 (CH2); 29.15 (CH2); 29.00
(CH2); 28.24 (CH2); 28.06 (CH2); 26.19 (CH2); 26.14 (CH2); 25.38
(CH2). HRMS (ESI) calculated for C35H41N4O8S
+ [M + H]+
677.2640, found 677.2612.
4,11-Bis((2-aminoethyl)amino)-biotinyl-N-(6-aminohexyl)-5,10-
dioxo-5,10-dihydroanthra[2,3-b]furan-2-carboxamide (6, b-2a). A
mixture of compound 5 (0.27 g, 0.40 mmol) and ethylenediamine (1.5
mL) in THF (5.0 mL) was heated at 50 °C for 2−3 h. During this
time, the yellow color of the reaction mixture changed to dark blue,
and after the complete conversion of 5 (as determined by TLC) the
solution was cooled and quenched with water. An aqueous solution of
HCl (1%) was added to make the pH = 8.0, the solution was saturated
with NaCl, and the product was extracted with warm n-butanol (3 ×
25 mL). The extract was washed twice with brine, dried, and
evaporated. The residue was purified by column chromatography using
chloroform−methanol−concentrated NH4OH (10:2:0 → 10:4:1) as
the eluting solvent. The purified residue was dissolved in a warm
aqueous solution of HCl (1 N) and reprecipitated with acetone. The
precipitated crystals were filtered, washed with acetone, and dried to
yield 0.22 g (68%) of the dark blue powder of dihydrochloride 6; mp
204−206 °C (decomp); HPLC Kromasil-100-5-mkm C-18 column (4
× 250 mm, LW = 260 nm), eluent: A, H3PO4 (0.01 M), B, MeCN;
gradient B 20 → 60% (30 min), elution time 9.4 min, purity 96%. 1H
NMR (400 MHz, DMSO-d6) δ 12.18 (t, 1H, J = 5.0 Hz, NH); 11.36
(t, 1H, J = 5.5 Hz, NH); 9.32 (t, 1H, J = 5.4 Hz, NH); 8.55 (s, 1H,3-
H); 8.41 (br s, 3H, NH3); 8.25−8.22 (m, 2H, 6,9-H); 8.18 (br s, 3H,
NH3); 7.82 (br s, 1H, NH); 7.80−7.78 (m, 2H, 7,8-H); 6.44 (br s, 1H,
NH-biotin); 6.39 (br s, 1H, NH-biotin); 4.31−4.28 (m, 1H, CH);
4.13−4.10 (m, 3H, CH, NCH2); 4.08−4.06 (m, 2H, 2NCH2); 3.29−
3.26 (m, 4H, 2NCH2); 3.10−3.06 (m, 1H, SCHCH2); 3.05−3.00 (m,
2H, NCH2); 2.81 (dd, 1H,
1J = 5.1, 2J = 7.3 Hz, SCHH); 2.57 (d, 1H, J
= 12.4 Hz, SCHH); 2.05 (t, 2H, J = 7.3 Hz, COCH2CH2); 1.60−1.30
(m, 14H, 7CH2). HRMS (ESI) calculated for C37H49N8O6S
+ [M +
H]+ 733.3490, found 733.3494.
Cell Culture, Metabolic Activity, and Proliferation Assays.
Panc-1 and BxPC-3 cells (human pancreatic cancer cells) were
maintained in exponential growth in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 100 U/mL penicillin, 100 mg/mL
streptomycin, 20 mM L-glutamine, and 10% fetal bovine serum
(Euroclone, Italy). The cell lines have been genotyped by Microsynth
(Switzerland) to verify their identity. They matched 100% with the
DNA-profiles of Panc-1 (ATCC CRL-1469TM) and BxPC-3 (ATCC
CRL-1687TM). The metabolic activity assay was performed by
seeding the cells (10 × 103 cells/well) in a 96-well plate. After 1 day,
the cells have been treated with the compounds and after an
incubation of 72 h the resazurin assay was performed following a
standard procedure.
Colony forming assays have been carried out with Panc-1 and
BxPC-3 cells plated on a 60 mm plate and treated with 0.25 and 0.5
μΜ 2a or 1 and 1.5 μΜ 2b. After 18 days, the cells were fixed and
stained for 10 min with 2.5% methylene blue in 50% ethanol. Colonies
with >50 cells were counted.
Circular Dichroism Spectra and UV-Melting Curves. CD
spectra have been obtained on a JASCO J-600 spectropolarimeter,
equipped with a thermostated cell holder, with 5 μM oligonucleotide
solutions in 50 mM Na-cacodylate pH 7.4, 100 mM KCl or LiCl
(RNase free). The CD spectra (for KRAS utr-1, utr-c, and utr-z) and
NRAS were registered at 25 °C and 90 °C. Spectra were recorded in
0.5 cm quartz cuvette. The spectra were calculated with J-700 Standard
Analysis software (Japan Spectroscopic Co, Ltd.). Each spectrum was
recorded three times, smoothed, and the baseline subtracted.
UV melting curves were obtained by using JASCO V-750 UV−
visible spectrophotometer equipped with a temperature control system
that heats/cools the sample through Peltier technology (ETCS-761)
(Jasco, Portland, OR). Melting curves were recorded at 260 and 296
nm in a 0.5 cm path length quartz cuvette, heating the sample from 20
°C to 100 °C. The samples were prepared at a final concentration of 5
μΜ in 100 mM KCl and 50 mM Na-cacodylate, pH 7.4. Incubation
with increasing amounts of the molecules (2a and 2b) (r = 1, 2, and 4)
was performed for 1 h at room temperature.
RNase T1 Footprinting and Electrophoretic Mobility-Shift
Assay. Single-stranded RNAs were purified by PAGE and 5′-end
labeled with T4 polynucleotide kinase (ThermoFisher, Waltham, MA)
and [32P]-ATP (PerkinElmer, Waltham, MA) for 1.5 h at 37 °C.
RNase T1 footprinting was performed with 30 nM s-80 heated for 5
min at 85 °C and then incubated overnight at 25 °C in 10x Structure
Buffer (RNase T1 Biochemistry grade, ThermoFisher) with 100 mM
KCl or LiCl. The reactions were performed with 0.05 units of RNase
T1 (ThermoFisher) for 10 min at 25 °C and stopped with 20 μL
inactivation/precipitation buffer (ThermoFischer). RNA was precipi-
tated at −80 °C for 2 h and centrifuged for 30 min at 13000 rpm.
Precipitated RNA was resuspended with loading buffer (Thermo-
Fisher), heated for 5 min at 95 °C, and electrophoresed on a 20%
denaturing gel, pre-equilibrated at 55 °C in a Sequi-Gen GT Nucleic
Acids Electrophoresis Apparatus (Bio-Rad, Hercules, CA), equipped
with a thermocouple that allows precise temperature control. EMSA
assays were performed with 20 nM utr-z or s-80 labeled at the 5′-end
with [32P]-ATP. The mixture was incubated for 30 min at 37 °C with
increasing concentrations of antibody BG4 (1 and 2 μg). BG4 was
produced according to Studier et al.78 The samples were run in a 5%
TBE 1x gel for 2 h. After running, the gel was fixed in a solution
containing 10% acetic acid and 10% methanol, dried at 80 °C, and
exposed to Hyperfilm MP (GE Healthcare) for autoradiography.
Western Blots. Total protein lysates (15 μg) were electrophoresed
on 12% SDS-PAGE and transferred to a nitrocellulose membrane at 70
V for 2 h. The filter was blocked for 1 h with 5% BSA solution in PBS
0.05% Tween (Sigma-Aldrich, St. Louis, MO) at room temperature.
The primary antibodies used are antiactin (clone JLA20, IgM mouse, 1
× 10−4 μg/mL, Calbiochem, Merck Millipore, Germany) and anti-
KRAS (IgG rabbit polyclonal antibody, diluted 1:250, ab 102007,
Abcam, United Kingdom). Membranes with the samples were
incubated overnight at 4 °C with primary antibodies. The filters
were washed with 0.05% Tween in PBS and subsequently incubated
for 1 h with the secondary antibodies, horseradish peroxidase
conjugated: antimouse IgM (diluted 1:2000) and antirabbit IgG
(diluted 1:5000) (Calbiochem, Merck Millipore, Germany). The
signal of the proteins was developed with Super Signal West PICO and
FEMTO (ThermoFisher) and detected with ChemiDOC XRS,
Quantity One 4.6.5 software (BioRad Laboratories).
RNA Extraction and Quantitative Real-Time PCR. Panc-1 cells
were plated in a 96-well plate (18 × 103 cells/well). The following day
(24 h), we treated the cells with 2a, 2b, 1a, and 1b, and total RNA was
extracted by using iScript RT-qPCR Sample Preparation Reagent
(BioRad) 6 and 24 h after treatment, following the manufacturer’s
instructions. For the cDNA synthesis, 1.25 μL of RNA was heated at
70 °C and placed on ice. The solution was added to 11.5 μL of a mix
containing: 1x buffer, 0.01 M DTT (Invitrogen, Carlsbad, CA), 1.6 μM
primer dT [MWG Biotech, Germany; d(T)16], 1.6 μM random
hexamer primers (Mycrosynth, Switzerland), 0.4 mM dNTPs solution
containing equimolar amounts of dATP, dCTP, dGTP, and dTTP
(Euroclone, Italy), 0.8 U/μL RNase OUT, and 8 U/μL of M-MLV
reverse transcriptase (Invitrogen). The mixtures were incubated for 1
h at 37 °C and stopped by heating at 95 °C for 5 min. As a negative
control, the reverse transcription reaction was performed with a
sample containing DEPC-treated water.
To determine the levels of KRAS and housekeeping genes
hypoxanthine-guanine phosphoribosyltransferase (HPRT) and β2-
microglobulin, quantitative real-time multiplex reactions were
performed. We used 1x Kapa Probe fast qPCR kit (KAPA Biosystems,
Wilmington, MA), 2.2 μL of cDNA, and primers/probes (sequences
are reported in Supporting Information S8). The PCR cycle was 3 min
at 95 °C, 50 cycles 10 s at 95 °C, and 60 s at 58 °C. PCR reactions
were carried out with a CFX-96 real-time PCR apparatus controlled by
an Optical System software (version 3.1) (Bio-Rad Laboratories). The
KRAS transcript level was normalized with the housekeeping genes.
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Dual Luciferase Assays. Panc-1 cell were plated (20 × 103) and
the following day treated with increasing concentrations of compounds
2a, 2b, 1a, and 1b (0.3−1.6 μM). After 6 h of treatment, the cells were
transfected with the plasmids. The 192 nt of KRAS 5′UTR
(NM_033360) was cloned between Hind III and Nhe I of pRL-
CMV plasmid (GenScript, Piscataway, NJ). Transfection was
performed by mixing vectors (10 ng/well) p-light-SwitchGear KRAS
(SwitchGear Genomics, Carlsbad, CA) (in the text pRL-KRAS) or
pRL-CMV-UTR or pRL-CMV (Renilla luciferase) with 200 ng of
control plasmid (pHRAS-mutA-luc) (Firef ly luciferase) using jet-PEI
(Polyplus, France) as transfectant agent. Renilla luciferase in cell
lysates was measured and normalized by Firef ly luciferase. Luciferase
assays were performed 48 h after transfection with Dual-Glo Luciferase
Assay System (Promega, Fitchburg, WI) following the supplier
instructions. Samples were read on a Turner Luminometer and the
relative luminescence expressed as (T/C × 100) where T = Renilla
luciferase/Firef ly luciferase in treated cells and C = Renilla luciferase/
Firef ly luciferase in untreated cells.
Uptake Analysis. Panc-1 cells were plated in a 24-well plate at
density of 5 × 104 cells/well. After 1 day, the cells were treated with
the molecules: time and concentration are indicated in figure captions.
The cells were trypsinized and pelleted. The pellets were resuspended
in 200 μL of PBS and immediately analyzed by FACScan Flow
Cytometer (Becton Dickinson, Franklin Lakes, NJ) equipped with a
488 nm argon laser. A minimum of 104 cells for each sample were
acquired in list mode and analyzed using Cell Quest software. The cell
population was analyzed by FSC light and SSC light. The signal was
detected by FL3 (680 nm) channel in log scale.
Apoptosis Assays. Caspase activity assay was performed with
Apo-ONE Homogeneous Caspase-3/7 Assay (Promega,), according to
the manufacturer’s protocol. Annexin V−propidium iodide assay was
performed with Annexin V Apoptosis Detection Kit (Santa Cruz
Biotechnology, Inc., Dallas, TX), following the manufacturer’s
instructions. Flow cytometry measurements were performed with
FACScan Flow Cytomer (Becton Dickinson).
Biotin−Streptavidin Pull-Down Experiments. To construct the
calibration plot for biotin−streptavidin pull-down assays, we prepared
several mixtures of 115- and 89-nt sequences in 50 mM Tris-HCl, pH
7.4, 100 mM KCl, at a total concentration of 0.2 μM and 115-nt/89-nt
ratio varying from 1 to 5000. The mixtures have been amplified with
KAPA2G Robust HotStart PCR Kit (KAPA Biosystems) using the
same couple of primers (sequences reported in Supporting
Information S8) (0.5 μM) and dNTPs (0.2 mM). The program
used was 5 min at 95 °C, 15 s at 95 °C, 15 s at 55 °C, and 30 s at 72
°C, for 35 cycles. The products have been separated by 8% PAGE and
the bands stained with ethidium bromide. Their intensities were
measured with a ChemiDOC XRS, Quantity One 4.6.5 software
(BioRad Laboratories). We reported in a plot the ratio of the
intensities of the amplified bands (115-nt/89-nt) as a function of the
logarithm of the ratio (r) of the two sequences in the mixtures. We
obtained a straight line that correlated the band intensities with the
mixture composition.
Total RNA was extracted from Panc-1 cells, and its concentration
was measured by UV absorption. Eight micrograms of cellular RNA in
50 mM KCl, 50 mM Tris-HCl, pH 7.4, was incubated overnight with
increasing concentrations of b-2a (from 0.4 to 0.8 μM). We incubated
the magnetic beads, after saturation with ssDNA (vide infra), with
cellular RNA treated with the biotinylated ligand for 20 min at 25 °C.
The supernatant was removed, and the beads were washed twice with
Tris buffer. We then recovered the bound RNA with a solution 0.8 M
NaCl. The recovered RNA was retrotranscribed with 0.8 U/μL RNase
OUT and 8 U/μL of M-MLV reverse transcriptase (Life Technologies,
ThermoFisher) and amplified by quantitative real-time PCR (vide
infra). We amplified KRAS and the housekeeping genes HPRT and β2-
microglobulin (for primers, see Supporting Information S8).
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.jmed-
chem.7b00622.
Scheme illustrating how RG4 can regulate translation
initiation, thermal difference spectra of RG4s, KRAS 5′-
UTR sequences in mammals, fluorescence titrations, UV
and NMR spectra and HPLC-chromatograms, confocal
microscopy, colony forming assay, and DNA and RNA
sequences used in the study (PDF)
SMILES data (CSV)
■ AUTHOR INFORMATION
Corresponding Author
*Tel: +39.0432.494395. Fax: +39.0432.494301. E-mail: luigi.
xodo@uniud.it.
ORCID
Giovanni Capranico: 0000-0002-8708-6454
Luigi E. Xodo: 0000-0003-3344-7207
Author Contributions
This study was conceived and written by L.E.X. and G.M.
A.S.T. and A.S. designed and synthesized the G4 ligands, and
G.M. and S.C. performed the experiments. J.M. and G.C.
prepared and purified BG4. All authors have given approval to
the final version of the manuscript.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
This work has been carried out with the financial support of
AIRC (Italian association for cancer research). IG2013, project
code 143.
■ ABBREVIATIONS USED
KRAS, Kirsten ras gene; PDAC, pancreatic ductal adenocarci-
noma cells; RG4, RNA G-quadruplex; Panc-1, pancreatic
cancer cells; BxPC-3, pancreatic cancer cells; ATPD,
antrathiophenediones; 5′-UTR, 5′-untranslated region; ATFD,
antrafurandiones; DCM, dichloromethane; HATU, 1-[bis-
(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]-
pyridinium 3-oxide hexafluorophosphate; NMM, N-methyl-
morpholine; PyBOP, benzotriazol-1-yl-oxytripyrrolidinophos-
phonium hexafluorophosphate; DIPEA, ethyldiisopropylamine;
THF, tetrahydrofuran; TFA, trifluoroacetic acid; ThT,
thioflavin T
■ REFERENCES
(1) Vigil, D.; Cherfils, J.; Rossman, K. L.; Der, C. J. Ras superfamily
GEFs and GAPs: validated and tractable targets for cancer therapy?
Nat. Rev. Cancer 2010, 10, 842−857.
(2) Rodriguez-Viciana, P.; Sabatier, C.; McCormick, F. Signaling
specificity by Ras family GTPases is determined by the full spectrum of
effectors they regulate. Mol. Cell. Biol. 2004, 24, 4943−4945.
(3) Wortzel, I.; Seger, R. The ERK cascade: distinct functions within
various subcellular organelles. Genes Cancer 2011, 2, 195−209.
(4) Castellano, E.; Downward, J. Ras interaction with PI3K: more
than just another effector pathway. Genes Cancer 2011, 2, 261−274.
(5) Schubbert, S.; Shannon, K.; Bollag, G. Hyperactive Ras in
developmental disorders and cancer. Nat. Rev. Cancer 2007, 7, 295−
308.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b00622
J. Med. Chem. 2017, 60, 9448−9461
9459
(6) Ryan, D. P.; Hong, T. S.; Bardeesy, N. Pancreatic
adenocarcinoma. N. Engl. J. Med. 2014, 371, 2140−2141.
(7) Prior, I. A.; Lewis, P. D.; Mattos, C. A comprehensive survey of
Ras mutations in cancer. Cancer Res. 2012, 72, 2457−2467.
(8) Karnoub, A. E.; Weinberg, R. A. Ras oncogenes: split
personalities. Nat. Rev. Mol. Cell Biol. 2008, 9, 517−531.
(9) Collins, M. A.; Bednar, F.; Zhang, Y.; Brisset, J. C.; Galbań, S.;
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ABSTRACT 
Datasets reporting microRNA expression profiles in normal and cancer cells 
showed that miR-216b is aberrantly downregulated in pancreatic ductal 
adenocarcinoma (PDAC). Oncogenic KRAS, which drives the pathogenesis of PDAC, 
is a target of miR-216b. We designed single-stranded miR-216b mimics, engineered 
with unlocked nucleic acid (UNA) modifications, and found that they strongly 
suppress KRAS in PDAC cells. We also report a new delivery strategy for miR-216b, 
which is based on the use of palmitoyl-oleyl-phosphatidylcholine (POPC) 
liposomes functionalized with lipid-modified miR-216b and lipid-modified cell 
penetrating TAT peptide. 
 
1. Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is one of the major causes of death in 
western countries [1, 2]. As current treatments are not effective, there is an urgent 
need to develop new therapies [3]. The main genetic lesion present in > 90 % of 
PDAC patients is a mutation in the KRAS proto-oncogene, mainly in exon 1 at codon 
12, G12D (GlyàAsp) or G12C (GlyàCys) [4]. It has been demonstrated that mutant 
KRAS is the major driver of PDAC [4-6] and that the expression of KRAS G12D in the 
pancreas of transgenic mice causes intraepithelial neoplasia lesions that progress 
into full malignancy [6]. The expression of KRAS G12D is necessary for tumour 
maintenance and its extinction leads to a rapid tumour regression [6]. Pancreatic 
cancer cells are indeed “addicted” to mutant KRAS, as this oncogene reprograms the 
glucose and glutamine metabolism in the tumour cells [7, 8]. 
Recent studies have shown that several functions in cancer cells, including 
proliferation, migration, invasion and gene expression, are regulated by small 
noncoding microRNAs [9-14]. They are synthesised as long RNA strands that fold 
into hairpin-loop structures processed by Drosha and Dicer into mature duplexes 
ranging from 17 to 26 nt in length [9-13]. The guide strand of the mature RNA 
duplexes forms a complex with Ago proteins that binds to a 3'-UTR mRNA target. 
This mediates two modes of gene silencing: translation repression and/or RNA 
decay [12, 13]. Synthetic double-stranded (ds) miRNAs gave encouraging results as 
antigene molecules [15] and recent studies have demonstrated that single-stranded 
(ss) RNAs, mimicking the guide strand of miRNAs, can also mediate an Ago-
dependent inhibition of the target gene [16-21]. These findings provided new 
perspectives on the use of synthetic miRNAs as therapeutic agents [17]. 
We designed single-stranded miRNA mimics to inhibit KRAS in pancreatic 
cancer cells. We started from the observation that certain small noncoding RNAs 
are aberrantly expressed in cancer tissues [23-27]. It is now common knowledge that 
miRNAs inhibiting the expression of tumour suppressor genes are oncogenic in 
nature and favour the development of cancer [22-27]. In contrast, miRNAs down-
regulating the expression of oncogenes behave as tumour suppressors and inhibit 
cancer growth [22-27]. In this study, we focused on a miRNA aberrantly down-
regulated in PDAC, miR-216b, with the aim of obtaining a therapeutic agent capable 
to potently suppress KRAS in PDAC cells. We found that single-stranded miR-216b 
with one or two unlocked nucleic acid modifications, strongly suppress oncogenic 
KRAS in PDAC cells. We also report data regarding the activity of miR-216b 
conjugated to a palmityl chain and fixed on the surface of palmitoyl-oleyl-
phosphatidylcholine (POPC) liposomes functionalized with the trans-activator of 
transcription of the human immune-deficiency virus (TAT) cell penetrating peptide.  
 
2. Results and discussion 
We started our study from the observation that abnormally high levels of oncogenic 
miRNAs and low levels of tumour suppressor miRNAs have been found in PDAC 
[27, 28]. To identify miRNAs specific for oncogenic KRAS, we compared three 
datasets reporting miRNA expression profiles in normal and PDAC cells: E-MTAB-
753, GSE43796 and GSE41372 [29]. Among the abnormally downregulated miRNAs 
we focused on miR-216b (from now on 216b), which showed an expression fold 
change from 2.27 to 27.95 (Supplementary Data, S1). A direct link between 216b 
and KRAS has been found in nasopharyngeal tumours [30]. Additionally, in a 
transgenic mouse model, 216b was found to be downregulated during PDAC 
development, confirming its tumour suppressor nature [31]. As single-stranded (ss) 
siRNAs act through the RNAi pathway and silence gene expression as the duplex 
analogues do [20, 21], ss-miRNAs might also be bioactive. Indeed, ss-miRNAs are 
also loaded into the RNA-induced silencing complex and inhibit gene expression 
[16-19]. In the light of these studies, we designed synthetic ss-miRNA to suppress 
KRAS in pancreatic cancer cells. One might wonder why using ss-miRNAs, 
considering that ds-miRNAs are potent tools for gene silencing. There are mainly 
two reasons: (i) ds-miRNAs, being more complex than ss-miRNAs, are not so 
efficiently transported into the cells as their single-stranded analogues [32]; (ii) ds-
miRNAs are composed by the seed and passenger strands, and the latter may cause 
undesired off-target effects [33]. Figure 1A shows the sequence of 216b and its KRAS 
target in the 3'-untranslated region (3'-UTR) of mRNA. The sequence at the 5'-end 
of 216b, UCUCUAAA-5', is perfectly complementary to the mRNA target and 
represents the “seed region”. Some complementarity with the target is also present 
at the 3' half of 216b: 5'-UAAAC is base-paired with mRNA. This should improve the 
interactions between the miRNA and the target gene [34, 35]. In order to increase 
the nuclease stability, we designed 216b mimics with one or two unlocked nucleic 
acid (UNA) modifications [36, 37]. The key feature of UNA is the loss of C2'-C3' 
bond of the ribose, a modification that makes the strand more flexible than the 
native oligonucleotide (Figure 1B) [38]. Previous studies have shown that a single 
UNA modification in the middle of a RNA/RNA duplex can lower the Tm by 5–10 °C, 
but when the UNA-modified base is placed near the duplex end, it causes a rather 
modest drop in Tm of 1–3 °C [38, 39]. 
We designed two UNA-modified 216b mimics: U1 with one modified adenine (uA) 
at the 3'-end; U2 with two uAs, at the 3'-end and in the middle of the 
oligoribonucleotide (Figure 1, Supplementary Table S2, Table S3). The uA 
incorporated in the middle of the sequence is located outside the seed sequence. 
The uA at the 3'-end is also located in a portion of 216b that does not pair with 
mRNA. The UNA modifications introduced in 216b should therefore not affect the 
hybridization of the UNA-modified mimics to the RNA target. Previous studies 
have reported that (i) ss-miRNAs with 2'-methyl, 2'-fluoro, 2'-O-methoxyethyl 
and with a phosphorothioate backbone are fairly active [16-19]; (ii) the binding of 
Ago2 to modified siRNAs (including UNA-modified siRNAs) is not affected by the 
chemical modifications [18]. We introduced UNA modifications in our mimics, as 
they can be considered less “invasive” than those mentioned above. Chorn et al. 
compared the activity of fluorinated and 2'-O-methyl modified ss-miRNAs with 
and without a 5'-phosphate, and found that phosphorylation increases the 
activity, although not in all constructs tested [16-19]. We therefore designed 
UNA-modified ss-miRNAs with and without a phosphate group at the 5'-end 
(Figure 1A). To investigate the gain in stability given by the UNA insertions, we 
subjected the wild-type and UNA-modified mimics to the action of cellular 
nucleases of a total cell extract. Figure 2A shows the integrity of ss-miRNAs with 
a phosphate at the 5' end after incubation in a total Panc-1 extract for 1, 2 and 4 h, 
at 37 °C. It can be seen that after 4 h, only ~ 10 % of 216b-P is intact. This 
percentage increases to ~ 20 and ~ 65 %, respectively, when one or two UNA 
modifications are introduced in the oligonucleotide. Figure 2B shows that the 
non-phosphorylated analogues are slightly more resistant: after 4 h, ~ 27 % of 
216b is intact, while the percentage of undigested U1 and U2 is ~ 30 and ~80 %, 
respectively. These data clearly show that the insertion of UNA at the 3'-end and 
in the middle of the sequence boosts the resistance of the designed mimics to the 
cellular nucleases in PDAC cells. There is only one study in the literature 
reporting that a replacement strategy with 216b is effective in down-regulating 
oncogenic KRAS, but this was found in nasopharyngeal cancer cells. Although 
216b is aberrantly downregulated in PDAC cells, its therapeutic potential in 
pancreatic cancer cells has not been investigated so far. Considering that no 
effective anti-KRAS therapeutic agents have been found up to now, to investigate 
the potency of 216b in PDAC is an important issue. Against this background, our 
first step was to demonstrate that 216b is indeed KRAS specific in PDAC cells. For 
this purpose, we hybridized wild-type and UNA-modified 216b miRNAs to the 
complementary sequence to obtain 22-mer ds-mimics with or without UNA 
insertions, as well as a mutated ds-UNA-modified miRNA. Panc-1 cells were 
transfected two times with the duplexes and after an incubation of 48 h, a 
Western blot was performed to measure the level of protein KRAS. Duplexes ds-
U1 and ds-U2 dramatically reduced the level of protein KRAS to ~ 10 % of the 
control (mutated duplex) (Figure 3). Instead, the wild-type duplex produced a 
weaker effect on protein expression (~ 35 % of the control). This experiment 
clearly demonstrates that in PDAC cells oncogenic KRAS is a target of miR-216b.  
Next, we examined the capacity of the designed ss-miRNA mimics, with or 
without a phosphate at the 5' end, to suppress KRAS in Panc-1 cells. As miRNAs 
inhibit gene expression by translation repression and/or mRNA decay, [12-14] we 
determined by quantitative RT-PCR the level of the KRAS transcript in Panc-1 
cells treated with the various forms of 216b. As observed in the nasopharyngeal 
cells, [30] we did not notice any significant reduction of KRAS mRNA at 16, 40 or 
72 h (Supplementary Data, S4). Instead, when we measured by Western blot the 
level of the KRAS protein in Panc-1 cells treated with the various ss-miRNA 
mimics, we observed a dramatic suppression of the protein. In keeping with the 
nuclease stability data, the compound showing the highest capacity to suppress 
protein KRAS was the miRNA with two UNA modifications. Figure 4A, B shows 
that both phosphorylated and non-phosphorylated mimics caused a strong 
suppression of the protein. The UNA modifications turned out to be essential for 
the activity of the mimics, which brought the protein down to < 10 % of the 
control, while the 5’ phosphorylation is not essential, at least for this specific 
miRNA [16]. Note that the mutated sequence (mut) did not impact KRAS 
expression. As a next issue, we wondered what the specificity of 216b for KRAS is, 
since the oncogene is highly homologous to HRAS and NRAS. As illustrated in 
Figure 4C, D, none of the designed 216b mimics had effect on HRAS and NRAS 
proteins. This was expected, as the matching between the seed region of the 
designed mimics and the 3'-UTR sequence in these genes is suboptimal. In these 
cases, the base pairing in the miRNA 3' half would assume importance for 
stabilizing the interaction [12-14]. The lack of complementarity at the 3' end 
makes the mimics ineffective against HRAS and NRAS. We can therefore 
conclude that, at least in pancreatic cancer cells, 216b regulates only one gene of 
the ras family.  
To obtain further experimental evidence that the designed UNA-modified ss-
miRNA mimics are active, we tested them in a luciferase assay. We used plasmid 
pGL4.75-KRAS LCS6m, carrying Renilla luciferase driven by the CMV promoter 
and the human KRAS 3'-UTR (3200 bp) containing the 216b target. Panc-1 cells 
were treated with 10 nM mimics complexed with Interferin (Polyplus, France) and 
with 30 ng pGL4.75-KRAS LCS6m and 70 ng pGL3-Control Vector carrying Firefly 
luciferase driven by the SV40 promoter. The cells were treated twice with single-
stranded 216b, U1 and U2: one treatment 24 h after the other. The three ss-
miRNAs were able to reduce luciferase to an extent that correlates with the 
modifications introduced in 216b (Figure 5). The molecule with the strongest 
anti-KRAS activity was U2, which decreased luciferase to ~ 40 % of the control 
(luciferase expressed in mut-treated Panc-1 cells). A roughly similar result was 
obtained with the 5’ phosphorylated mimics (not shown). The luciferase 
experiment unambiguously proved that oncogenic KRAS is downregulated by 
216b. The luciferase assay gave a weaker effect compared to the western blot assay 
probably because: (i) CMV is a promoter stronger than the KRAS promoter; (ii) 
the luciferase assay is based on a non-natural target.  
Finally, since KRAS stimulates the survival and proliferation pathways, the 
suppression of protein KRAS should result in the inhibition of colony formation. 
Indeed we found that in Panc-1 and MIA PaCa-2 pancreatic cancer cells the 
number of colonies was reduced ~ 50 % by the designed miRNAs. 
Since KRAS stimulates the pathway controlling cell growth, the suppression of 
protein KRAS should result in the inhibition of proliferation. To assess the effect 
of 216b, U1 and U2 on the growth of PDAC cells we carried out colony formation 
assays with Panc-1 and MIA PaCa-2 cells, carrying the KRAS mutations G12D and 
G12V, respectively. The PDAC cells were seeded in a medium after being diluted 
in a way that a single colony could be formed from each cell. After ~10 days of 
growth, the colonies of at least 50 cells were counted and the results plotted in a 
histogram. Figure 6 shows the results of a typical colony-formation assay 
obtained with Panc-1 and MIA PaCa-2 cells. Note that the number of colonies in 
the untreated plate is similar to that measured on the plate treated with the 
control mut, which does not suppress oncogenic KRAS. In contrast, 216b and its 
UNA-analogues strongly reduced the number of colonies from both types of cells. 
U2 reduced the number of MIA PaCa-2 colonies by ~ 60 %. As KRAS controls cell 
adhesion via the integrin-linked kinase (ILK) [40-42] its suppression in Panc-1 
cells resulted in some cell aggregation. The number of colonies was reduced by ~ 
50 %.  
In the experiments described above, the miRNAs were delivered to the cells as 
complexes with Interferin (Polyplus, France), a commercial transfecting agent.  To 
improve the delivery of miR-216b, we used a transport system based on the low toxicity 
of palmitoyl-oleyl-phosphatidylcholine (POPC) liposomes in combination with surface 
attached functionalities [43]. The POPC liposomes were functionalized with the trans-
activator of transcription of the human immune-deficiency virus (TAT) as a cell-
penetrating peptide and with 216b, as previously reported [44, 45]. Both 216b and TAT 
were chemically modified with a palmitoyl membrane anchor to allow their rapid 
attachment to the liposome surface [46]. The strategy is illustrated in Figure 7A. The 
POPC liposomes were treated with both lipid-modified 216b and TAT, which 
spontaneously anchored to the liposome surface. Oligonucleotide 216b being not 
covalently attached to the liposomes, can move freely on the lipid surface and interact 
efficiently with the mRNA target. The membrane anchor of miR-216b consists of a 3-
amino-1,2-propanediol unit with two saturated palmityl chains (membrane anchor Y) 
[46]. We treated two times the PDAC cells Panc-1, MIA PaCa-2 with the POPC 
liposomes functionalized with TAT and miR-216b and measured by Western blot the 
level of protein KRAS (Figure 7B). It can be seen that KRAS protein is reduced to about 
half the level present in untreated cells or cells treated with a mutant miRNA. This 
result suggests that POPC liposome are an attractive vehicle to deliver miR-26b in vivo. 
Finally, the bioactivity of miR-216b delivered via POPC was tested in a colony formation 
assay. Figure 8 shows that the miR-216b fixed on POPC reduce Panc-1 colony formation 
by about 50%. 
 
3. Conclusion 
In conclusion, our results show that 216b, which is aberrantly downregulated in 
PDAC, is a microRNA that targets the KRAS oncogene. When UNA modifications 
are introduced outside the seed region, single-stranded 216b, with and without a 
5’phosphate, show a strong activity and promotes a dramatic suppression of the 
KRAS protein. This results in the inhibition of colony formation by PDAC cells. 
We have shown for the first time that 216b behaves as a tumour suppressor 
miRNA in PDAC cells. The UNA modifications make 216b stable against the 
cellular nucleases and quite a strong therapeutic agent for PDAC. In addition, we 
conjugated miR-216b to a palmityl chain and fixed the effector oligonucleotide to 
the surface of POPC liposome, which were functionalized with TAT peptide. The 
results obtained with three PADC cell lines showed that the nanoparticle 
functionalized with TAT and miR-216b cause a 50 % decrease of protein KRAS 
and a 40% inhibition of colony formation. Our data suggest that this delivery 
strategy will be helpful for in vivo studies. 
 
 
4. Experimental part 
4.1 General 
Detailed procedures for cell culture transfections, dual luciferase assay, Western blots, RT-
PCR, oligonucleotide stability in cell environment are given in the Supplementary material. 
 
4.2 Synthesis of UNA-modified miRNAs.  
The synthesis of the UNA-modified miRNA 216b mimics (216b, U1, U2, mut, U1-P, U2-P) 
was performed on an automated nucleic acid synthesizer as previously reported [43]. The 
oligonucleotides were purified by HPLC by using a C18 3 µm 300 Å reversed phase column 
as previously described [46]. Maldi MS analyses were carryout out to confirm the structure 
of the designed UNA-modified miRNAs and evaluate their purity (See Supplementary). 
Calculated and experimental masses were almost identical for all the oligonucleotides 
(Table 2) and Supplementary data.   
4.3 Synthesis of lipid-conjugated TAT and miR-216b 
The oligonucleotide was synthesized on an ExpediteTM 8900 nucleic acid synthesis system 
(Perceptive Biosystems Inc.). The synthesis was performed on a 1.0 µmol scale on GE 
Healthcare Custom Primer SupportTM T40s using standard conditions for automated 
synthesis with DCI as activator. However, the lipid modified phosphor amidite was 
dissolved in 2:1 DCE: MeCN at a concentration of 0.1 M, 42® was used as activator (Proligo 
reagent/Sigma-Aldrich) and the coupling time was increased to 20 min. The DMT 
protecting group on the last nucleotide in the sequence was removed. After deprotection 
and cleavage from the solid support using standard conditions (conc. NH3 (aq.) over night 
at 55 ºC), the oligonucleotides were purified by HPLC. 
TAT was synthesized on a Liberty 1 Microwave Peptide Synthesizer using a Rink Amide 
resin and an amino acid concentration of 0.2 M for unmodified amino acids and 0.1 M for 
the lipid-modified amino acid. After synthesis, the peptide was cleaved from the resin, 
deprotected and purified by HPLC using a C18 5 µm 10 x150 mm column, as previously 
described  
4.4 Colony forming assay. 
Since KRAS stimulates the pathway controlling cell growth, the suppression of 
protein KRAS should result in the inhibition of proliferation. To assess the effect of 
216b, U1 and U2 on the growth of PDAC cells we carried out colony formation assays 
with Panc-1 and MIA PaCa-2 cells, carrying the KRAS mutations G12D and G12V, 
respectively. The PDAC cells were seeded in a medium after being diluted in a way 
that a single colony could be formed from each cell. After 7-13 days of growth, the 
colonies of at least 50 cells were counted and the results plotted in a histogram. The 
figure below shows the results of a typical colony-formation assay obtained with 
Panc-1 and MIA PaCa-2 cells. Note that the number of colonies in the untreated 
plate is similar to that measured on the plate treated with the control mut, which 
does not suppress oncogenic KRAS. In contrast, 216b and its UNA-analogues 
strongly reduced the number of colonies from both types of cells. U2 reduced the 
number of MIA PaCa-2 colonies by ~ 60 %. As KRAS controls cell adhesion via the 
integrin-linked kinase (ILK) [40-42] its suppression in Panc-1 cells resulted in some 
cell aggregation. The number of colonies was reduced by ~ 50 %. MiRNA 216b and 
the UNA-modified mimics U1 and U2 decrease the % of colonies in Panc-1 and MIA 
PaCa-2 cancer cells. NT= untreated cells. Histogram shows the % colonies in 
miRNA-treated cells compared to NT. Values obtained from three independent 
experiments. *=P < 0.05.  
 
Cell Culture and transfections 
Human pancreatic adenocarcinoma Panc-1 and MIA PaCa-2 cells were maintained in 
exponential growth in Dulbecco’s Modified Eagle’s Medium (DMEME) containing 100 
U/mL penicillin, 100 mg/mL streptomycin, 20 mM L-glutamine and 10 % fetal bovine 
serum (Euroclone, Italy). The cell lines have been genotyped by Microsynth (Switzerland) 
and found that they matched 100% with the DNA-profiles of Panc-1 (ATCC® CRL-1469TM) 
and MIA PaCa-2. The cells were transfected with the various miRNAs twice after 24 h of 
incubation in a humidified atmosphere containing 5 % CO2  at 37 °C. The expression 
vectors were transfected with jet PEI (Polyplus, France) while the miRNas were transfected 
with Interferin (Polyplus, France) following manufacturer’s instructions. Double-stranded 
miRNA mimics have been prepared in 100 mM NaCl and 50 mM Tris-HCl pH 7.4, heated 5 
min at 80 °C and annealed overnight at room temperature. 
 
Stability of miRNAs in cellular environment 
To determine their nuclease resistance, the designed miRNAs (3 µM) have been incubated 
for 1, 2 and 4 h at 37°C in a total nuclear extract from Panc-1 cancer cells (2 µg) obtained as 
previously described (Nucleic Acids Res. 2008, 36, 3765-80). After incubation the 
oligonucleotides have been run in a denaturing 20 % polyacrylamide gel (7 M urea, 1 x 
TBE), which was stained with “stains all”.   
 
Dual luciferase assays 
Panc-1 cells were plated (15 x 103) in 96-well plate and after one day transfected with 
miRNA 216b or UNA-analogues and with plasmids pGL4.75-KRAS LCS6m (a gift from 
Frank Slack, Plasmid # 44571, Addgene) and pGL3 Control Vector (Promega, USA). 
Transfection was performed by mixing 70 ng of pGL3 Control Vector (Firefly luciferase) 
with 30 ng of pGL4.75-KRAS LCS6m (Renilla luciferase), by using jet-PEI (Polyplus) as a 
transfectant agent. A second miRNA transfection was performed 24 h after the first 
transfection and the luciferase assays were performed 48 h after the second transfection. A 
Dual-Glo Luciferase Assay System (Promega, USA) was used. Samples were read on a 
Turner Luminometer and the relative luminescence expressed as (T/C x 100) where T= 
Renilla luciferase/Firefly luciferase in miRNA treated cells and C= Renilla luciferase/Firefly 
luciferase in mut-treated cells. 
 
Western blots 
Total protein lysates (10-15 µg) extracted from Panc-1 cells were sonicated for 10 minutes 
and the lysates were electrophoresed on 12 % SDS-PAGE and transferred into a 
nitrocellulose membrane, at 70 V for 2 h. The filter was blocked for 1 h with 5 % nonfat dry 
milk solution in PBS 0.05 % Tween (Sigma-Aldrich, Italy) at room temperature. 
Membranes were incubated overnight at 4 °C with the primary antibodies: monoclonal 
anti-KRAS (clone 3B10-2F2, IgG1 mouse, 2.5 µg/mL, Sigma-Aldrich, USA), polyclonal anti-
HRAS (IgG rabbit, diluted 1:300, Santa Cruz Biotechnology Inc, USA), monoclonal anti-
NRAS (clone F155-227, IgG1 mouse, 2.5 µg/mL) and  monoclonal anti-actin (clone JLA20, 
IgM mouse, 1x10-4 µg/mL, Calbiochem, Merck Millipore, Germany). The membranes were 
washed with a 0.05 % Tween in PBS and then incubated 1 h with the secondary antibodies 
horseradish peroxidase conjugated: anti-mouse IgG (diluted 1:5000) and anti-mouse IgM 
(diluted 1:2000) (Calbiochem, Merck Millipore, Germany) and anti-rabbit IgG (diluted 
1:5000) (Calbiochem, Merck Millipore, Germany). To detect the protein we used Super 
signal ® West PICO and FEMTO (ThermoFisher Scientific Pierce, USA). The exposure time 
depended on the antibody used and was usually between 30 s and 5 min. The protein levels 
were quantified by the Image Quant TL Version 2003 software (Amersham). 
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Figure 1. (A) Sequence of the KRAS 3'-UTR recognized by miR-216b (called 216b). We 
designed single-stranded UNA-modified 216b mimics with and without a phosphate at 
the 5' end: wild-type 216b and 216b-P; 216b with one UNA (U1 and U1-P) or two UNA (U2 
and U2-P) at the 3' end. Mutated miRNAs with UNA (mut) or with a 5' phosphate (mut-
P) were used as a control (Supplementary Data, S2); (B). The structures of RNA and 
UNA, lacking the covalent bond between C2' and C3' of the ribose. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (A,B) Denaturing (7 M urea) polyacrylamide gel showing the integrity of 
wild-type and UNA-modified mimics with and without a 5' phosphate, after 
incubation for 1, 2 and 4 h with 2 g Panc-1 cellular extract (E) at 37 °C. The mobility 
of E is shown in panels 1 and 3 from left. The arrow shows the undegraded miRNA. 
The % of undegraded miRNA at the various times is shown in the histograms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of double-stranded UNA-modified mimics (ds-216b, ds-U1, ds-U2, 
ds-mut) on KRAS expression in Panc-1 cells. 216b, U1, U2 and mut were 
hybridized to the complementary strand. The Western blot with Panc-1 cells was 
performed 48 h after the second transfection. The histogram shows the % KRAS 
protein determined as T/C x 100 where T= (KRAS/actin) in cells treated with the 
216b-mimics, C= (KRAS/actin ) in mut-treated cells. Values are the average of two 
independent experiments. 
 
. 
Figure 4. Effect of single-stranded miRNA mimics with and without a phosphate at the 
5' end on the expression of KRAS in Panc-1 cells. The cells, 24 h after seeding, were 
treated with the mimics, using Interferin. A second treatment was carried out 24 h after 
the first treatment. A Western blot was carried out 48 h after the second treatment. (A) 
Base-pairing between KRAS 3'-UTR mRNA and miRNA 216b. The Western blot shows 
the impact of the designed UNA-modified mimics with a phosphate at the 5' end on 
protein KRAS. The % KRAS protein in miRNA-treated cells compared to mut-treated 
cells is reported. The results are the average of three independent experiments; (B) as in 
A but with single-stranded mimics without a phosphate at the 5' end. Results from two 
independent experiments; (C) and (D) Matching between HRAS and NRAS 3’-UTR 
mRNA and 216b. The Western blots show the levels of HRAS and NRAS proteins in 
Panc-1 cells treated with the designed single-stranded miRNAs. 
 
 
 
 
 
 
Figure 5. (A) Plasmids used for the luciferase experiments; (B) Outline of the 
luciferase experiments. T1: plasmids transfection and first miRNA treatment; T2: 
second miRNA treatment; (C) Histograms show the levels of Renilla luciferase in 
Panc-1 cells treated with miR-216b-mut (mut); miR-216b (216b); miR-216b-U1 (U1) 
and miR-216b-U2 (U2). The ordinate of the histogram reports Renilla/Firefly in 
Panc-1 cells treated with miR-216b-mut and with miR-216b or UNA analogue. T/M 
x 100 = % Renilla luciferase in miRNA treated cells (T) compared to mut-treated 
cells (M). *=P< 0.05. 
 
 
 
 
 
 
 
 
Figure 6. Clonogenic assays. MiR-216b (216b) and UNA-modified analogues miR-
miR-216b-U1 (U1) and miR-216b-U2 (U2) decrease the % of colonies in Panc-1 and 
Mia PaCa-2 pancreatic cancer cells. NT= untreated cells. Histogram shows the % 
colonies in miRNA-treated cells compared to NT. Error bar is the average of three 
independent experiments. *=P < 0.05. As for Panc-1 cells the designed miRNAs 
reduced the number of colonies by at least 50 %.  
 
 
 
 
 
 
 
Figure 7. (A) Sequence of miR-216b with two palmitoyl chains and of the TAT peptide with 
two X insertions containing two saturated palmityl chains in order to anchor the peptide to 
the liposomes. MiR-216b is chemically modified with two A(Pal) residues, each containing  
a saturated palmityl chains in order to anchor the oligonucleotides to the liposomes. The 
POPC liposomes spontaneously self-assembles into spherically closed bilayer membrane 
on the surface of which TAT and 216b-Pal are attached through their lipid modifications. 
 
 
 
Figure 8. Clonogenic assays. POPC liposome functionalized with 216b-pal  decrease 
the % of colonies in Panc-1 and Mia PaCa-2 pancreatic cancer cells. NT= untreated 
cells, 216-pal= cells treated with POPC liposomes functionalized with 216b-pal and 
TAT; Liposome= cells treated with POPC non-functionalized with the effector 
molecules. Histogram shows the % colonies in miRNA-treated, liposome-treated 
and non treated (NT) cells. Error bar is the average of three independent 
experiments.  
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 Supplementary Data, S1.  miRNA and FC values calculated for three dataset 
(GSE43796, E-MTAB-753 and E-GEOD-41372). 
 
 
 
 
 
 
 
 
 
Table S2. Oligonucleotides used in this study. 
 
216b 5’-rArArArUrCrUrCrUrGrCrArGrGrCrArArArUrGrUrGrA  
U1 5’-rArArArUrCrUrCrUrGrCrArGrGrCrArArArUrGrUrGuA 
U2 5’-rArArArUrCrUrCrUrGrCuArGrGrCrArArArUrGrUrGuA 
mut 5’-rArArArCrUrGrUrGrGrCrArGrGrCrArCrCrUrGrUrGuA 
216b-P 5’P-rArArArUrCrUrCrUrGrCrArGrGrCrArArArUrGrUrGrA  
U1-P 5’P-rArArArUrCrUrCrUrGrCrArGrGrCrArArArUrGrUrGuA 
U2-P 5’P-rArArArUrCrUrCrUrGrCuArGrGrCrArArArUrGrUrGuA 
mut-P 5’P-rArArArCrUrGrUrGrGrCrArGrGrCrArCrCrUrGrUrGrA 
comlementary-216b  5’-rCrArCrArUrUrUrGrCrCrUrGrCrArGArGrArUrUrUrU 
complementary-mut: 5’-rCrArCrArGrGrUrGrCrCrUrGrCrCrArCrArGrUrUrUrU 
 uA= unlocked nucleic acid modification; 
 
 
Table S3. Molecular masses of UNA-modified RNAs by MALDI MS. 
 
miRNA sequence* Name Calculated Found 
5’-rArArArUrCrUrCrUrGrCrArGrGrCrArArArUrGrUrGuA U1 7051,4 7051,3 
5’-rArArArUrCrUrCrUrGrCuArGrGrCrArArArUrGrUrGuA U2 7053,4 7053,4 
5’-rArArArCrUrGrUrGrGrCrArGrGrCrArCrCrUrGrUrGuA mut 7082,4 7082,7 
5’P-rArArArUrCrUrCrUrGrCrArGrGrCrArArArUrGrUrGuA U1-P 7131,3 7131,3 
5’P-rArArArUrCrUrCrUrGrCuArGrGrCrArArArUrGrUrGuA U2-P 7133,3 / 7133,6 
* uA= unlocked nucleic acid 
 
Supplementary Data, S4. Determination of the level of KRAS mRNA in Panc-1 cells by 
quantitative real-time PCR. The assay has been performed after 24h of the miR-216b and 
UNA-modified analogs transfection.  
 
 
132 
 
4. CONCLUSION 
 
The main aim of my PhD work has been to investigate the impact of unusual DNA 
structures formed in the ras promoter and their involvement in biological processes such as 
transcription and translation. Moreover I focused on the development of innovative ras-
specific anticancer strategies. As the expression of the ras genes is crucial for cancer 
initiation and maintenance, they are attractive therapeutic targets. The identification and 
characterization of ras non-canonical DNA structures is a pre-requisite to develop 
alternative anti-ras strategies.  
First, I focused on the HRAS promoter. I have investigated the C-rich strands of two C-rich 
regions near TSS, to understand their ability to fold into a DNA unusual structure named i-
motif (iM). My work demonstrated that the HRAS C-rich strands fold into the iM under 
slightly acidic conditions and under crowding conditions. Such iM conformation provides a 
chemical scaffold that is recognized by hnRNP A1 nuclear factor. I found that this protein 
binds tightly to the iM and, by means of FRET experiments, I also found that it unfolds the 
iM in vitro. We also address the question of elucidating the possible role of hnRNP A1 in 
HRAS transcription. Based on my work and data previously obtained in my laboratory, I 
have proposed a dynamic molecular G-quadruplex/iM switch for the control of HRAS 
expression. Secondly, I have proposed and discussed a decoy strategy for repressing HRAS 
transcription in bladder cancer cells. Previous studies showed that HRAS expression is 
regulated by two neighbouring G-quadruplexes (hras-1 and hras-2) near TSS [117]. Their 
biological function is to promote the recruitment of proteins such as MAZ and hnRNP A1 to 
the promoter G4 motifs. These proteins should unfold the G-quadruplexes and thus activate 
transcription. We designed a decoy strategy to inhibit HRAS in bladder cancer cells. The 
oligonucleotides carried chemical modifications (anthraquinone insertions and LNA nucleic 
acid modification) to increase their nuclease resistance. I designed decoy oligonucleotides 
mimicking either the iM or the G4 structures of the HRAS promoter. The decoy 
oligonucleotides effectively decreased the recruitment of MAZ to the HRAS promoter and 
inhibited transcription.  
The last part of my PhD program focused on KRAS, specifically on the 5’- and 3’-
untranslated regions (UTRs). The KRAS 5’-UTR is characterized by a high GC content (77 
%). By using bioinformatic tools we evaluated and selected sequences with a high propensity 
to form RNA G-quadruplex structures (G4s). By using different techniques I have 
demonstrated the presence of non-overlapping RG4s in the first 80 nt of the KRAS 5’-UTR 
(Circular Dicroism, RNase footprinting, Electrophoretic Mobility Shift Assay, UV melting 
curves and Thioflavin T assay). In addition, I have developed an efficient anti-KRAS strategy 
by using small molecules (anthraquinone derivatives) that easily penetrate the cells and 
bind to the KRAS RG4s. I have developed a pull-down assay to demonstrate that the small 
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molecules effectively recognize and bind to the KRAS transcripts under low abundance 
cellular condition. Anthraquinone derivatives, upon binding to the KRAS RG4s, showed to 
be able to downregulate the KRAS expression. As pancreatic cancer cells are addicted to 
KRAS, the decrease of KRAS protein promoted apoptosis and a strong antiproliferative effect 
in PDAC cells. Simultaneously we also proposed an anti-KRAS strategy targeting the 3’-UTR 
of the KRAS transcript. Starting from the observation that in pancreatic tumours miR-216b, 
of which KRAS is a target, is abnormally downregulated, we proposed an alternative strategy 
based on restoring the level of this miRNA to inhibit KRAS translation. We used single 
stranded RNA mimics of miR-216b which were engineered with unlocked nucleic acid 
(UNA) modifications to improved their nuclease resistance in vivo. The transfections of 
pancreatic cancer cells with the designed miRNAs mimics resulted in a significant reduction 
of KRAS protein level. The designed miRNAs decreased the number of colonies in two 
different pancreatic cell lines. We also tested a new delivery strategy based on the use of 
palmitoyl-oleyl-phosphatidylcholine (POPC) liposomes functionalized with lipid-modified 
miR-216b and lipid-modified cell penetrating TAT peptide. 
 
  
 
134 
 
BIBLIOGRAPHY 
 
[1] J. J. Harvey, “An unidentified virus which causes the rapid production of tumours in mice,” 
Nature, vol. 204, no. 4963, pp. 1104–1105, 1964. 
[2] W. H. Kirsten and L. A. Mayer, “Morphologic Responses to a Murine Erythroblastosis Virus 2,” 
J. Natl. Cancer Inst., vol. 39, no. 2, pp. 311–335, 1967. 
[3] E. M. Scolnick and W. P. Parks, “Harvey sarcoma virus: a second murine type C sarcoma virus 
with rat genetic information.,” J. Virol., vol. 13, no. 6, pp. 1211–9, 1974. 
[4] E. M. Scolnick, E. Rands, D. Williams, and W. P. Parks, “Studies on the nucleic acid sequences 
of Kirsten sarcoma virus: a model for formation of a mammalian RNA-containing sarcoma 
virus.,” J. Virol., vol. 12, no. 3, pp. 458–63, 1973. 
[5] T. Y. Shih, M. O. Weeks, H. A. Young, and E. M. Scholnick, “Identification of a sarcoma virus-
coded phosphoprotein in nonproducer cells transformed by Kirsten or Harvey murine 
sarcoma virus,” Virology, vol. 96, no. 1, p. 64—79, 1979. 
[6] E. M. Scolnick, A. G. Papageorge, and T. Y. Shih, “Guanine nucleotide-binding activity as an 
assay for src protein of rat-derived murine sarcoma viruses,” Proc. Natl. Acad. Sci. U. S. A., vol. 
76, no. 10, p. 5355—5359, 1979. 
[7] M. C. Willingham, I. Pastan, T. Y. Shih, and E. M. Scolnick, “Localization of the src gene 
product of the Harvey strain of MSV to plasma membrane of transformed cells by electron 
microscopic immunocytochemistry,” Cell, vol. 19, no. 4, p. 1005—1014, Apr. 1980. 
[8] M. Janakiraman, E. Vakiani, Z. Zeng, C. A. Pratilas, B. S. Taylor, D. Chitale, E. Halilovic, M. 
Wilson, K. Huberman, J. C. Ricarte Filho, Y. Persaud, D. A. Levine, J. A. Fagin, S. C. Jhanwar, J. 
M. Mariadason, A. Lash, M. Ladanyi, L. B. Saltz, A. Heguy, P. B. Paty, and D. B. Solit, 
“Genomic and biological characterization of exon 4 KRAS mutations in human cancer,” 
Cancer Res., vol. 70, no. 14, pp. 5901–5911, 2010. 
[9] C. Shih, B.-Z. Shilo, M. P. Goldfarb, A. Dannenberg, and R. A. Weinberg, “Passage of 
phenotypes of chemically transformed cells via transfection of DNA and chromatin (chemical 
carcinogenesis/transformation alleles/Southern blotting),” Cell Biol., vol. 76, no. 11, pp. 5714–
5718, 1979. 
[10] T. G. Krontiris and G. M. Cooper, “Transforming activity of human tumor DNAs.,” Proc. Natl. 
Acad. Sci. U. S. A., vol. 78, no. 2, pp. 1181–4, 1981. 
[11] M. J. Murray, B. Z. Shilo, C. Shih, D. Cowing, H. W. Hsu, and R. a Weinberg, “Three different 
human tumor cell lines contain different oncogenes.,” Cell, vol. 25, no. 2, pp. 355–361, 1981. 
[12] C. Shih, L. C. Padhy, M. Murray, and R. A. Weinberg, “Transforming genes of carcinomas and 
neuroblastomas introduced into mouse fibroblasts,” Nature, vol. 290, no. 5803, p. 261—264, 
1981. 
[13] M. Perucho, M. Goldfarb, K. Shimizu, and M. Wigler, “Human-Tumor-Derived Common and 
Different Cell Lines Contain Transforming Genes,” vol. 27, no. December, pp. 467–476, 1981. 
[14] C. J. Marshall, A. Hall, and R. A. Weiss, “A transforming gene present in human sarcoma cell 
lines,” Nature, vol. 299, no. 5879, p. 171—173, 1982. 
 
135 
 
[15] E. Santos, S. R. Tronick, S. A. Aaronson, S. Pulciani, and M. Barbacid, “T24 human bladder 
carcinoma oncogene is an activated form of the normal human homologue of BALB- and 
Harvey-MSV transforming genes.,” Nature, vol. 298, no. 5872, pp. 343–347, 1982. 
[16] L. F. Parada, C. J. Tabin, C. Shih, and R. A. Weinberg, “Human EJ bladder carcinoma oncogene 
is homologue of Harvey sarcoma virus ras gene,” Nature, vol. 297, no. 5866, pp. 474–478, Jun. 
1982. 
[17] E. Taparowsky, Y. Suard, O. Fasano, K. Shimizu, M. Goldfarb, and M. Wigler, “Activation of 
the T24 bladder carcinoma transforming gene is linked to a single amino acid change,” 
Nature, vol. 300, no. 5894, p. 762—765, 1982. 
[18] C. J. Tabin, S. M. Bradley, C. I. Bargmann, R. A. Weinberg, A. G. Papageorge, E. M. Scolnick, R. 
Dhar, D. R. Lowy, and E. H. Chang, “Mechanism of activation of a human oncogene,” Nature, 
vol. 300, no. 5888, pp. 143–149, 1982. 
[19] K. Shimizu, M. Goldfarb, Y. Suard, M. Perucho, Y. Li, T. Kamata, J. Feramisco, E. Stavnezer, J. 
Fogh, and M. H. Wigler, “Three human transforming genes are related to the viral ras 
oncogenes.,” Proc. Natl. Acad. Sci. U. S. A., vol. 80, no. 8, pp. 2112–6, 1983. 
[20] A. Hall, C. J. Marshall, N. K. Spurr, and R. A. Weiss, “Identification of transforming gene in 
two human sarcoma cell lines as a new member of the ras gene family located on chromosome 
1,” Nature, vol. 303, no. 5916, p. 396—400, 1983. 
[21] P. a Boriack-Sjodin, S. M. Margarit, D. Bar-Sagi, and J. Kuriyan, “The structural basis of the 
activation of Ras by Sos.,” Nature, vol. 394, no. 6691, pp. 337–343, 1998. 
[22] J. F. Hancock, “Ras proteins: different signals from different locations,” Nat. Rev. Mol. Cell 
Biol., vol. 4, no. 5, pp. 373–385, 2003. 
[23] M. E. Furth, T. H. Aldrich, and C. Cordon-Cardo, “Expression of ras proto-oncogene proteins 
in normal human tissues,” Oncogene, vol. 1, no. 1, p. 47—58, 1987. 
[24] J. Leon, I. Guerrero, and A. Pellicer, “Differential expression of the ras gene family in mice,” 
Mol. Cell. Biol., vol. 7, no. 4, p. 1535—1540, Apr. 1987. 
[25] G. Fiorucci and A. Hall, “All three human ras genes are expressed in a wide range of tissues,” 
Biochim. Biophys. Acta, vol. 950, no. 1, p. 81—83, 1988. 
[26] J. Leon, I. Guerrero, and  a Pellicer, “Differential expression of the ras gene family in mice.,” 
Mol. Cell. Biol., vol. 7, no. 4, pp. 1535–40, 1987. 
[27] L. Johnson, D. Greenbaum, K. Cichowski, K. Mercer, E. Murphy, E. Schmitt, R. T. Bronson, H. 
Umanoff, W. Edelmann, R. Kucherlapati, and T. Jacks, “K-ras is an essential gene in the mouse 
with partial functional overlap with N-ras,” Genes Dev., vol. 11, no. 19, pp. 2468–2481, 1997. 
[28] D. R. Lowy and B. M. Willumsen, “Function and Regulation of Ras,” Annu. Rev. Biochem., vol. 
62, no. 1, pp. 851–891, Jun. 1993. 
[29] B. M. Willumsen, A. Christensen, N. L. Hubbert, A. G. Papageorge, and D. R. Lowy, “The p21 
ras C-terminus is required for transformation and membrane association,” Nature, vol. 310, no. 
5978, pp. 583–586, Aug. 1984. 
[30] J. F. Hancock, H. Paterson, and C. J. Marshall, “A polybasic domain or palmitoylation is 
required in addition to the CAAX motif to localize p21ras to the plasma membrane,” Cell, vol. 
 
136 
 
63, no. 1, pp. 133–139, 1990. 
[31] M. M. McKay and D. K. Morrison, “Integrating signals from RTKs to ERK/MAPK,” Oncogene, 
vol. 26, no. 22, pp. 3113–3121, 2007. 
[32] F. D. Tsai, M. S. Lopes, M. Zhou, H. Court, O. Ponce, J. J. Fiordalisi, J. J. Gierut, A. D. Cox, K. 
M. Haigis, and M. R. Philips, “K-Ras4A splice variant is widely expressed in cancer and uses a 
hybrid membrane-targeting motif,” Proc. Natl. Acad. Sci., vol. 112, no. 3, pp. 779–784, 2015. 
[33] I. A. Prior and J. F. Hancock, “Ras trafficking, localization and compartmentalized signalling,” 
Semin. Cell Dev. Biol., vol. 23, no. 2, pp. 145–153, 2012. 
[34] S. L. Moores, M. D. Schaber, S. D. Mosser, E. Rands, M. B. O’Hara, V. M. Garsky, M. S. 
Marshall, D. L. Pompliano, and J. B. Gibbs, “Sequence dependence of protein isoprenylation,” 
J. Biol. Chem., vol. 266, no. 22, pp. 14603–14610, 1991. 
[35] D. B. Whyte, P. Kirschmeier, T. N. Hockenberry, I. Nunez-Oliva, L. James, J. J. Catino, W. R. 
Bishop, and J. K. Pai, “K- and N-Ras are geranylgeranylated in cells treated with farnesyl 
protein transferase inhibitors,” J. Biol. Chem., vol. 272, no. 22, pp. 14459–14464, 1997. 
[36] L. Johnson, D. Greenbaum, K. Cichowski, K. Mercer, E. Murphy, E. Schmitt, R. T. Bronson, H. 
Umanoff, W. Edelmann, R. Kucherlapati, and T. Jacks, “K- ras is an essential gene in the 
mouse with partial functional overlap with N- ras,” Genes Dev., vol. 11, no. Bos 1989, pp. 2468–
2481, 1997. 
[37] K. Koera, K. Nakamura, K. Nakao, J. Miyoshi, K. Toyoshima, T. Hatta, H. Otani, A. Aiba, and 
M. Katsuki, “K-Ras is essential for the development of the mouse embryo,” Oncogene, vol. 15, 
no. 10, pp. 1151–1159, 1997. 
[38] N. Potenza, C. Vecchione, A. Notte, A. De Rienzo, A. Rosica, L. Bauer, A. Affuso, M. De Felice, 
T. Russo, R. Poulet, G. Cifelli, G. De Vita, G. Lembo, and R. Di Lauro, “Replacement of K-Ras 
with H-Ras supports normal embryonic development despite inducing cardiovascular 
pathology in adult mice.,” EMBO Rep., vol. 6, no. 5, pp. 432–7, 2005. 
[39] H. Umanoff, W. Edelmann, A. Pellicer, and R. Kucherlapati, “The murine N-ras gene is not 
essential for growth and development.,” Proc. Natl. Acad. Sci. U. S. A., vol. 92, no. 5, pp. 1709–
1713, 1995. 
[40] P. P. Fotiadou, C. Takahashi, H. N. Rajabi, and M. E. Ewen, “Wild-type NRas and KRas 
perform distinct functions during transformation.,” Mol. Cell. Biol., vol. 27, no. 19, pp. 6742–
6755, 2007. 
[41] R. Khosravi-Far and C. J. Der, “The Ras signal transduction pathway,” Cancer Metastasis Rev., 
vol. 13, no. 1, pp. 67–89, 1994. 
[42] Lefort, “Ras activation by insulin and epidermal growth factor through enhanced of guanine 
nucleotides on p21ras,” Mol. Cell. Biol., vol. 13, no. 1, pp. 155–162, 1993. 
[43] S. Traverse, N. Gomez, H. Paterson, C. Marshall, and P. Cohen, “Sustained activation of the 
mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 
cells. Comparison of the effects of nerve growth factor and epidermal growth factor.,” 
Biochem. J., vol. 288 ( Pt 2, pp. 351–5, 1992. 
[44] C.-H. Heldin, “Dimerization of cell surface receptors in signal transduction,” Cell, vol. 80, no. 
2, pp. 213–223, 1995. 
 
137 
 
[45] C. . Marshall, “Specificity of receptor tyrosine kinase signaling: Transient versus sustained 
extracellular signal-regulated kinase activation,” Cell, vol. 80, no. 2, pp. 179–185, 1995. 
[46] K. Rajalingam, R. Schreck, U. R. Rapp, and S. Albert, “Ras oncogenes and their downstream 
targets,” Biochim. Biophys. Acta - Mol. Cell Res., vol. 1773, no. 8, pp. 1177–1195, 2007. 
[47] J. Schlessinger, “Cell Signaling by Receptor Tyrosine Kinases A large group of genes in all 
eukaryotes encode for,” October, vol. 103, no. 2, pp. 211–225, 2000. 
[48] P. Gideon, J. John, M. Frech,  a Lautwein, R. Clark, J. E. Scheffler, and  a Wittinghofer, 
“Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the 
C-terminal domain of GAP is not sufficient for full activity.,” Mol. Cell. Biol., vol. 12, no. 5, pp. 
2050–2056, 1992. 
[49] M. Malumbres and M. Barbacid, “RAS oncogenes: the first 30 years,” Nat. Rev. Cancer, vol. 3, 
no. 6, pp. 459–465, 2003. 
[50] R. Ballester, D. Marchuk, M. Boguski, A. Saulino, R. Letcher, M. Wigler, and F. Collins, “The 
NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins,” 
Cell, vol. 63, no. 4, pp. 851–859, 1990. 
[51] G. Xu, P. O’Connell, D. Viskochil, R. Cawthon, M. Robertson, M. Culver, D. Dunn, J. Stevens, 
R. Gesteland, R. White, and R. Weiss, “The neurofibromatosis type 1 gene encodes a protein 
related to GAP,” Cell, vol. 62, no. 3, pp. 599–608, 1990. 
[52] A. Bernards and J. Settleman, “GAP control: Regulating the regulators of small GTPases,” 
Trends Cell Biol., vol. 14, no. 7, pp. 377–385, 2004. 
[53] G. A. Repasky, E. J. Chenette, and C. J. Der, “Renewing the conspiracy theory debate: Does Raf 
function alone to mediate Ras oncogenesis?,” Trends Cell Biol., vol. 14, no. 11, pp. 639–647, 
2004. 
[54] H. Chong, H. G. Vikis, and K. L. Guan, “Mechanisms of regulating the Raf kinase family,” Cell. 
Signal., vol. 15, no. 5, pp. 463–469, 2003. 
[55] J. T. Winston, S. R. Coats, Y. Z. Wang, and W. J. Pledger, “Regulation of the cell cycle 
machinery by oncogenic ras,” Oncogene, vol. 12, no. 1, p. 127—134, 1996. 
[56] J. Yan, S. Roy, A. Apolloni, A. Lane, and J. F. Hancock, “Ras isoforms vary in their ability to 
activate Raf-1 and phosphoinositide 3-kinase,” J. Biol. Chem., vol. 273, no. 37, pp. 24052–24056, 
1998. 
[57] M. Cully, H. You, A. J. Levine, and T. W. Mak, “Beyond PTEN mutations: the PI3K pathway as 
an integrator of multiple inputs during tumorigenesis,” Nat. Rev. Cancer, vol. 6, no. 3, pp. 184–
192, 2006. 
[58] M. P. Scheid and J. R. Woodgett, “PKB/AKT: functional insights from genetic models.,” Nat. 
Rev. Mol. Cell Biol., vol. 2, no. 10, pp. 760–768, 2001. 
[59] M. G. Kazanietz and M.-J. Caloca, “The Rac GTPase in cancer: from old concepts to new 
paradigms,” Cancer Res., p. canres.1456.2017, 2017. 
[60] L. A. Feig, T. Urano, and S. Cantor, “Evidence for a Ras/Ral signaling cascade,” Trends 
Biochem. Sci., vol. 21, no. 11, pp. 438–441, 1996. 
[61] L. A. Quilliam, J. F. Rebhun, and A. F. B. T.-P. in N. A. R. and M. B. Castro, “A growing family 
 
138 
 
of guanine nucleotide exchange factors is responsible for activation of ras-family GTPases,” 
vol. 71, no. Supplement C, Academic Press, 2002, pp. 391–444. 
[62] Y. Chien and M. A. White, “RAL GTPases are linchpin modulators of human tumour-cell 
proliferation and survival.,” EMBO Rep., vol. 4, no. 8, pp. 800–6, 2003. 
[63] L. A. Feig, “Ral-GTPases: Approaching their 15 minutes of fame,” Trends Cell Biol., vol. 13, no. 
8, pp. 419–425, 2003. 
[64] J. L. Bos, “ras Oncogenes in Human Cancer : A Review,” pp. 4682–4689, 1989. 
[65] I. A. Prior, P. D. Lewis, and C. Mattos, “A comprehensive survey of ras mutations in cancer,” 
Cancer Res., vol. 72, no. 10, pp. 2457–2467, 2012. 
[66] R. Shepherd, S. A. Forbes, D. Beare, S. Bamford, C. G. Cole, S. Ward, N. Bindal, P. 
Gunasekaran, M. Jia, C. Y. Kok, K. Leung, A. Menzies, A. P. Butler, J. W. Teague, P. J. 
Campbell, M. R. Stratton, and P. A. Futreal, “Data mining using the catalogue of somatic 
mutations in cancer biomart,” Database, vol. 2011, no. October, pp. 2–7, 2011. 
[67] K. Scheffzek, “The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss 
in Oncogenic Ras Mutants,” Science (80-. )., vol. 277, no. 5324, pp. 333–338, 1997. 
[68] P. H. Seeburg, W. W. Colby, D. J. Capon, D. V Goeddel, and A. D. Levinson, “Biological 
properties of human c-Ha-ras1 genes mutated at codon 12,” Nature, vol. 312, no. 5989, p. 71—
75, 1984. 
[69] S. M. Franken, A. J. Scheidig, U. Krengel, H. Rensland, A. Lautwein, M. Geyer, K. Scheffzek, R. 
S. Goody, H. R. Kalbitzer, E. F. Pai, and A. Wittinghofer, “Three-Dimensional Structures and 
Properties of a Transforming and a Nontransforming Glycine-12 Mutant of p21H-ras,” 
Biochemistry, vol. 32, no. 33, pp. 8411–8420, 1993. 
[70] W. W. Colby, J. S. Hayflick, S. G. Clark, and  a D. Levinson, “Biochemical characterization of 
polypeptides encoded by mutated human Ha-ras1 genes.,” Mol. Cell. Biol., vol. 6, no. 2, pp. 
730–734, 1986. 
[71] M. Castillo-Martin, J. Domingo-Domenech, O. Karni-Schmidt, T. Matos, and C. Cordon-
Cardo, “Molecular pathways of urothelial development and bladder tumorigenesis,” Urol. 
Oncol. Semin. Orig. Investig., vol. 28, no. 4, pp. 401–408, 2010. 
[72] J. I. E. N. Eble, G. Sauter and I. A. Sesterhenn, “Pathology and Genetics of Tumours of the 
Urinary System and Male Genital Organs,” Res. Policy, vol. 34, no. 2, pp. 249–250, 2005. 
[73] F. M. Torti, B. L. Lum, D. Aston, N. MacKenzie, M. Faysel, L. D. Shortliffe, and F. Freiha, 
“Superficial bladder cancer: the primacy of grade in the development of invasive disease.,” J. 
Clin. Oncol., vol. 5, no. 1, pp. 125–130, Jan. 1987. 
[74] E. Santos, S. R. Tronick, S. A. Aaronson, S. Pulciani, and M. Barbacid, “T24 human bladder 
carcinoma oncogene is an activated form of the normal human homologue of BALB- and 
Harvey-MSV transforming genes,” Nature, vol. 298, no. 5872, pp. 343–347, Jul. 1982. 
[75] I. Boulalas, A. Zaravinos, I. Karyotis, D. Delakas, and D. A. Spandidos, “Activation of RAS 
Family Genes in Urothelial Carcinoma,” J. Urol., vol. 181, no. 5, pp. 2312–2319, 2009. 
[76] C. P. N. Dinney, D. J. McConkey, R. E. Millikan, X. Wu, M. Bar-Eli, L. Adam, A. M. Kamat, A. 
O. Siefker-Radtke, T. Tuziak, A. L. Sabichi, H. B. Grossman, W. F. Benedict, and B. Czerniak, 
 
139 
 
“Focus on bladder cancer,” Cancer Cell, vol. 6, no. 2, pp. 111–116, 2004. 
[77] R. Shepherd, S. A. Forbes, D. Beare, S. Bamford, C. G. Cole, S. Ward, N. Bindal, P. 
Gunasekaran, M. Jia, C. Y. Kok, K. Leung, A. Menzies, A. P. Butler, J. W. Teague, P. J. 
Campbell, M. R. Stratton, and P. A. Futreal, “Data mining using the Catalogue of Somatic 
Mutations in Cancer BioMart,” Database, vol. 2011, p. bar018-bar018, Jan. 2011. 
[78] B. L. Cheng, R. M. Neumann, A. L. Weaver, B. E. Spotts, and D. G. Bostwick, “Bladder 
Carcinoma,” vol. 17, no. 10, pp. 3182–3187, 1999. 
[79] D. Vageli, H. Kiaris, D. Delakas, P. Anezinis, A. Cranidis, and D. A. Spandidos, 
“Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder 
tumors,” Cancer Lett., vol. 107, no. 2, pp. 241–247, 1996. 
[80] A. Membrino, S. Cogoi, E. B. Pedersen, and L. E. Xodo, “G4-DNA formation in the HRAS 
promoter and rational design of decoy oligonucleotides for cancer therapy,” PLoS One, vol. 6, 
no. 9, 2011. 
[81] S. Cogoi, S. Zorzet, A. E. Shchekotikhin, and L. E. Xodo, “Potent Apoptotic Response Induced 
by Chloroacetamidine Anthrathiophenediones in Bladder Cancer Cells,” J. Med. Chem., vol. 58, 
no. 14, pp. 5476–5485, 2015. 
[82] D. P. Ryan, T. S. Hong, and N. Bardeesy, “Pancreatic Adenocarcinoma,” pp. 1039–1049, 2014. 
[83] R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer Statistics , 2014,” vol. 64, no. 1, pp. 9–29, 2014. 
[84] I. T. Konstantinidis, A. L. Warshaw, J. N. Allen, L. S. Blaszkowsky, C. F.-D. Castillo, V. 
Deshpande, T. S. Hong, E. L. Kwak, G. Y. Lauwers, D. P. Ryan, J. A. Wargo, K. D. Lillemoe, and 
C. R. Ferrone, “Pancreatic ductal adenocarcinoma: is there a survival difference for R1 
resections versus locally advanced unresectable tumors? What is a ‘true’ R0 resection?,” Ann. 
Surg., vol. 257, no. 4, p. 731—736, Apr. 2013. 
[85] V. T. H. B. M. Smit, A. J. M. Boot, A. M. M. Smits, G. J. Fleuren, C. J. Cornelisse, and J. L. Bos, 
“KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas,” Nucleic 
Acids Res., vol. 16, no. 16, pp. 7773–7782, Aug. 1988. 
[86] C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim, and M. Perucho, “Most human 
carcinomas of the exocrine pancreas contain mutant c-K-ras genes,” Cell, vol. 53, no. 4, pp. 
549–554, 1988. 
[87] S. Jones, S. Jones, X. Zhang, D. W. Parsons, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. 
Carter, H. Kamiyama, A. Jimeno, S. Hong, B. Fu, M. Lin, E. S. Calhoun, M. Kamiyama, K. 
Walter, T. Nikolskaya, Y. Nikolsky, J. Hartigan, D. R. Smith, M. Hidalgo, S. D. Leach, A. P. 
Klein, E. M. Jaffee, M. Goggins, A. Maitra, C. Iacobuzio-donahue, J. R. Eshleman, S. E. Kern, R. 
H. Hruban, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu, and 
K. W. Kinzler, “Core Signaling Pathways in Human,” vol. 1801, 2008. 
[88] A. J. Aguirre, N. Bardeesy, M. Sinha, L. Lopez, D. A. Tuveson, J. Horner, M. S. Redston, and R. 
A. Depinho, “Activated Kras and Ink4a / Arf deficiency cooperate to produce metastatic 
pancreatic ductal adenocarcinoma,” pp. 3112–3126, 2003. 
[89] A. Singh, P. Greninger, D. Rhodes, L. Koopman, S. Violette, and N. Bardeesy, “A Gene 
Expression Signature Associated with ‘“ K-Ras Addiction ”’ Reveals Regulators of EMT and 
Tumor Cell Survival,” Cancer Cell, vol. 15, no. 6, pp. 489–500, 2009. 
 
140 
 
[90] M. A. Collins, F. Bednar, Y. Zhang, J. Brisset, S. Galbán, C. J. Galbán, S. Rakshit, K. S. 
Flannagan, N. V. Adsay, and M. Pasca, “Oncogenic Kras is required for both the initiation and 
maintenance of pancreatic cancer in mice,” vol. 26, no. 16. 
[91] H. Ying, A. C. Kimmelman, C. a. Lyssiotis, S. Hua, G. C. Chu, E. Fletcher-Sananikone, J. W. 
Locasale, J. Son, H. Zhang, J. L. Coloff, H. Yan, W. Wang, S. Chen, A. Viale, H. Zheng, J. H. 
Paik, C. Lim, A. R. Guimaraes, E. S. Martin, J. Chang, A. F. Hezel, S. R. Perry, J. Hu, B. Gan, Y. 
Xiao, J. M. Asara, R. Weissleder, Y. A. Wang, L. Chin, L. C. Cantley, and R. a. Depinho, 
“Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose 
metabolism,” Cell, vol. 149, no. 3, pp. 656–670, 2012. 
[92] G. M. DeNicola and D. A. Tuveson, “RAS in cellular transformation and senescence,” Eur. J. 
Cancer, vol. 45, no. SUPPL. 1, pp. 211–216, Oct. 2009. 
[93] C. Guerra, M. Collado, C. Navas, A. J. Schuhmacher, I. Hernández-Porras, M. Cañamero, M. 
Rodriguez-Justo, M. Serrano, and M. Barbacid, “Pancreatitis-Induced Inflammation 
Contributes to Pancreatic Cancer by Inhibiting Oncogene-Induced Senescence,” Cancer Cell, 
vol. 19, no. 6, pp. 728–739, Oct. 2017. 
[94] A. Singh, P. Greninger, D. Rhodes, L. Koopman, S. Violette, N. Bardeesy, and J. Settleman, “A 
Gene Expression Signature Associated with ‘K-Ras Addiction’ Reveals Regulators of EMT and 
Tumor Cell Survival,” Cancer Cell, vol. 15, no. 6, pp. 489–500, Jun. 2009. 
[95] L. Elghazi, A. J. Weiss, D. J. Barker, J. Callaghan, L. Staloch, E. P. Sandgren, M. Gannon, V. N. 
Adsay, and E. Bernal–Mizrachi, “Regulation of Pancreas Plasticity and Malignant 
Transformation by Akt Signaling,” Gastroenterology, vol. 136, no. 3, p. 1091–1103.e8, Mar. 2009. 
[96] S. Eser, N. Reiff, M. Messer, B. Seidler, K. Gottschalk, M. Dobler, M. Hieber, A. Arbeiter, S. 
Klein, B. Kong, C. W. Michalski, A. M. Schlitter, I. Esposito, A. J. Kind, L. Rad, A. E. Schnieke, 
M. Baccarini, D. R. Alessi, R. Rad, R. M. Schmid, G. Schneider, and D. Saur, “Selective 
Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and 
Cancer,” Cancer Cell, vol. 23, no. 3, pp. 406–420, Mar. 2013. 
[97] I. B. Weinstein, “Disorders in cell circuitry during multistage carcinogenesis: the role of 
homeostasis,” Carcinogenesis, vol. 21, no. 5, pp. 857–864, 2000. 
[98] I. B. Weinstein and A. Joe, “Oncogene addiction,” Cancer Res., vol. 68, no. 9, pp. 3077–3080, 
2008. 
[99] I. B. Weinstein, “Cancer. Addiction to oncogenes--the Achilles heal of cancer,” Science, vol. 
297, no. 5578, p. 63—64, 2002. 
[100] D. W. Felsher and J. M. Bishop, “Reversible tumorigenesis by MYC in hematopoietic lineages,” 
Mol. Cell, vol. 4, no. 2, pp. 199–207, 1999. 
[101] M. Jain, C. Arvanitis, K. Chu, W. Dewey, E. Leonhardt, M. Trinh, C. D. Sundberg, J. M. Bishop, 
and D. W. Felsher, “Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC,” 
Science (80-. )., vol. 297, no. 5578, pp. 102–104, 2002. 
[102] T. Holien, T. K. Våtsveen, H. Hella, A. Waage, A. Sundan, W. Dc, T. Holien, T. K. Våtsveen, H. 
Hella, A. Waage, and A. Sundan, “Addiction to c-MYC in multiple myeloma,” vol. 120, no. 12, 
pp. 2450–2453, 2013. 
[103] L. Chin, A. Tam, J. Pomerantz, M. Wong, J. Holash, N. Bardeesy, Q. Shen, R. O’Hagan, J. 
Pantginis, H. Zhou, J. W. Horner, C. Cordon-Cardo, G. D. Yancopoulos, and R. A. DePinho, 
 
141 
 
“Essential role for oncogenic Ras in tumour maintenance,” Nature, vol. 400, no. 6743, p. 468—
472, 1999. 
[104] S. Shirasawa, M. Furuse, N. Yokoyama, and T. Sasazuki, “Altered Growth of Human Colon 
Cancer Cell Lines Disrupted at Activated Ki-ras,” Science (80-. )., vol. 260, no. 5104, pp. 85–88, 
2009. 
[105] M. A. Collins, F. Bednar, Y. Zhang, J. Brisset, S. Galbán, C. J. Galbán, S. Rakshit, K. S. 
Flannagan, N. V. Adsay, M. Pasca di Magliano, and M. Pasca, “Oncogenic Kras is required for 
both the initiation and maintenance of pancreatic cancer in mice,” J. Clin. Invest., vol. 122, no. 
2, pp. 639–653, 2012. 
[106] K. L. Bryant, J. D. Mancias, A. C. Kimmelman, and C. J. Der, “KRAS: Feeding pancreatic cancer 
proliferation,” Trends Biochem. Sci., vol. 39, no. 2, pp. 91–100, 2014. 
[107] J. Son, C. A. Lyssiotis, H. Ying, X. Wang, S. Hua, M. Ligorio, R. M. Perera, C. R. Ferrone, E. 
Mullarky, N. Shyh-Chang, Y. Kang, J. B. Fleming, N. Bardeesy, J. M. Asara, M. C. Haigis, R. A. 
DePinho, L. C. Cantley, and A. C. Kimmelman, “Glutamine supports pancreatic cancer growth 
through a KRAS-regulated metabolic pathway,” Nature, vol. 496, no. 7443, pp. 101–105, 2013. 
[108] H. Ledford, “The ras renaissance,” Nature, vol. 520, pp. 278–280, 2015. 
[109] V. González-Pérez, D. J. Reiner, J. K. Alan, C. Mitchell, L. J. Edwards, V. Khazak, C. J. Der, and 
A. D. Cox, “Genetic and functional characterization of putative Ras/Raf interaction inhibitors 
in C. elegans and mammalian cells.,” J. Mol. Signal., vol. 5, p. 2, 2010. 
[110] J. Kato-Stankiewicz, I. Hakimi, G. Zhi, J. Zhang, I. Serebriiskii, L. Guo, H. Edamatsu, H. Koide, 
S. Menon, R. Eckl, S. Sakamuri, Y. Lu, Q.-Z. Chen, S. Agarwal, W. R. Baumbach, E. A. Golemis, 
F. Tamanoi, and V. Khazak, “Inhibitors of Ras/Raf-1 interaction identified by two-hybrid 
screening revert Ras-dependent transformation phenotypes in human cancer cells,” Proc. 
Natl. Acad. Sci., vol. 99, no. 22, pp. 14398–14403, 2002. 
[111] D. Nayak, T. L. Roth, and D. B. Mcgavern, “An Orthosteric Inhibitor of the Ras-Sos 
Interaction,” Nat. Chem. Biol., vol. 7, no. 2, pp. 367–402, 2014. 
[112] S. M. S. Norbert Berndt, Andrew D. Hamilton, “Targeting protein prenylation for cancer 
therapy,” Nat. Rev. Cancer, vol. 11, no. 11, pp. 775–791, 2011. 
[113] A. D. Cox, S. W. Fesik, A. C. Kimmelman, J. Luo, and C. J. Der, “Drugging the undruggable 
Ras: mission possible?,” vol. 13, no. 11, pp. 828–851, 2015. 
[114] A. J. Levine and A. M. Puzio-Kuter, “The Control of the Metabolic Switch in Cancers by 
Oncogenes and Tumor Suppressor Genes,” Science (80-. )., vol. 330, no. 6009, pp. 1340–1344, 
2010. 
[115] K. Shukla, D. V. Ferraris, A. G. Thomas, M. Stathis, B. Duvall, G. Delahanty, J. Alt, R. Rais, C. 
Rojas, P. Gao, Y. Xiang, C. V. Dang, B. S. Slusher, and T. Tsukamoto, “Design, synthesis, and 
pharmacological evaluation of bis-2-(5- phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 
(BPTES) analogs as glutaminase inhibitors,” J. Med. Chem., vol. 55, no. 23, pp. 10551–10563, 
2012. 
[116] R. Perera, J. Son, C. A. Lyssiotis, H. Ying, X. Wang, S. Hua, M. Ligorio, R. M. Perera, C. R. 
Ferrone, E. Mullarky, and N. Shyh-Chang, “Glutamine supports pancreatic cancer growth 
through a KRAS-regulated metabolic pathway.” 2013. 
 
142 
 
[117] S. Cogoi, A. E. Shchekotikhin, and L. E. Xodo, “HRAS is silenced by two neighboring G-
quadruplexes and activated by MAZ, a zinc-finger transcription factor with DNA unfolding 
property,” Nucleic Acids Res., vol. 42, no. 13, pp. 8379–8388, 2014. 
[118] S. Cogoi, M. Paramasivam, A. Membrino, K. K. Yokoyama, and L. E. Xodo, “The KRAS 
promoter responds to Myc-associated zinc finger and poly(ADP-ribose) polymerase 1 proteins, 
which recognize a critical quadruplex-forming GA-element,” J. Biol. Chem., vol. 285, no. 29, 
pp. 22003–22016, 2010. 
[119] M. Paramasivam, A. Membrino, S. Cogoi, H. Fukuda, H. Nakagama, and L. E. Xodo, “Protein 
hnRNP A1 and its derivative Up1 unfold quadruplex DNA in the human KRAS promoter: 
Implications for transcription,” Nucleic Acids Res., vol. 37, no. 9, pp. 2841–2853, 2009. 
[120] S. Cogoi, S. Zorzet, V. Rapozzi, I. Géci, E. B. Pedersen, and L. E. Xodo, “MAZ-binding G4-
decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses 
KRAS in pancreatic cancer cells and delays tumor growth in mice,” Nucleic Acids Res., vol. 41, 
no. 7, pp. 4049–4064, 2013. 
[121] S. Cogoi, U. Jakobsen, E. B. Pedersen, S. Vogel, and L. E. Xodo, “Lipid-modified G4-decoy 
oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells,” 
Sci. Rep., vol. 6, no. November, p. 38468, 2016. 
[122] E. Huntzinger and E. Izaurralde, “Gene silencing by microRNAs: contributions of translational 
repression and mRNA decay,” Nat. Rev. Genet., vol. 12, no. 2, p. 99—110, 2011. 
[123] H. oki Iwakawa and Y. Tomari, “The Functions of MicroRNAs: mRNA Decay and Translational 
Repression,” Trends Cell Biol., vol. 25, no. 11, pp. 651–665, 2015. 
[124] R. Garzon, G. A. Calin, and C. M. Croce, “MicroRNAs in Cancer,” Annu. Rev. Med., vol. 60, no. 
1, pp. 167–179, Feb. 2009. 
[125] F. J. Slack and J. B. Weidhaas, “MicroRNA in cancer prognosis,” N. Engl. J. Med., vol. 359, no. 
25, p. 2720—2722, 2008. 
[126] S. M. Johnson, H. Grosshans, J. Shingara, M. Byrom, R. Jarvis, A. Cheng, E. Labourier, K. L. 
Reinert, D. Brown, and F. J. Slack, “RAS is regulated by the let-7 microRNA family,” Cell, vol. 
120, no. 5, pp. 635–647, 2005. 
[127] S. Yu, Z. Lu, C. Liu, Y. Meng, and Y. Ma, “miRNA-96 Suppresses KRAS and Functions as a 
Tumor Suppressor Gene in Pancreatic Cancer,” pp. 6015–6025. 
[128] M. Deng, H. Tang, Y. Zhou, M. Zhou, W. Xiong, Y. Zheng, Q. Ye, X. Zeng, Q. Liao, X. Guo, X. 
Li, J. Ma, and G. Li, “miR-216b suppresses tumor growth and invasion by targeting KRAS in 
nasopharyngeal carcinoma.,” J. Cell Sci., vol. 124, no. Pt 17, pp. 2997–3005, 2011. 
[129] A. Osorio, J. Benitez, and B. Martinez-delgado, “Deregulated miRNAs in Hereditary Breast 
Cancer Revealed a Role for miR-30c in Regulating KRAS Oncogene,” vol. 7, no. 6, 2012. 
[130] M. Matsui and D. R. Corey, “Non-coding RNAs as drug targets,” Nat. Rev. Drug Discov., vol. 16, 
no. 3, pp. 167–179, 2016. 
[131] H. Ling, M. Fabbri, and G. A. Calin, “MicroRNAs and other non-coding RNAs as targets for 
anticancer drug development,” Nat. Rev. Drug Discov., vol. 12, no. 11, pp. 847–865, 2013. 
[132] N. Langkjær, A. Pasternak, and J. Wengel, “UNA (unlocked nucleic acid): A flexible RNA 
 
143 
 
mimic that allows engineering of nucleic acid duplex stability,” Bioorganic Med. Chem., vol. 17, 
no. 15, pp. 5420–5425, 2009. 
[133] Q. Ge, A. Dallas, H. Ilves, J. Shorenstein, M. A. Behlke, and B. H. Johnston, “Effects of chemical 
modification on the potency, serum stability, and immunostimulatory properties of short 
shRNAs,” Rna, vol. 16, no. 1, pp. 118–130, 2010. 
[134] I. Bang, “Untersuchungen über die Guanylsäure,” Biochem. Z., vol. 26, pp. 293–311, 1910. 
[135] I. Gellert, M. N. Lipsett, and D. R. Davies, “Helix formation by guanylic acid,” Proc. Natl. Acad. 
Sci. U. S. A., vol. 48, pp. 2013–2018, 1962. 
[136] S. Burge, G. N. Parkinson, P. Hazel, A. K. Todd, and S. Neidle, “Quadruplex DNA: Sequence, 
topology and structure,” Nucleic Acids Res., vol. 34, no. 19, pp. 5402–5415, 2006. 
[137] J. L. Huppert and S. Balasubramanian, “Prevalence of quadruplexes in the human genome,” 
Nucleic Acids Res., vol. 33, no. 9, pp. 2908–2916, 2005. 
[138] A. Bedrat, L. Lacroix, and J. L. Mergny, “Re-evaluation of G-quadruplex propensity with 
G4Hunter,” Nucleic Acids Res., vol. 44, no. 4, pp. 1746–1759, 2016. 
[139] N. Beaume, R. Pathak, V. K. Yadav, S. Kota, H. S. Misra, H. K. Gautam, and S. Chowdhury, 
“Genome-wide study predicts promoter-G4 DNA motifs regulate selective functions in 
bacteria: Radioresistance of D. radiodurans involves G4 DNA-mediated regulation,” Nucleic 
Acids Res., vol. 41, no. 1, pp. 76–89, 2013. 
[140] M. Metifiot, S. Amrane, S. Litvak, and M.-L. Andreola, “G-quadruplexes in viruses: function 
and potential therapeutic applications,” Nucleic Acids Res., vol. 42, no. 20, pp. 12352–12366, 
2014. 
[141] C. Schaffitzel, I. Berger, J. Postberg, J. Hanes, H. J. Lipps, and A. Plückthun, “In vitro generated 
antibodies specific for telomeric guanine-quadruplex DNA react with Stylonychia lemnae 
macronuclei.,” Proc. Natl. Acad. Sci. U. S. A., vol. 98, no. 15, pp. 8572–7, 2001. 
[142] A. Henderson, Y. Wu, Y. C. Huang, E. A. Chavez, J. Platt, F. B. Johnson, R. M. Brosh, D. Sen, 
and P. M. Lansdorp, “Detection of G-quadruplex DNA in mammalian cells,” Nucleic Acids 
Res., vol. 42, no. 2, pp. 860–869, 2014. 
[143] G. Biffi, D. Tannahill, J. McCafferty, and S. Balasubramanian, “Quantitative visualization of 
DNA G-quadruplex structures in human cells,” Nat. Chem., vol. 5, no. 3, pp. 182–186, 2013. 
[144] H. G. Kazemier, K. Paeschke, and P. M. Lansdorp, “Guanine quadruplex monoclonal antibody 
1H6 cross-reacts with restrained thymidine-rich single stranded DNA,” Nucleic Acids Res., vol. 
45, no. 10, pp. 5913–5919, 2017. 
[145] V. S. Chambers, G. Marsico, J. M. Boutell, M. Di Antonio, G. P. Smith, and S. 
Balasubramanian, “High-throughput sequencing of DNA G-quadruplex structures in the 
human genome,” Nat. Biotechnol., vol. 33, no. July, pp. 1–7, 2015. 
[146] R. Hänsel-Hertsch, D. Beraldi, S. V Lensing, G. Marsico, K. Zyner, A. Parry, M. Di Antonio, J. 
Pike, H. Kimura, M. Narita, D. Tannahill, and S. Balasubramanian, “G-quadruplex structures 
mark human regulatory chromatin.,” Nat. Genet., vol. 48, no. 10, pp. 1267–72, 2016. 
[147] D. Rhodes and H. J. Lipps, “Survey and summary G-quadruplexes and their regulatory roles in 
biology,” Nucleic Acids Res., vol. 43, no. 18, pp. 8627–8637, 2015. 
 
144 
 
[148] L. Hayflick, “The limited in vitro lifetime of human diploid cell strains,” Exp. Cell Res., vol. 37, 
no. 3, pp. 614–636, 1965. 
[149] C. W. Greider and E. H. Blackburn, “Identification of a specific telomere terminal transferase 
activity in tetrahymena extracts,” Cell, vol. 43, no. 2 PART 1, pp. 405–413, 1985. 
[150] N. W. Kim, M. A. Piatyszek, K. R. Prowse, C. B. Harley, M. D. West, P. L. C. Ho, G. M. Coviello, 
W. E. Wright, S. L. Weinrich, and J. W. Shay, “Specific Association of Human Telomerase 
Activity with Immortal Cells and Cancer,” Science (80-. )., vol. 266, no. 5193, pp. 2011–2015, 
2016. 
[151] R. K. Moyzis, J. M. Buckingham, L. S. Cram, M. Dani, L. L. Deaven, M. D. Jones, J. Meyne, R. L. 
Ratliff, and J. R. Wu, “A highly conserved repetitive DNA sequence, (TTAGGG)n, present at 
the telomeres of human chromosomes.,” Proc. Natl. Acad. Sci. U. S. A., vol. 85, no. 18, pp. 
6622–6, 1988. 
[152] G. N. Parkinson, M. P. H. Lee, and S. Neidle, “Crystal structure of parallel quadruplexes from 
human telomeric DNA.,” Nature, vol. 417, no. 6891, pp. 876–80, 2002. 
[153] Y. Wang and D. J. Patel, “Solution structure of the human telomeric repeat d[AG3(T2AG3)3] 
G-tetraplex,” Structure, vol. 1, no. 4, pp. 263–282, 1993. 
[154] H.-L. Bao, T. Ishizuka, T. Sakamoto, K. Fujimoto, T. Uechi, N. Kenmochi, and Y. Xu, 
“Characterization of human telomere RNA G-quadruplex structures in vitro and in living cells 
using 19F NMR spectroscopy,” Nucleic Acids Res., vol. 45, no. 9, pp. 1–11, 2017. 
[155] H. T. Le, W. L. Dean, R. Buscaglia, J. B. Chaires, and J. O. Trent, “An Investigation of G ̻ 
Quadruplex Structural Polymorphism in the Human Telomere Using a Combined Approach 
of Hydrodynamic Bead Modeling and Molecular Dynamics Simulation,” J. Phys. Chem. B, vol. 
118, pp. 5390–5405, 2014. 
[156] Anh Tuân Phan and Dinshaw J. Patel, “Two-Repeat Human Telomeric d(TAGGGTTAGGGT) 
Sequence Forms Interconverting Parallel and Antiparallel G-Quadruplexes in Solution: 
Distinct Topologies, Thermodynamic Properties, and Folding/Unfolding Kinetics Anh,” J. Am. 
Chem. Soc., vol. 2, no. 74, pp. 15021–15027, 2015. 
[157] A. T. Phan, K. N. Luu, and D. J. Patel, “Different loop arrangements of intramolecular human 
telomeric (3+1) G-quadruplexes in K+ solution,” Nucleic Acids Res., vol. 34, no. 19, pp. 5715–
5719, 2006. 
[158] D. Sun, B. Thompson, B. E. Cathers, M. Salazar, S. M. Kerwin, J. O. Trent, T. C. Jenkins, S. 
Neidle, and L. Hurley, “Inhibition of human telomerase by a G-Quadruplex-Interactive 
compound,” J. Med. Chem., vol. 40, no. 14, pp. 2113–2116, 1997. 
[159] A. M. Zahler, J. R. Williamson, T. R. Cech, and D. M. Prescott, “Inhibition of telomerase by G-
quartet DNA structures,” Nature, vol. 350, no. 6320, pp. 718–720, 1991. 
[160] J. F. Riou, L. Guittat, P. Mailliet, A. Laoui, E. Renou, O. Petitgenet, F. Mégnin-Chanet, C. 
Hélène, and J. L. Mergny, “Cell senescence and telomere shortening induced by a new series of 
specific G-quadruplex DNA ligands.,” Proc. Natl. Acad. Sci. U. S. A., vol. 99, no. 5, pp. 2672–
2677, 2002. 
[161] M. a Shammas, R. J. Shmookler Reis, C. Li, H. Koley, L. Hurley, K. C. Anderson, and N. C. 
Munshi, “Telomerase inhibition and cell growth arrest after telomestatin treatment in 
multiple myeloma.,” Clin. Cancer Res., vol. 10, no. 2, pp. 770–776, 2004. 
 
145 
 
[162] R. A. Heald, C. Modi, J. C. Cookson, I. Hutchinson, C. A. Laughton, S. M. Gowan, L. R. 
Kelland, and M. F. G. Stevens, “Activity of Methylated Pentacyclic Acridinium Salts,” pp. 590–
597, 2002. 
[163] S. K. Noureini, H. Esmaeili, F. Abachi, S. Khiali, B. Islam, M. Kuta, A. A. Saboury, M. 
Hoffmann, J. Sponer, G. Parkinson, and S. Haider, “Selectivity of major isoquinoline alkaloids 
from Chelidonium majus towards telomeric G-quadruplex: A study using a transition-FRET (t-
FRET) assay,” Biochim. Biophys. Acta - Gen. Subj., vol. 1861, no. 8, pp. 2020–2030, 2017. 
[164] A. Kerkour, J. L. Mergny, and G. F. Salgado, “NMR based model of human telomeric repeat G-
quadruplex in complex with 2,4,6-triarylpyridine family ligand,” Biochim. Biophys. Acta - Gen. 
Subj., vol. 1861, no. 5, pp. 1293–1302, 2017. 
[165] N. H. Campbell, G. N. Parkinson, A. P. Reszka, and S. Neidle, “Structural basis of DNA 
quadruplex recognition by an acridine drug,” J. Am. Chem. Soc., vol. 130, no. 21, pp. 6722–6724, 
2008. 
[166] A. M. Burger, F. Dai, C. M. Schultes, A. P. Reszka, M. J. Moore, J. A. Double, and S. Neidle, 
“The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with 
telomere targeting and interference with telomerase function,” Cancer Res., vol. 65, no. 4, pp. 
1489–1496, 2005. 
[167] G. Zhou, X. Liu, Y. Li, S. Xu, C. Ma, X. Wu, Y. Cheng, Z. Yu, G. Zhao, and Y. Chen, “Telomere 
targeting with a novel G-quadruplex-interactive ligand BRACO-19 induces T-loop disassembly 
and telomerase displacement in human glioblastoma cells.,” Oncotarget, vol. 7, no. 12, 2016. 
[168] S. Neidle, “Human telomeric G-quadruplex: The current status of telomeric G-quadruplexes as 
therapeutic targets in human cancer,” FEBS J., vol. 277, no. 5, pp. 1118–1125, 2010. 
[169] E. Salvati, C. Leonetti, A. Rizzo, M. Scarsella, M. Mottolese, R. Galati, I. Sperduti, M. F. G. 
Stevens, M. D’Incalci, M. Blasco, G. Chiorino, S. Bauwens, B. Horard, E. Gilson, A. 
Stoppacciaro, G. Zupi, and A. Biroccio, “Telomere damage induced by the G-quadruplex 
ligand RHPS4 has an antitumor effect,” J. Clin. Invest., vol. 117, no. 11, pp. 3236–3247, 2007. 
[170] S. Müller, D. A. Sanders, M. Di Antonio, S. Matsis, J.-F. Riou, R. Rodriguez, and S. 
Balasubramanian, “Pyridostatin analogues promote telomere dysfunction and long-term 
growth inhibition in human cancer cells,” Org. Biomol. Chem., vol. 10, no. 32, p. 6537, 2012. 
[171] P. Bedinger, M. Munn, and B. M. Alberts, “Sequence-specific pausing during in vitro DNA 
replication on double-stranded DNA templates.,” J. Biol. Chem., vol. 264, no. 28, pp. 16880–
16886, 1989. 
[172] K. Usdin and K. J. Woodford, “CGG repeats associated with DNA instability and chromosome 
fragility form structures that block DNA synthesis in vitro,” Nucleic Acids Res., vol. 23, no. 20, 
pp. 4202–4209, 1995. 
[173] K. J. Woodford, R. M. Howell, and K. Usdin, “A novel K+-dependent DNA synthesis arrest site 
in a commonly occurring sequence motif in eukaryotes,” J. Biol. Chem., vol. 269, no. 43, pp. 
27029–27035, 1994. 
[174] O. Mendoza, A. Bourdoncle, J. B. Boulé, R. M. Brosh, and J. L. Mergny, “G-quadruplexes and 
helicases,” Nucleic Acids Res., vol. 44, no. 5, pp. 1989–2006, 2016. 
[175] K. L. Katrin Paeschke, Matthew L. Bochman , P. Daniela Garcia Petr Cejka and S. C. K. and V. 
A. Z. Friedman, “Pif1 family helicases suppress genome instability at G- quadruplex motifs 
 
146 
 
Katrin,” vol. 21, no. 10, pp. 3240–3248, 2015. 
[176] Y. Wu, K. Shin-ya, and R. M. Brosh, “FANCJ Helicase Defective in Fanconia Anemia and Breast 
Cancer Unwinds G-Quadruplex DNA To Defend Genomic Stability,” Mol. Cell. Biol., vol. 28, 
no. 12, pp. 4116–4128, 2008. 
[177] C. M. Sanders, “Human Pif1 helicase is a G-quadruplex DNA-binding protein with G-
quadruplex DNA-unwinding activity,” Biochem J, vol. 430, no. 1, pp. 119–128, 2010. 
[178] K. Paeschke, J. A. Capra, and V. A. Zakian, “DNA Replication through G-Quadruplex Motifs Is 
Promoted by the Saccharomyces cerevisiae Pif1 DNA Helicase,” Cell, vol. 145, no. 5, pp. 678–
691, 2011. 
[179] T. B. C. London, L. J. Barber, G. Mosedale, G. P. Kelly, S. Balasubramanian, I. D. Hickson, S. J. 
Boulton, and K. Hiom, “FANCJ is a structure-specific DNA helicase associated with the 
maintenance of genomic G/C tracts,” J. Biol. Chem., vol. 283, no. 52, pp. 36132–36139, 2008. 
[180] P. Castillo Bosch, S. Segura-Bayona, W. Koole, J. T. van Heteren, J. M. Dewar, M. Tijsterman, 
and P. Knipscheer, “FANCJ promotes DNA synthesis through G-quadruplex structures.,” 
EMBO J., vol. 33, no. 21, pp. 2521–33, 2014. 
[181] J. L. Huppert and S. Balasubramanian, “G-quadruplexes in promoters throughout the human 
genome,” Nucleic Acids Res., vol. 35, no. 2, pp. 406–413, 2007. 
[182] R. Perrone, E. Lavezzo, E. Riello, R. Manganelli, G. Palù, S. Toppo, R. Provvedi, and S. N. 
Richter, “Mapping and characterization of G-quadruplexes in Mycobacterium tuberculosis 
gene promoter regions,” Sci. Rep., vol. 7, no. 1, p. 5743, 2017. 
[183] S. G. Hershman, Q. Chen, J. Y. Lee, M. L. Kozak, P. Yue, L. S. Wang, and F. B. Johnson, 
“Genomic distribution and functional analyses of potential G-quadruplex-forming sequences 
in Saccharomyces cerevisiae,” Nucleic Acids Res., vol. 36, no. 1, pp. 144–156, 2008. 
[184] J. Eddy, A. C. Vallur, S. Varma, H. Liu, W. C. Reinhold, Y. Pommier, and N. Maizels, “G4 
motifs correlate with promoter-proximal transcriptional pausing in human genes,” Nucleic 
Acids Res., vol. 39, no. 12, pp. 4975–4983, 2011. 
[185] M. L. Bochman, K. Paeschke, and V. A. Zakian, “DNA secondary structures: stability and 
function of G-quadruplex structures,” Nat Rev Genet, vol. 13, no. 11, pp. 770–780, Nov. 2012. 
[186] J. Eddy and N. Maizels, “Gene function correlates with potential for G4 DNA formation in the 
human genome,” Nucleic Acids Res., vol. 34, no. 14, pp. 3887–3896, 2006. 
[187] T. A. Brooks and L. Hurley, “Targeting MYC Expression through G-Quadruplexes,” Genes 
Cancer, vol. 1, no. 6, pp. 641–649, 2010. 
[188] K. B. Marcu, S. A. Bossone, and A. J. Patel, “myc Function and Regulation,” Annu. Rev. 
Biochem., vol. 61, no. 1, pp. 809–858, Jun. 1992. 
[189] A. Siddiqui-Jain, C. L. Grand, D. J. Bearss, and L. Hurley, “Direct evidence for a G-quadruplex 
in a promoter region and its targeting with a small molecule to repress c-MYC transcription.,” 
Proc. Natl. Acad. Sci. U. S. A., vol. 99, no. 18, pp. 11593–8, 2002. 
[190] A. T. Phan, Y. S. Modi, and D. J. Patel, “Propeller-type parallel-stranded G-quadruplexes in the 
human c-myc promoter,” J. Am. Chem. Soc., vol. 126, no. 28, pp. 8710–8716, 2004. 
[191] S. Balasubramanian and L. Hurley, “Targeting G-quadruplexes in gene promoters : a novel 
 
147 
 
anticancer,” Nat. Rev. Drug Discov., vol. 10, no. 4, pp. 261–275, 2011. 
[192] F. Yamamoto and M. Perucho, “Characterization of the human cK-ras gene promoter.,” 
Oncogene Res., vol. 3, no. 2, pp. 125–130, 1988. 
[193] S. Cogoi, M. Paramasivam, B. Spolaore, and L. E. Xodo, “Structural polymorphism within a 
regulatory element of the human KRAS promoter: Formation of G4-DNA recognized by 
nuclear proteins,” Nucleic Acids Res., vol. 36, no. 11, pp. 3765–3780, 2008. 
[194] R. K. Morgan, H. Batra, V. C. Gaerig, J. Hockings, and T. A. Brooks, “Identification and 
characterization of a new G-quadruplex forming region within the kRAS promoter as a 
transcriptional regulator,” Biochim. Biophys. Acta - Gene Regul. Mech., vol. 1859, no. 2, pp. 235–
245, 2016. 
[195] J. Jean-Philippe, S. Paz, and M. Caputi, “hnRNP A1: The Swiss Army Knife of gene expression,” 
Int. J. Mol. Sci., vol. 14, no. 9, pp. 18999–19024, 2013. 
[196] A. C. Krüger, M. K. Raarup, M. M. Nielsen, M. Kristensen, F. Besenbacher, J. Kjems, and V. 
Birkedal, “Interaction of hnRNP A1 with telomere DNA G-quadruplex structures studied at the 
single molecule level,” Eur. Biophys. J., vol. 39, no. 9, pp. 1343–1350, 2010. 
[197] H. Fukuda, M. Katahira, N. Tsuchiya, Y. Enokizono, T. Sugimura, M. Nagao, and H. 
Nakagama, “Unfolding of quadruplex structure in the G-rich strand of the minisatellite repeat 
by the binding protein UP1.,” Proc. Natl. Acad. Sci. U. S. A., vol. 99, no. 20, pp. 12685–90, 2002. 
[198] P.-C. Chu, M.-C. Yang, S. K. Kulp, S. B. Salunke, L. E. Himmel, C.-S. Fang, A. M. Jadhav, Y.-S. 
Shan, C.-T. Lee, M.-D. Lai, L. A. Shirley, T. Bekaii-Saab, and C.-S. Chen, “Regulation of 
oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop 
in human pancreatic cancer cells,” Oncogene, vol. 35, no. 30. Macmillan Publishers Limited, 
pp. 3897–3908, 28-Jul-2016. 
[199] M. Paramasivam, S. Cogoi, and L. E. Xodo, “Primer extension reactions as a tool to uncover 
folding motifs within complex G-rich sequences: analysis of the human KRAS NHE.,” Chem. 
Commun. (Camb)., vol. 47, no. 17, pp. 4965–7, 2011. 
[200] A. Kerkour, J. Marquevielle, S. Ivashchenko, L. A. Yatsunyk, J. L. Mergny, and G. F. Salgado, 
“High-resolution three-dimensional NMR structure of the KRAS proto-oncogene promoter 
reveals key features of a G-quadruplex involved in transcriptional regulation,” J. Biol. Chem., 
vol. 292, no. 19, pp. 8082–8091, 2017. 
[201] C. E. Kaiser, N. A. Van Ert, P. Agrawal, R. Chawla, D. Yang, and J. L. Huppert, “Insight into the 
Complexity of the i-Motif and G-Quadruplex DNA Structures Formed in the KRAS Promoter 
and Subsequent Drug-Induced Gene Repression,” J. Am. Chem. Soc., vol. 139, no. 25, pp. 8522–
8536, 2017. 
[202] Y. Yarden, W. J. Kuang, T. Yang-Feng, L. Coussens, S. Munemitsu, T. J. Dull, E. Chen, J. 
Schlessinger, U. Francke, and A. Ullrich, “Human proto-oncogene c-kit: a new cell surface 
receptor tyrosine kinase for an unidentified ligand.,” EMBO J., vol. 6, no. 11, pp. 3341–51, 1987. 
[203] D. E. Williams, J. Eisenman, A. Baird, C. Rauch, K. Van Ness, C. J. March, L. S. Park, U. Martin, 
D. Y. Mochizukl, H. S. Boswell, G. S. Burgess, D. Cosman, and S. D. Lyman, “Identification of a 
ligand for the c-kit proto-oncogene,” Cell, vol. 63, no. 1, pp. 167–174, 1990. 
[204] S. Hirota, “Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors,” 
Science (80-. )., vol. 279, no. 5350, pp. 577–580, 1998. 
 
148 
 
[205] C. M. V de Silva and R. Reid, “Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 
expression, differential diagnosis and targeted cancer therapy with Imatinib.,” Pathol. Oncol. 
Res., vol. 9, no. 1, pp. 13–9, 2003. 
[206] M. C. Heinrich, D. J. Griffith, B. J. Druker, C. L. Wait, K. a Ott, and  a J. Zigler, “Inhibition of c-
kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.,” Blood, 
vol. 96, no. 3, pp. 925–32, 2000. 
[207] G. D. Demetri, A. T. van Oosterom, C. R. Garrett, M. E. Blackstein, M. H. Shah, J. Verweij, G. 
McArthur, I. R. Judson, M. C. Heinrich, J. A. Morgan, J. Desai, C. D. Fletcher, S. George, C. L. 
Bello, X. Huang, C. M. Baum, and P. G. Casali, “Efficacy and safety of sunitinib in patients with 
advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled 
trial,” Lancet, vol. 368, no. 9544, pp. 1329–1338, 2006. 
[208] M. E. Gorre, “Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene 
Mutation or Amplification,” Science (80-. )., vol. 293, no. 5531, pp. 876–880, 2001. 
[209] D. Wei, J. Husby, and S. Neidle, “Flexibility and structural conservation in a c-KIT G-
quadruplex,” Nucleic Acids Res., vol. 43, no. 1, pp. 629–644, 2015. 
[210] S. T. D. Hsu, P. Varnai, A. Bugaut, A. P. Reszka, S. Neidle, and S. Balasubramanian, “A G-rich 
sequence within the c-kit oncogene promoter forms a parallel G-quadruplex having 
asymmetric G-tetrad dynamics,” J. Am. Chem. Soc., vol. 131, no. 37, pp. 13399–13409, 2009. 
[211] D. Wei, G. N. Parkinson, A. P. Reszka, and S. Neidle, “Crystal structure of a c-kit promoter 
quadruplex reveals the structural role of metal ions and water molecules in maintaining loop 
conformation,” Nucleic Acids Res., vol. 40, no. 10, pp. 4691–4700, 2012. 
[212] V. Kuryavyi, A. T. Phan, and D. J. Patel, “Solution structures of all parallel-stranded 
monomeric and dimeric G-quadruplex scaffolds of the human c-kit2 promoter,” Nucleic Acids 
Res., vol. 38, no. 19, pp. 6757–6773, 2010. 
[213] E. A. Raiber, R. Kranaster, E. Lam, M. Nikan, and S. Balasubramanian, “A non-canonical DNA 
structure is a binding motif for the transcription factor SP1 in vitro,” Nucleic Acids Res., vol. 
40, no. 4, pp. 1499–1508, 2012. 
[214] K. Yamamoto, A. Tojo, N. Aoki, and M. Shibuya, “Characterization of the promoter region of 
the human c-kit proto-oncogene.,” Japanese journal of cancer research : Gann, vol. 84, no. 11. 
pp. 1136–44, 1993. 
[215] R. Rigo and C. Sissi, “Characterization of G4–G4 Crosstalk in the c-KIT Promoter Region,” 
Biochemistry, p. acs.biochem.7b00660, 2017. 
[216] M. Bejugam, S. Sewitz, P. S. Shirude, R. Rodriguez, R. Shahid, and S. Balasubramanian, 
“Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands: Small molecule 
regulation of c-kit oncogene expression,” J. Am. Chem. Soc., vol. 129, no. 43, pp. 12926–12927, 
2007. 
[217] K. I. E. McLuckie, Z. A. E. Waller, D. A. Sanders, D. Alves, R. Rodriguez, J. Dash, G. J. 
McKenzie, A. R. Venkitaraman, and S. Balasubramanian, “G-Quadruplex-Binding 
benzo[a]phenoxazines down-regulate c-KIT expression in human gastric carcinoma cells,” J. 
Am. Chem. Soc., vol. 133, no. 8, pp. 2658–2663, 2011. 
[218] E. Zorzan, S. Da Ros, C. Musetti, L. Z. Shahidian, N. F. R. Coelho, F. Bonsembiante, S. Létard, 
M. E. Gelain, M. Palumbo, P. Dubreuil, M. Giantin, C. Sissi, and M. Dacasto, “Screening of 
 
149 
 
candidate G-quadruplex ligands for the human c-KIT promotorial region and their effects in 
multiple in-vitro models.,” Oncotarget, vol. 7, no. 16, pp. 21658–75, 2016. 
[219] M. M. Fay, S. M. Lyons, and P. Ivanov, “RNA G-Quadruplexes in Biology: Principles and 
Molecular Mechanisms,” J. Mol. Biol., vol. 429, no. 14, pp. 2127–2147, 2017. 
[220] H. Guiset Miserachs, D. Donghi, R. Börner, S. Johannsen, and R. K. O. Sigel, “Distinct 
differences in metal ion specificity of RNA and DNA G-quadruplexes,” J. Biol. Inorg. Chem., 
vol. 21, no. 8, pp. 975–986, 2016. 
[221] D. J. Patel, A. T. Phan, and V. Kuryavyi, “Human telomere, oncogenic promoter and 5′-UTR G-
quadruplexes: Diverse higher order DNA and RNA targets for cancer therapeutics,” Nucleic 
Acids Res., vol. 35, no. 22, pp. 7429–7455, 2007. 
[222] J. L. Huppert, A. Bugaut, S. Kumari, and S. Balasubramanian, “G-quadruplexes: The beginning 
and end of UTRs,” Nucleic Acids Res., vol. 36, no. 19, pp. 6260–6268, 2008. 
[223] C. K. Kwok, A. B. Sahakyan, and S. Balasubramanian, “Structural Analysis using SHALiPE to 
Reveal RNA G-Quadruplex Formation in Human Precursor MicroRNA,” Angew. Chemie - Int. 
Ed., vol. 55, no. 31, pp. 8958–8961, 2016. 
[224] M. J. Morris, Y. Negishi, C. Pazsint, J. D. Schonhoft, and S. Basu, “An RNA G-quadruplex is 
essential for cap-independent translation initiation in human VEGF IRES,” J. Am. Chem. Soc., 
vol. 132, no. 50, pp. 17831–17839, 2010. 
[225] C. K. Kwok, G. Marsico, A. B. Sahakyan, V. S. Chambers, and S. Balasubramanian, “rG4-seq 
reveals widespread formation of G-quadruplex structures in the human transcriptome,” Nat. 
Methods, vol. 13, no. 10, pp. 841–844, 2016. 
[226] J. U. Guo and D. P. Bartel, “RNA G-quadruplexes are globally unfolded in eukaryotic cells and 
depleted in bacteria,” Science (80-. )., vol. 353, no. 6306, p. aaf5371-aaf5371, 2016. 
[227] D. Boehringer and N. Ban, “Trapping the Ribosome to Control Gene Expression,” Cell, vol. 130, 
no. 6, pp. 983–985, 2007. 
[228] J. R. Babendure, J. L. Babendure, J. Ding, and R. Y. Tsien, “Control of mammalian translation 
by mRNA structure near caps Control of mammalian translation by mRNA structure near 
caps,” Rna, no. Kozak 1994, pp. 851–861, 2006. 
[229] J. Mandel, B. Ehresmann, and C. Ehresmann, “The fragile X mental retardation protein binds 
specifically to its mRNA via a purine quartet motif speci ® cally to its mRNA via a purine 
quartet motif,” EMBO J., vol. 4813, no. 17, pp. 4803–4813, 2001. 
[230] S. Kumari, A. Bugaut, J. L. Huppert, and S. Balasubramanian, “An RNA G-quadruplex in the 5′ 
UTR of the NRAS proto-oncogene modulates translation,” Nat. Chem. Biol., vol. 3, no. 4, pp. 
218–221, 2007. 
[231] S. Kumari, A. Bugaut, and S. Balasubramanian, “Position and Stability Are Determining 
Factors for Translation Repression by an RNA G-Quadruplex-Forming Sequence within the 5 ′ 
UTR of the NRAS,” pp. 12664–12669, 2008. 
[232] A. Bugaut and S. Balasubramanian, “5-UTR RNA G-quadruplexes: Translation regulation and 
targeting,” Nucleic Acids Res., vol. 40, no. 11, pp. 4727–4741, 2012. 
[233] S. Kumari, A. Bugaut, J. L. Huppert, and S. Balasubramanian, RNA G-quadruplex in the 5 ′ 
 
150 
 
UTR of the NRAS proto- oncogene modulates translation,” vol. 3, no. 4, pp. 218–221, 2008. 
[234] R. Shahid, A. Bugaut, and S. Balasubramanian, “The BCL-2 5- untranslated region contains an 
RNA G-quadruplex-forming motif that modulates protein expression,” Biochemistry, vol. 49, 
no. 38, pp. 8300–8306, 2010. 
[235] A. Arora and B. Suess, “An RNA G-quadruplex in the 3’ UTR of the proto-oncogene PIM1 
represses translation,” RNA Biol., vol. 8, no. February 2015, pp. 802–805, 2011. 
[236] E. Crenshaw, B. P. Leung, C. K. Kwok, M. Sharoni, K. Olson, N. P. Sebastian, S. Ansaloni, R. 
Schweitzer-Stenner, M. R. Akins, P. C. Bevilacqua, and A. J. Saunders, “Amyloid precursor 
protein translation is regulated by a 3’UTR guanine quadruplex,” PLoS One, vol. 10, no. 11, pp. 
1–18, 2015. 
[237] A. Arora, M. Dutkiewicz, V. Scaria, M. Hariharan, S. Maiti, and J. Kurreck, “Inhibition of 
translation in living eukaryotic cells by an RNA G-quadruplex motif.,” RNA, vol. 14, no. 7, pp. 
1290–1296, 2008. 
[238] R. Kostadinov, N. Malhotra, M. Viotti, R. Shine, L. D’Antonio, and P. Bagga, “GRSDB: a 
database of quadruplex forming G-rich sequences in alternatively processed mammalian pre-
mRNA sequences.,” Nucleic Acids Res., vol. 34, no. Database issue, pp. D119–D124, 2006. 
[239] O. Kikin, Z. Zappala, L. D’Antonio, and P. S. Bagga, “GRSDB2 and GRS_UTRdb: Databases of 
quadruplex forming G-rich sequences in pre-mRNAs and mRNAs,” Nucleic Acids Res., vol. 36, 
no. SUPPL. 1, pp. 141–148, 2008. 
[240] M. C. Didiot, Z. Tian, C. Schaeffer, M. Subramanian, J. L. Mandel, and H. Moine, “The G-
quartet containing FMRP binding site in FMR1 mRNA is a potent exonic splicing enhancer,” 
Nucleic Acids Res., vol. 36, no. 15, pp. 4902–4912, 2008. 
[241] D. Gomez, T. Lamarteleur, L. Lacroix, P. Mailliet, J. L. Mergny, and J. F. Riou, “Telomerase 
downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by 
hTERT RNA alternative splicing,” Nucleic Acids Res., vol. 32, no. 1, pp. 371–379, 2004. 
[242] A. K. Byrd and K. D. Raney, “A parallel quadruplex DNA is bound tightly but unfolded slowly 
by Pif1 helicase,” J. Biol. Chem., vol. 290, no. 10, pp. 6482–6494, 2015. 
[243] L. Federici, A. Arcovito, G. L. Scaglione, F. Scaloni, C. Lo Sterzo, A. Di Matteo, B. Falini, B. 
Giardina, and M. Brunori, “Nucleophosmin C-terminal leukemia-associated domain interacts 
with G-rich quadruplex forming DNA,” J. Biol. Chem., vol. 285, no. 48, pp. 37138–37149, 2010. 
[244] M. A. Islam, S. D. Thomas, V. V. Murty, K. J. Sedoris, and D. M. Miller, “c-Myc quadruplex-
forming sequence Pu-27 induces extensive damage in both telomeric and nontelomeric 
regions of DNA,” J. Biol. Chem., vol. 289, no. 12, pp. 8521–8531, 2014. 
[245] V. González and L. H. Hurley, “The C-terminus of nucleolin promotes the formation of the c-
MYC G-quadruplex and inhibits c-MYC promoter activity,” Biochemistry, vol. 49, no. 45, pp. 
9706–9714, 2010. 
[246] S. L. Cree, R. Fredericks, A. Miller, F. G. Pearce, V. Filichev, C. Fee, and M. A. Kennedy, “DNA 
G-quadruplexes show strong interaction with DNA methyltransferases in vitro,” FEBS Lett., 
vol. 590, pp. 2870–2883, 2016. 
[247] R. K. Thakur, P. Kumar, K. Halder, A. Verma, A. Kar, J. L. Parent, R. Basundra, A. Kumar, and 
S. Chowdhury, “Metastases suppressor NM23-H2 interaction with G-quadruplex DNA within 
 
151 
 
c-MYC promoter nuclease hypersensitive element induces c-MYC expression,” Nucleic Acids 
Res., vol. 37, no. 1, pp. 172–183, 2009. 
[248] B. Guyen, C. M. Schultes, P. Hazel, J. Mann, and S. Neidle, “Synthesis and evaluation of 
analogues of 10H-indolo[3,2-b]quinoline as G-quadruplex stabilising ligands and potential 
inhibitors of the enzyme telomerase.,” Org. Biomol. Chem., vol. 2, pp. 981–988, 2004. 
[249] V. Caprio, B. Guyen, Y. Opoku-Boahen, J. Mann, S. M. Gowan, L. M. Kelland, M. a Read, and S. 
Neidle, “A Novel Inhibitor of Human Telomerase Derived from 10H-Indolo [3, 2- b] 
quinoline,” Bioorg. Med. Chem. Lett., vol. 10, pp. 2063–2066, 2000. 
[250] D. Monchaud and M.-P. Teulade-Fichou, “A hitchhiker’s guide to G-quadruplex ligands,” Org. 
Biomol. Chem., vol. 6, no. 4, pp. 627–636, 2008. 
[251] L. Martino, B. Pagano, I. Fotticchia, S. Neidle, and C. Giancola, “Shedding light on the 
interaction between TMPyP4 and human telomeric quadruplexes,” J. Phys. Chem. B, vol. 113, 
no. 44, pp. 14779–14786, 2009. 
[252] J. Seenisamy, S. Bashyam, V. Gokhale, H. Vankayalapati, D. Sun, A. Siddiqui-Jain, N. Streiner, 
K. Shin-ya, E. White, W. D. Wilson, and L. H. Hurley, “Design and synthesis of an expanded 
porphyrin that has selectivity for the c-MYC G-quadruplex structure,” J. Am. Chem. Soc., vol. 
127, no. 9, pp. 2944–2959, 2005. 
[253] W. M. Clark, W. Brooks, A. Mackey, M. D. Hill, P. P. Leimgruber, A. J. Sheffet, D. Ph, V. J. 
Howard, D. Ph, W. S. Moore, J. H. Voeks, D. Ph, L. N. Hopkins, D. E. Cutlip, D. J. Cohen, J. J. 
Popma, R. D. Ferguson, S. N. Cohen, J. L. Blackshear, F. L. Silver, J. P. Mohr, B. K. Lal, J. F. 
Meschia, and C. Investigators, “New England Journal,” N. Engl. J. Med., vol. 351, no. 21, pp. 
2159–2169, 2004. 
[254] D. Drygin, A. Siddiqui-Jain, S. O’Brien, M. Schwaebe, A. Lin, J. Bliesath, C. B. Ho, C. Proffitt, K. 
Trent, J. P. Whitten, J. K. C. Lim, D. Von Hoff, K. Anderes, and W. G. Rice, “Anticancer activity 
of CX-3543: A direct inhibitor of rRNA biogenesis,” Cancer Res., vol. 69, no. 19, pp. 7653–7661, 
2009. 
[255] H. Xu, M. Di Antonio, S. McKinney, V. Mathew, B. Ho, N. J. O’Neil, N. Dos Santos, J. Silvester, 
V. Wei, J. Garcia, F. Kabeer, D. Lai, P. Soriano, J. Banáth, D. S. Chiu, D. Yap, D. D. Le, F. B. Ye, 
A. Zhang, K. Thu, J. Soong, S. Lin, A. H. C. Tsai, T. Osako, T. Algara, D. N. Saunders, J. Wong, 
J. Xian, M. B. Bally, J. D. Brenton, G. W. Brown, S. P. Shah, D. Cescon, T. W. Mak, C. Caldas, P. 
C. Stirling, P. Hieter, S. Balasubramanian, and S. Aparicio, “CX-5461 is a DNA G-quadruplex 
stabilizer with selective lethality in BRCA1/2 deficient tumours,” Nat. Commun., vol. 8, no. 
205, p. 14432, 2017. 
[256] K. Gehring, J.-L. Leroy, and M. Gueron, “A tetrameric DNA structure with protonated 
cytosine-cytosine base pairs,” Nature, vol. 363, no. 6429, pp. 561–565, Jun. 1993. 
[257] J. Laskar, F. Joutel, and P. Robutel, “© 19 9 3 Nature Publishing Group,” Nature, vol. 361, 1993. 
[258] D. Liu and S. Balasubramanian, “A Proton-Fuelled DNA Nanomachine,” Angew. Chemie - Int. 
Ed., vol. 42, no. 46, pp. 5734–5736, 2003. 
[259] J. Sharma, R. Chhabra, H. Yan, and Y. Liu, “pH-driven conformational switch of ‘i-motif’ DNA 
for the reversible assembly of gold nanoparticles,” Chem. Commun., no. 5, pp. 477–479, 2007. 
[260] W. Wang, H. Liu, D. Liu, Y. Xu, Y. Yang, and D. Zhou, “Use of the interparticle i-motif for the 
controlled assembly of gold nanoparticles,” Langmuir, vol. 23, no. 24, pp. 11956–11959, 2007. 
 
152 
 
[261] S. Modi, M. G.Swetha, D. Goswami, G. D. Gupta, S. Mayor, and Y. Krishnan, “A DNA 
nanomachine that maps spatial and temporal pH changes inside living cells,” Nat Nano, vol. 4, 
no. 5, pp. 325–330, May 2009. 
[262] S. Surana, J. M. Bhat, S. P. Koushika, and Y. Krishnan, “An autonomous DNA nanomachine 
maps spatiotemporal pH changes in a multicellular living organism,” Nat. Commun., vol. 2, 
no. May, p. 340, 2011. 
[263] T. Li, D. Ackermann, A. M. Hall, and M. Famulok, “Input-dependent induction of 
oligonucleotide structural motifs for performing molecular logic,” J. Am. Chem. Soc., vol. 134, 
no. 7, pp. 3508–3516, 2012. 
[264] J. Elbaz, Z. G. Wang, R. Orbach, and L. Willner, “pH-stimulated concurrent mechanical 
activation of two DNA ‘tweezers’. A ‘SET-RESET’ logic gate system,” Nano Lett., vol. 9, no. 12, 
pp. 4510–4514, 2009. 
[265] R. E. Marsh, R. Bierstedt, and E. L. Eichhorn, “The crystal structure of cytosine-5-acetic acid,” 
Acta Crystallogr., vol. 15, no. 4, pp. 310–316, 1962. 
[266] S. Ahmed and E. Henderson, “Formation of novel hairpin structures by telemeric C-strand 
oligonucleotides,” Nucleic Acids Res., vol. 20, no. 3, pp. 507–511, 1992. 
[267] A. T. Phan and J.-L. Leroy, “Intramolecular i-Motif Structures of Telomeric DNA,” J. Biomol. 
Struct. Dyn., vol. 17, no. sup1, pp. 245–251, Jan. 2000. 
[268] L. Cai, L. Chen, S. Raghavan, R. Ratliff, R. Moyzis, and A. Rich, “Intercalated cytosine motif 
and novel adenine clusters in the crystal structure of the Tetrahymena telomere,” Nucleic 
Acids Res., vol. 26, no. 20, pp. 4696–4705, 1998. 
[269] J. Weil, T. Min, C. Yang, S. Wang, C. Sutherland, N. Sinha, and C. Kang, “Stabilization of the 
{\it i}-motif by intramolecular adenine{--}adenine{--}thymine base triple in the {\-}structure of 
d(ACCCT),” Acta Crystallogr. Sect. D, vol. 55, no. 2, pp. 422–429, Feb. 1999. 
[270] N. Khan, A. Aviñó, R. Tauler, C. González, R. Eritja, and R. Gargallo, “Solution equilibria of the 
i-motif-forming region upstream of the B-cell lymphoma-2 P1 promoter,” Biochimie, vol. 89, 
no. 12, pp. 1562–1572, 2007. 
[271] T. A. Brooks, S. Kendrick, and L. Hurley, “Making sense of G-quadruplex and i-motif functions 
in oncogene promoters,” FEBS J., vol. 277, no. 17, pp. 3459–3469, 2010. 
[272] L. Lacroix, J. L. Mergny, J. L. Leroy, and C. Hélène, “Inability of RNA to form the i-motif: 
Implications for triplex formation,” Biochemistry, vol. 35, no. 26, pp. 8715–8722, 1996. 
[273] S. Kendrick and L. H. Hurley, “The role of G-quadruplex/i-motif secondary structures as cis-
acting regulatory elements.,” Pure Appl. Chem., vol. 82, no. 8, pp. 1609–1621, 2010. 
[274] D. Sun and L. H. Hurley, “The importance of negative superhelicity in inducing the formation 
of G-quadruplex and i-motif structures in the c-Myc promoter: Implications for drug targeting 
and control of gene expression,” J. Med. Chem., vol. 52, no. 9, pp. 2863–2874, 2009. 
[275] D. Hanahan and R. a. Weinberg, “Hallmarks of cancer: The next generation,” Cell, vol. 144, no. 
5, pp. 646–674, 2011. 
[276] M. Vander Heiden, L. Cantley, and C. Thompson, “Understanding the Warburg effect: The 
metabolic Requiremetns of cell proliferation,” Science (80-. )., vol. 324, no. 5930, pp. 1029–1033, 
 
153 
 
2009. 
[277] E. B. Affar, R. G. Shah, A.-K. Dallaire, V. Castonguay, and G. M. Shah, “Role of poly(ADP-
ribose) polymerase in rapid intracellular acidification induced by alkylating DNA damage.,” 
Proc Natl Acad Sci U S A, vol. 99, no. 1, pp. 245–250, 2002. 
[278] A. Rajendran, S. Nakano, and N. Sugimoto, “Molecular crowding of the cosolutes induces an 
intramolecular i-motif structure of triplet repeat DNA oligomers at neutral pH,” Chem. 
Commun., vol. 46, no. 8, p. 1299, 2010. 
[279] J. Cui, P. Waltman, V. H. Le, and E. A. Lewis, “The effect of molecular crowding on the 
stability of human c-MYC promoter sequence I-motif at neutral pH,” Molecules, vol. 18, no. 10, 
pp. 12751–12767, 2013. 
[280] J. J. Wenzel, H. Rossmann, C. Fottner, S. Neuwirth, C. Neukirch, P. Lohse, J. K. Bickmann, T. 
Minnemann, T. J. Musholt, B. Schneider-Rätzke, M. M. Weber, and K. J. Lackner, 
“Identification and prevention of genotyping errors caused by G-quadruplex- and i-motif-like 
sequences,” Clin. Chem., vol. 55, no. 7, pp. 1361–1371, 2009. 
[281] G. Manzini, N. Yathindra, and L. E. Xodo, “Evidence for intramolecularly folded I-DNA 
structures in biologically relevant CCC-repeat sequences,” Nucleic Acids Res., vol. 22, no. 22, 
pp. 4634–4640, 1994. 
[282] T. Simonsson, M. Pribylova, and M. Vorlickova, “A Nuclease Hypersensitive Element in the 
Human c-myc Promoter Adopts Several Distinct i-Tetraplex Structures,” Biochem. Biophys. 
Res. Commun., vol. 278, no. 1, pp. 158–166, 2000. 
[283] S. Kendrick, Y. Akiyama, S. M. Hecht, and L. H. Hurley, “The i-motif in the bcl-2 P1 promoter 
forms an unexpectedly stable structure with a unique 8:5:7 loop folding pattern,” J. Am. Chem. 
Soc., vol. 131, no. 48, pp. 17667–17676, 2009. 
[284] K. Guo, V. Gokhale, L. H. Hurley, and D. Sun, “Intramolecularly folded G-quadruplex and i-
motif structures in the proximal promoter of the vascular endothelial growth factor gene,” 
Nucleic Acids Res., vol. 36, no. 14, pp. 4598–4608, 2008. 
[285] K. Guo, A. Pourpak, K. Beetz-Rogers, V. Gokhale, D. Sun, and L. H. Hurley, “Formation of 
pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of 
the RET oncogene,” J. Am. Chem. Soc., vol. 129, no. 33, pp. 10220–10228, 2007. 
[286] Y. Xu and H. Sugiyama, “Formation of the G-quadruplex and i-motif structures in 
retinoblastoma susceptibility genes (Rb),” Nucleic Acids Res., vol. 34, no. 3, pp. 949–954, 2006. 
[287] L. Lacroix, H. Liénard, E. Labourier, M. Djavaheri-Mergny, J. Lacoste, H. Leffers, J. Tazi, C. 
Hélène, and J. L. Mergny, “Identification of two human nuclear proteins that recognise the 
cytosine-rich strand of human telomeres in vitro.,” Nucleic Acids Res., vol. 28, no. 7, pp. 1564–
1575, 2000. 
[288] H. Kang, S. Kendrick, S. M. Hecht, and L. H. Hurley, “Is a Molecular Switch for Control of 
Gene Expression That Can Be,” 2014. 
[289] V. González and L. H. Hurley, “The c-MYC NHE III1: Function and Regulation,” Annu. Rev. 
Pharmacol. Toxicol., vol. 50, no. 1, pp. 111–129, Jan. 2010. 
[290] P. H. Backe, A. C. Messias, R. B. G. Ravelli, M. Sattler, and S. Cusack, “X-ray crystallographic 
and NMR studies of the third KH domain of hnRNP K in complex with single-stranded nucleic 
 
154 
 
acids,” Structure, vol. 13, no. 7, pp. 1055–10607, 2005. 
[291] J. F. Cornuel, A. Moraillon, and M. Guéron, “Participation of yeast inosine 5′-monophosphate 
dehydrogenase in an in vitro complex with a fragment of the C-rich telomeric strand,” 
Biochimie, vol. 84, no. 4, pp. 279–289, 2002. 
[292] G. Sarig, P. Weisman-Shomer, R. Erlitzki, and M. Fry, “Purification and characterization of 
qTBP42, a new single-stranded and quadruplex telomeric DNA-binding protein from rat 
hepatocytes,” J. Biol. Chem., vol. 272, no. 7, pp. 4474–4482, 1997. 
[293]  a Cortés and F. Azorín, “DDP1, a heterochromatin-associated multi-KH-domain protein of 
Drosophila melanogaster, interacts specifically with centromeric satellite DNA sequences.,” 
Mol. Cell. Biol., vol. 20, no. 11, pp. 3860–3869, 2000. 
 
